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Abstract 
The evolutionary pressure to prevent re-replication by inactivating licensing during S phase leaves 
higher-eukaryotes with large genomes, such as human cells, vulnerable to replication stresses. 
Origins licensed in G1 must be sufficient to complete replication as new origins cannot be licensed 
in response to irreversible replication fork stalling. Interdisciplinary approaches between cellular 
biology and biophysics predict that replication of the genome is routinely incomplete in G2, even in 
the absence of external stressors. The frequency of converging replication forks that never terminate 
due to irreversible stalling (double fork stall), which result in a segment of unreplicated DNA, was 
modelled using high quality origin-mapping data in HeLa and IMR-90 cells. From this, hypotheses 
were generated that related an increase in unreplicated segments of DNA to reduced functional 
origin number. Presented in this thesis is the confirmation of this relation by quantifying 
chromosome mis-segregation and DNA damage responses when origin number was reduced using 
RNAi against licensing factors. The number of ultrafine anaphase bridges and 53BP1 nuclear 
bodies are in remarkable concordance with the theoretical predictions for the number of double fork 
stalls, indicating that cells are able to tolerate under-replication through such post-replicative 
cellular responses. 53BP1 preferentially binds to chromatin associated with large replicons, and 
functions synergistically with dormant origins to protect the stability of the genome. Additional 
candidates, inspired by common fragile site research, have also been characterised as responders to 
spontaneous under-replication, and include FANCD2 and MiDAS, which function in early mitosis 
to facilitate completion of replication before cells enter anaphase. In conclusion, a series of 
mechanisms that sequentially function throughout the cell cycle protects the stability of the human 
genome against inevitable spontaneous under-replication brought about by its large size.
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1.1) The Cell Cycle 
Cells function to proliferate the genetic information stored within their DNA by first replicating 
their genome and second dividing into daughter cells, each with at least one copy of the genome. 
These two processes are conserved across all life and are described as the cell division cycle, which 
in eukaryotes is composed of four sequential phases. The genome is replicated in the synthesis 
phase (S phase) and the cell divides in mitosis (M phase), which are separated by two growth 
phases: G1 follows mitosis and G2 follows S phase. The cell cycle is tightly regulated and varies 
between different organisms. In this thesis, the focus is on the human cell cycle, but it is highly 
conserved amongst other mammals and even well conserved in yeasts. 
 
The human cell cycle is regulated by the oscillations of activity by a family of serine/threonine 
kinases known as CDKs (cyclin dependent kinases). There are 20 known mammalian CDKs (CDK1 
through CDK20), however, a large number regulate transcription or are tissue specific and are not 
main players in the progression of the cell cycle (Malumbres, 2014, Malumbres and Barbacid, 
2005). The regular mammalian cell cycle is regulated by CDK1, CDK2, CDK4 and CDK6. These 
kinases promote transitions through the cell cycle phases but, by definition, must be associated with 
a regulatory subunit for correctly timed activity. The regulatory subunits are known as cyclins and 
are themselves regulated by sequential proteolysis, which is the principal source of the oscillatory 
activity of CDKs. Like CDKs, there are a number cyclins with specialised roles, but the core of a 
normal mammalian cell cycle is regulated by the protein levels of CyclinA, CyclinB, CyclinD and 
CyclinE. The activity of different combinations of CDK•Cyclin heterodimers defines the phases of 
the cell cycle, and is summarised below. 
 
Cells are born into G1, which follows from mitosis. CDK1 activity promotes mitosis and drives 
progression through it, so must be inhibited to reverse physiological changes that are required for 
mitosis, such as chromatin condensation, nuclear envelope breakdown and spindle assembly. CDK1 
activity in mitosis requires CyclinB, and so repression of mitotic CDK1 activity is brought about by 
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proteolysis of CyclinB. CyclinB contains a domain called the KEN box, which is recognised by 
CDH1 (CDC20 homologue 1) and activates the APC/C (anaphase promoting complex/cyclosome). 
The APC/C is an E3 ubiquitin ligase that polyubiquitylates targets, marking them for destruction by 
the proteasome. CDK4 and CDK6 promote the G1/S transition, and are also inhibited in early G1 
by CDK inhibitors (CKIs) the INK4 family of proteins: p16INK4A, p15INK4B, p18INK4C and p19INK4D. 
APC/CCDH1- and INK4-mediated inhibition ensure that there is little to no CDK activity in early G1 
cells. The cell cycle phase transitions to come (G1/S and G2/M) are dependent upon CDK activity, 
so the drop in CDK activity that ends mitosis and is then resumed to commit cells into the next cell 
cycle is the primary oscillation of CDK activity. The cell monitors its environment before 
committing to the next cell cycle. CyclinD promotes the G1/S transition and is itself promoted by 
growth factors/mitogens. CyclinD complexes with CDK4 and CDK6, which when active, 
phosphorylate pRb (retinoblastoma protein). pRb, by its binding, inhibits the transcription factor 
family E2F which promote the expression of many genes, including CyclinE and proteins required 
for DNA replication. CDK-dependent phosphorylation of pRb reduces its ability to repress E2F-
driven transcription. CyclinE binds and activates CDK2 which further phosphorylates pRb. 
Hyperphosphorylated pRb unbinds E2F, further increasing expression of S phase cyclins and 
creates a positive feedback loop which ensures the transition to S phase is fast and irreversible. 
Another family of CKIs further contributes to the fast and irreversible transition between G1 phase 
CDK activity and S phase CDK activity, called CIP/KIP (CDK interacting protein/kinase inhibitory 
protein) and includes as its members p21CIP1/WAF1, p27KIP1 and p57KIP2. These three proteins promote 
the stable interaction between CDK4/6 and CyclinD and inhibit the association of CDK2 with 
CyclinA/E in G1. CIP/KIP proteins are sequestered to CyclinD, reducing their ability to inhibit 
CDK2•CyclinA/E after commitment to the cell cycle. High levels of CDK2•CyclinE promoted by 
E2F overwhelms and antagonises p27KIP1 by phosphorylating it, marking it for destruction by a 
second E3 ubiquitin ligase, the SCF complex (SKP, Cullin, F-box). This second layer of regulation 
further ensures that G1-CDK activity is mutually exclusive with S-CDK activity, and is irreversible. 
A third layer of control is the CDK phosphorylation of CDH1. APC/CCDH1 stabilises G1 by marking 
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Cyclins for proteolysis, but as CDK activity accumulates at the G1/S transition, CDH1 becomes 
phosphorylated which marks it for eventual proteolysis via the SCF complex, and the APC/C can no 
longer ubiquitylate Cyclins. Once cells have transitioned into S phase and p27KIP1 is proteolysed, 
CyclinA can bind to CDK2, the activity of which increases through S phase. CDK2•CyclinE 
activity promotes the transition from G1 phase to S phase, but CDK2•CyclinA takes over once S 
phase begins. CyclinE is marked for proteolysis by SCF to prevent re-replication (more on this 
later). As cells move from S phase to G2 phase, CyclinA associates with CDK1 and contributes to 
promoting the G2/M transitions. However, the main source of mitotic CDK activity is from 
CDK1•CyclinB. CyclinB expression starts in S phase and builds until the end of mitosis. However, 
CDK1•CyclinB remains inactive due to phosphorylation by the CDK inhibitor WEE1. The 
antagonistic phosphatase for WEE1 is CDC25, the activity of which is repressed throughout S and 
G2 phases by SCF-mediated proteolysis. CDK1 phosphorylates WEE1 and CDC25, but the effects 
are opposed: WEE1 is inhibited and CDC25 is activated. WEE1 is highly sensitive to inhibitory 
phosphorylation, so when CDK1 activity has reached a sufficient level, WEE1-mediated inhibition 
of CDK1•CyclinB stops and CDC25-mediated activation begins. Additionally, the specificity of 
SCF changes from CDC25 to WEE1. Together, these interactions form a bistable switch which 
ensures fast and irreversible activation of CDK1•CyclinB. Once cells enter mitosis, CDK1 
phosphorylates many targets that bring about chromosome condensation, breakdown of the nuclear 
envelope and spindle formation. CDK1•CyclinB also phosphorylates the APC/C, thereby activating 
it, and phosphorylates CDH1, thereby deactivating it. When microtubules attach to the 
kinetochores, the MAD1/2 heterodimer is displaced and CDC20 is activated. One unattached 
kinetochore is sufficient to repress CDC20, ensuring anaphase does not initiate until ready, reducing 
the possibility of mis-segregation and aneuploidy. Like CDH1, CDC20 recognises D-box motifs, 
and coordinates APC/C-mediated ubiquitylation. APC/CCDC20 targets CyclinB and securin for 
proteolysis. Securin binds and inhibits separase, which cleaves cohesin, meaning that APC/CCDC20 
activity allows the separation of sister-chromatids during anaphase. As APC/CCDC20 inhibits its own 
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promoter, its activity drops after sufficient CyclinB proteolysis, and CDK1•CyclinB repression 
results in more active CDH1. CDC20 contains a KEN box motif and so APC/CCDH1 targets CDC20 
for destruction, thus displacing APC/CCDC20 activity. As APC/CCDH1 does not target G1 and S phase 
cyclins for proteolysis, the switch from APC/CCDC20 to APC/CCDH1 ensures that cells irreversibly 
exit mitosis and enter G1 (Malumbres and Barbacid, 2005, Malumbres, 2014, Sherr and Roberts, 
1999, Murray, 2004, Sanchez and Dynlacht, 2005). 
 
The above summary is an idealised version of the mammalian cell cycle, however, there is a lot of 
redundancy built-in, where most CDK/Cyclin complexes can function redundantly and can be 
substituted for each other. For example, human and Xenopus CDK2 was discovered by cloning an 
uncharacterised kinase or a cDNA screen, respectively, and were able to complement a S. cerevisiae 
CDK1 mutant (cdc28) (Elledge and Spottswood, 1991, Paris et al., 1991). Mouse models which are 
null for CDK4, CDK6 or CDK2 are viable, as are CDK2/CDK6 double null mutants, and CDK2 
null mice have no detectable phenotype in their somatic cells (summarised in Malumbres & 
Barbacid, 2005). In fact, a mouse model lacking all interphase CDKs develop to mid-gestation, 
showing that CDK1 is sufficient to drive the mammalian cell cycle (Santamaria et al., 2007). 
Embryonic fibroblasts derived from this mouse model proliferate, are immortal, and CDK1 binds 
all the cyclins required for the cell cycle (Santamaria et al., 2007). Additionally, CyclinD and 
CyclinE are dispensable for mouse development (Geng et al., 2003, Kozar et al., 2004). Given the 
redundancy and number of CDK/Cyclin complexes, it was argued that all CDK heterodimers are 
essentially synonymous, but are variably regulated so that they can coordinate complex processes 
by when and where they are active, as opposed to having biochemically distinct properties for each 
heterodimer that define a specific set of substrates. To test this, the nuclear localisation signal of 
CyclinE was recombined with CyclinB, and the recombinant protein was added to Xenopus egg 
extracts depleted of Cyclins. Wild-type CyclinB induced mitosis, but the recombinant protein was 
able to induce DNA replication, showing that the fundamental difference between CyclinE and 
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CyclinB in interphase cells is that CyclinE localises to the nucleus and CyclinB does not (Moore et 
al., 2003). 
1.2) DNA replication 
The purpose of eukaryotic DNA replication is to duplicate one copy of the genome such that they 
can be segregated into two separate copies that are nearly identical to the original. Eukaryotic 
genomes are frequently large, and distributed over multiple chromosomes. Coordination of DNA 
replication is a significant challenge, and is thus a highly regulated cellular process. Initiation of 
classical DNA replication defines the beginning of S phase, and is mostly complete when S phase 
transitions into G2. DNA replication is regulated in space as well as time. During mitosis, the 
nuclear envelope is broken down so that the duplicated genome can be segregated. APC/CCDH1 
facilitates exit from mitosis by marking CyclinB for proteolysis, which restores the interphase 
characteristics of nuclei, including re-establishment of the nuclear envelope. As touched upon 
previously, the cell uses the boundary between the nucleoplasm and the cytoplasm as a layer of 
regulation; translation of mRNA into proteins only takes place in the cytoplasm, with a nuclear 
localisation sequence (NLS) required for a protein to enter the nucleus. 
 
1.2.1) Summary of DNA replication 
DNA is double-stranded, and one strand complements the other. In 'the most beautiful experiment', 
Meselson and Stahl demonstrated that DNA replication is semi-conservative by growing E. coli in 
media that contained heavy 15N and periodically took samples, extracted the DNA and fractionated 
them in a caesium chloride density gradient. After one cell cycle, the DNA settled at a density 
halfway in between 'light' 14N DNA and 'heavy' 15N DNA, forming a light/heavy fraction. With each 
successive cell cycle, the light/heavy fraction transitioned into a heavy/heavy fraction (Meselson 
and Stahl, 1958). Semi-conservative replication means that a double-stranded molecule of DNA 
(dsDNA) must be separated before it is replicated, into two single-stranded molecules (ssDNA), 
each of which can then be used as a template for DNA synthesis. Unwinding of dsDNA into two 
complementary ssDNA molecules is carried out by a class of proteins called helicases. Eukaryotes 
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have a number of helicases, many with specialised roles, but canonical DNA synthesis is facilitated 
by the heterohexamer MCM2-7 (minichromosome maintenance 2 through 7), the catalytic core of 
the replicative helicase (Tye, 1999, Labib and Diffley, 2001, Bell and Dutta, 2002). Forty MCM 
genes were discovered in a genetic screen for maintenance of an artificial minichromosome with an 
origin in S. cerevisiae (Maine et al., 1984). The six MCMs that the helicase is composed of are 
paralogues that are highly conserved across all eukaryotes (Chong et al., 1996, Forsburg, 2004), and 
form a toroid shape when complexed (Bochman and Schwacha, 2009). MCM2-7-mediated DNA 
unwinding is processive and moves along the DNA in one net direction, making the nascent ssDNA 
available as a template for DNA synthesis. DNA is synthesised in situ one base at a time on the 
template by DNA polymerases, complexes of proteins that incorporate and covalently bond dNTPs 
(deoxyribonucleotide triphosphates) to the 3' end of an existing complement to the template. This 
means that the processivity of DNA polymerases is strictly 5' to 3', and must start from the interface 
between a nucleic duplex and ssDNA. As MCM2-7 has separated dsDNA into two ssDNA 
molecules, there is no duplex that a polymerase can initiate DNA synthesis from, so a specialised 
polymerase called primase synthesises a short sequence of RNA that complements a section of the 
ssDNA template, from which DNA polymerase can start synthesising. The two strands of DNA in a 
dsDNA molecule are antiparallel, so one strand must be synthesised in the 5' to 3' direction, and the 
other must be 3' to 5'. The strand of DNA synthesised in the 3' to 5' direction need only be primed 
once and DNA polymerase can synthesis the complement DNA in the 5' to 3' direction, the same 
direction as the helicase, and is known as the leading strand. However, the other strand cannot be 
replicated in the same orientation, and so is replicated in short sections as the nascent ssDNA is 
made accessible by MCM2-7 helicase activity, known as the lagging strand. These short fragments 
of DNA are called Okazaki fragments and are 100-200 bp in length, with each one requiring 
priming by primase. DNA polymerisation in the lagging strand starts from the primer that 
complements nascent ssDNA, in the opposite direction of helicase, and stops at the previously 
synthesised primer. The lagging strand polymerase displaces the 5' end of the previous Okazaki 
fragment creating a single-stranded 5' flap, which is then removed by FEN1 (flap endonuclease 1). 
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The single-stranded nick between Okazaki fragments is then ligated together by DNA ligase 1 
(CDC9), completing synthesis of the lagging strand. The eukaryotic replisome contains three 
different polymerases, Pol ɑ, Pol δ and Pol ε. It was widely accepted that leading strand synthesis 
was exclusively carried out by Pol ε and the lagging strand by Pol δ, however, recent evidence in 
yeasts indicates that Pol δ can support leading strand synthesis, albeit at a slower rate, and is 
replaced by pol ε if it is available (Daigaku et al., 2015, Yeeles et al., 2017, Georgescu et al., 2014). 
Pol ɑ forms a complex with PRIM1 and PRIM2 subunits of primase and synthesises DNA 
immediately after the primer, and is quickly taken over by pol δ/ε. (Forsburg, 2004, Bell and Dutta, 
2002, Bochman and Schwacha, 2009). PCNA (proliferating cell nuclear antigen) is a homotrimeric 
sliding clamp that encircles nascent DNA and is loaded by the clamp loader RFC (replication factor 
C). PCNA topologically tethers pol δ and pol ε to their substrates and enhances their processivity, 
and is described as a 'docking bay' given the number of factors it binds and stabilises at the fork. For 
example, FEN1 and ligase 1 bind PCNA which enhances their activity at the lagging strand. When 
pol δ completes the synthesis of an Okazaki fragment, it is recycled and docked upstream to a 
newly loaded PCNA (Pomerantz and O'Donnell, 2007). 
 
The above model describes some core components of a single replication fork replicating an 
arbitrary strand of dsDNA. However, the structure of DNA and of the genome complicates matters. 
An origin of replication is a genomic locus from where two replication forks are initiated, which 
replicate DNA in opposite directions upstream and downstream of the origin. As the forks emerge 
from an origin they expand a replication bubble, as the 5' end of the leading strand of both forks 
corresponds to the 3' end of the lagging strand of the other fork. The human genome is distributed 
over 46 linear chromosomes, with origins of replication distributed throughout (the distribution and 
regulation of origin placement will be introduced later). Bidirectional extension of replication forks 
from adjacent origins necessitates the activity of topoisomerases, as DNA is a double helix and 
unwinding at both ends applies torsional stress to the DNA. 
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1.2.2) Replication of chromatin 
DNA is organised into a higher-order structure, called chromatin. ~150 bp of DNA is wrapped 
twice around a histone octamer, termed a nucleosome, with 50-100 bp of 'linker' DNA between 
nucleosomes. To allow timely progression of a replication fork, nucleosomes must be dynamically 
disassembled downstream of the fork and reassembled upstream of it on the newly synthesised 
DNA. This was neatly demonstrated with an in vitro system, where the rate of replication of 
nucleosomal DNA by a reconstituted eukaryotic replisome was significantly increased by addition 
of purified FACT (facilitate chromatin transcription), a histone chaperone (Kurat et al., 2017). 
Nucleosome disruption is highly localised to the replication fork, and is thought to be brought about 
by either direct collision with the replicative helicase, or positive supercoiling in front of the fork. 
Additionally, CDK2•CyclinA is recruited to replication forks by interacting with PCNA and 
MCM7, and phosphorylates histone H1 which increases chromatin decompaction (Alabert and 
Groth, 2012). Histone chaperones FACT and ASF1 are associated with the replication fork (FACT 
directly binds MCM2-7 and moves with the fork), and function to recycle H3-H4 subunits of 
disrupted nucleosomes. Newly synthesised histone subunits H3-H4 are established on the nascent 
strands by CAF1 (chromatin assembly factor 1), with ASF1, and recruited to the fork by PCNA 
(Alabert and Groth, 2012, Falbo and Shen, 2006). Histones are extensively post-translationally 
modified, commonly by methylation, acetylation, phosphorylation or ubiquitylation. These 
modifications regulate a number of processes, some of which are inherited from one generation to 
the next, and are thus epigenetic. For example, gene expression is partly regulated by epigenetic 
histone modifications, if all disrupted nucleosomes on the parental strand are retained in both 
daughter strands, then the epigenetic marks that regulate gene expression will be diluted amongst 
the newly synthesised nucleosome components. It is observed by chromatin precipitation that 
specific histone modifications are restored as an ongoing process through the cell cycle up until G1, 
and it is suggested that some histone modifiers are recruited to their modification and propagate that 
same modification to nearby nucleosomes, such as PRC2 at H3K27me3, thus restoring the pre-
replicative concentration of histone modifications (Alabert and Groth, 2012). It is also thought that 
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PCNA rings remain on newly synthesised DNA in the wake of the replication fork and can recruit 
DNMT1 (DNA methyltransferase 1) to re-establish DNA methylation at CpG sites (Alabert and 
Groth, 2012).  
 
There are a number of factors that associate with chromatin that have the potential to impede 
replication fork progression, such as DNA damage repair or transcription, and will be introduced 
later. 
 
1.2.3) Spatial regulation of DNA replication 
In higher eukaryotes, origins of replication are organised into clusters at two main levels. Firstly, a 
'replication unit' which can contain several origins and span 50-100 kbp (Fragkos et al., 2015). 
Replication units contain several origins which have the potential to be activated, but only one of 
which is stochastically activated, implying that activation of one origin represses the activation of 
the rest in the replicating unit (Lebofsky et al., 2006). This phenomenon is called 'negative origin 
interference' and is thought to be mediated by CHK1 and CHK2 signalling (Brewer and Fangman, 
1993, Lebofsky et al., 2006, Fragkos et al., 2015), but it was also shown that passive replication of 
neighbouring origins is sufficient to explain this phenomenon (Blow and Ge, 2009). This affords 
flexibility; if one part of the replication unit cannot initiate replication, due to localised DNA 
damage, then another origin within the unit can compensate. The second level of origin organisation 
is replication clusters, which consists of several replication units, and can span up to 1 Mbp in 
length. Clusters are thought to correspond to replication foci, or replication factories, which are 
made visible by incorporation of a thymidine analogues that can be fluorescently labelled, such as 
BrdU (5-bromo-2'-deoxyuridine) during S phase (Berezney et al., 2000, Jackson and Pombo, 1998). 
Origins within a cluster are synchronously activated, by 'positive replication interference' 
(Marheineke and Hyrien, 2004). There are ~800 replication foci activated at the peak of S phase, 
each containing ~2-5 active activated origins (Jackson and Pombo, 1998). This was more recently 
confirmed by comparing the number of replication foci in HeLa cells expressing GFP-PCNA 
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between wide-field microscopy (which applies to ~800 replication foci quantified previously) and 
super-resolution microscopy, producing a ratio of ~1:5, and calculating the number of active 
replicons and finding that under the super-resolution microscope one replication foci approximately 
corresponds to one replicon (Chagin et al., 2016). It is thought that replication units correspond to 
chromatin loops, and that cohesion brings several chromatin loops together to form a replication 
cluster (Guillou et al., 2010, Fragkos et al., 2015). Replication foci are stable units of chromosome 
structure that last several cell cycles (Jackson and Pombo, 1998) and do not move, merge or divide 
(Leonhardt et al., 2000), indicating that they are specialised sites that facilitate replication, as 
opposed to random chromatin coalescence. 
 
1.2.4) Temporal regulation of DNA replication 
All the origins that are activated in a given S phase are not activated simultaneously. The eukaryotic 
genome is replicated in segments which are activated in a predictable order. This is evident when 
imaging replication foci at time-points throughout S phase. Human cells synchronised and released 
from the G1/S boundary were pulsed with BrdU, which when immunolabelled form distinctive 
patterns of replication foci that are highly reproducible. At the onset of S phase, replication foci 
quickly appear throughout the nucleus, by mid S phase the signal is strongest at the periphery of the 
nucleus and in late S phase a few large bodies of BrdU incorporation can be seen nearer the middle 
of the nucleus. Five distinct replication foci patterns emerge and occur in the same order with 
similar timing, and is conserved among higher eukaryotes (O'Keefe et al., 1992). The replication 
timing programme is likely a consequence of the complex chromosomal structures and folds, co-
regulation with transcription and limiting concentrations of replication factors. Early-replicating 
segments occupy domains within the nucleus that are gene-rich and associated with high levels of 
transcription, and euchromatin, and are also enriched with replication origins. It is possible that the 
decompacted state of euchromatin is more permissible to the formation of replication origins, thus 
reducing the initiation time of replication at those loci. Late replication is associated with repetitive 
elements, heterochromatin and lamina, at the nuclear periphery and are origin-poor (Rhind and 
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Gilbert, 2013, Fragkos et al., 2015). The primary DNA sequence can also correlate with early 
replicating segments. Early replicating segments are LINE-poor (long interspersed nuclear 
elements, retrotransposons that make up ~20% of the human genome) and isochore-rich (high GC% 
regions) (Rhind and Gilbert, 2013). Chromatin state and primary DNA sequence correlate with 
replication timing but are not sufficient to define it. The greatest determinant yet discovered for 
replication timing is the spatial organisation of chromosomes. Chromosome conformation capture is 
a sequencing technique that can determine the spatial organisation of interphase chromatin, 
whereby DNA is crosslinked, digested, self-ligated, reverse-crosslinked and then sequenced. This 
technique identifies associated domains of chromatin where the DNA interacts internally within the 
domain, but less so with DNA within other domains. The boundaries between these self-interacting 
domains bear a striking resemblance to the boundaries between early replicating and late replicating 
segments, indicating that replication timing is regulated by nuclear compartments defined by 
chromatin folding (Ryba et al., 2010, Rhind and Gilbert, 2013). Modelling the replication timing 
programme in the context of euchromatin and heterochromatin convincingly simulates the patterns 
of replication foci seen throughout S phase. Löb et al. 2016, created a model in 3D space whereby 
origins in euchromatin can stochastically activate at a high probability, and so activate randomly but 
early in S phase, and then with a 'domino-like affect' activate origins in adjacent self-interacting 
domains. The last DNA to be replicated is associated with heterochromatin, and visually mimics the 
S phase replication foci pattern timings originally observed by O'keefe et al. 1992 (Lob et al., 
2016). 
 
1.2.5) Replication origins and origin 'licensing' 
Although the factors that are recruited to and define an origin of replication are highly conserved 
among eukaryotes, the properties of the genomic loci to which those factors are recruited differ 
between yeasts and metazoans. The majority of S. cerevisiae origins contain a consensus sequence, 
which is an essential component of the conserved ARS (autonomous replication sequence) which 
contains three non-essential motifs, all together spanning just over 100 bp. ARSs provide binding 
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sites for replication factors, and are AT-rich, thus requiring less energy to melt the DNA duplex at 
the initiation of replication (Bell, 1995). However, in higher eukaryotes, such as in humans, no such 
replicative elements have been discovered. Certain properties of the primary sequence and 
chromatin correlate with replication origin positions, but are not sufficient to define them. Genomic 
loci at replication origins in human cells are often GC-rich, have uncompacted chromatin, as 
facilitated by histone acetylation, and have a G-quadruplex ~220 bp 3' of the site of initiation. 
Additionally, replication origins are excluded from sites of active transcription (Gilbert, 2001, 
Prioleau and MacAlpine, 2016). A minority of human replication origins do have sequence-defined 
sites, such as the origin within the β-globin locus (Aladjem, 2004). 
Whether origins are at defined genomic loci or stochastically distributed within a domain, there is a 
set series of events that make a genomic locus competent for DNA replication, the product of which 
is a complex of proteins on DNA called the pre-replicative complex (pre-RC). This process is 
known as replication origin 'licensing' and is highly conserved among eukaryotes, with only a few 
differences between S. cerevisiae and vertebrates. The first step is the binding of DNA by ORC 
(origin recognition complex), which is necessary but not sufficient for eventual origin activation. 
ORC is a hexameric (ORC1 through ORC6) AAA+ ATPase, and ORC must be bound to ATP for 
the complex to bind to the DNA (Bell and Dutta, 2002). However, reconstitution of licensing with 
purified Xenopus egg extract showed that ORC binding to DNA can take place in the presence of 
ADP (Gillespie et al., 2001). In humans, the complex contains a stable core of ORC2-5, that weakly 
interacts with ORC1 and ORC6 (Masai et al., 2010). ORC1 is synthesised from the beginning of G1 
and then proteolysed via SCFSKP2-mediated ubiquitylation during S phase (Mendez et al., 2002, 
Masai et al., 2010). ORC2-5 binds to the DNA-bound ORC1•ATP, forming ORC1-5. ORC6 is not 
essential for licensing in Xenopus or HeLa cells (Vashee et al., 2001, Gillespie et al., 2001), but is 
required for DNA replication (Li and Herskowitz, 1993). ATP-bound CDC6 binds to DNA-bound 
ORC, and is another AAA+ ATPase, highly related to ORC1 (Bell and Dutta, 2002). Cryo-electron 
microscopy (EM) indicates that ORC1-5 and CDC6•ATP form a ring structure of a similar size to 
MCM2-7 (Speck et al., 2005). The DNA-binding motifs of ORC1-5 are orientated towards the 
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lumen of the ring, indicating ORC1-5•CDC6 forms a ring around DNA. In S. cerevisiae, the 
ATPase activity of CDC6 destabilises its interaction with ORC, which is suppressed by binding 
origin DNA (Yardimci and Walter, 2014). In S. cerevisiae, DNA-bound ORC•CDC6 provides a 
platform for the loading of CDT1-bound MCM2-7. Like ORC and CDC6, MCM2-7 is a member of 
the AAA+ ATPase family of proteins, and the heterohexamer forms a ring shape with a positively 
charged central channel that is wide enough to contain dsDNA, and was confirmed to do so by EM 
of reconstituted licensing with S. cerevisiae proteins (Remus et al., 2009, Evrin et al., 2009). The 
interface between MCM2 and MCM5 in the heterohexamer is open, and was demonstrated to be a 
'gate' through which DNA passes, as MCM2-7 loading was blocked by inducing the dimerisation of 
fusion proteins MCM2-FRB and MCM5-FKBP (Samel et al., 2014). The six members of the 
MCM2-7 complex are parallel with respect to the N- and C-termini of each protein (Yardimci and 
Walter, 2014). CDT1 (Cdc10-dependant transcript 1) forms a soluble heptamer with MCM2-7 in S. 
cerevisiae (Tanaka and Diffley, 2002), that docks at ORC•CDC6 as a stable unit (Yardimci and 
Walter, 2014). Cryo-EM of the OCCM structure (ORC•CDC6•CDT1•MCM2-7) on DNA indicates 
that ORC•CDC6 behaves like a clamp-loader for MCM2-7•CDT1, whereby the helical 
conformation of ORC•CDC6 causes MCM2-7 to adopt a similar conformation once bound, which 
opens that MCM2-5 gate (Sun et al., 2013). CDT1 could cause the open conformational change 
required for MCM2-7 to wrap around DNA, as it binds primarily to MCM2, and partially to MCM5 
(Sun et al., 2013). The OCCM forms in vitro with a non-hydrolysable form of ATP, but is salt-
sensitive (Masai et al., 2010). In the OCCM, CDC6 is closest to the C-terminus of MCM3, which is 
required for the loading of MCM2-7 to ORC•CDC6, orientating the N-terminus side of MCM2-7 
away from the ORC (Frigola et al., 2013). Soon after OCCM formation, CDT1 dissociates 
dependent on ATP-hydrolysis by MCM (Coster et al., 2014), which forms the OCM. The OCM is a 
platform to load a second MCM2-7•CDT1 heptamer. The mechanism of this step is not yet clear, 
but is known to require a second molecule of CDC6, and ATP hydrolysis, and results in head-to-
head contact between the two MCM2-7 complexes loaded on DNA (Deegan and Diffley, 2016, 
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Yardimci and Walter, 2014, Remus et al., 2009). The head-to-head orientation of loaded double 
hexamers is likely the source of the bidirectionality of replication forks away from the origin upon 
initiation and elongation. Reconstitution of Xenopus and S. cerevisiae purified proteins 
demonstrated that, in vitro, MCM2-7, ORC1-6, CDT1 and CDC6 were necessary and sufficient to 
support formation of the pre-RC and to license origins for replication (Gillespie et al., 2001, Remus 
et al., 2009). 
 
1.2.6) Origin activation 
Given the salt-resistance of the MCM2-7 double hexamer on DNA, ORC, CDT1 and CDC6 could 
be dissociated from DNA, leaving the MCM2-7 double hexamer as the only component of the pre-
RC required for origin activation, in a reconstituted in vitro system (On et al., 2014, Rowles et al., 
1999, Yeeles et al., 2015). Activation of the double hexamer requires phosphorylation events from 
CDK2•CyclinA/E and from DDK (Dbf4-dependent kinase, DBF4•CDC7). As with CDKs, CDC7 is 
expressed throughout the cell cycle, but depends on complexing with DBF4 to become an active 
kinase, and as with CyclinA/E, DBF4 is upregulated during S phase, and therefore CDK and DDK 
function in parallel to activate licensed origins in S phase. Purified DDK phosphorylates the N-
termini of MCM2, MCM4 and MCM6 within the double hexamer, with little to no phosphorylation 
of their soluble forms (Francis et al., 2009). Phosphorylated MCMs facilitate the recruitment of 
CDC45 (Jares and Blow, 2000, Sheu and Stillman, 2006) and SLD3/7 (Tanaka et al., 2011). CDK 
phosphorylation of SLD2 and SLD3 (RECQL4 and Treslin in humans) at the double hexamer, 
facilitates their interaction with Dpb11 (TOPBP1 in humans, topoisomerase II-binding protein 1) 
(Zegerman and Diffley, 2007, Tanaka et al., 2007). Phosphorylation of SLD2 also increases its 
association with the heterotetramer GINS (SLD5, PSF1, PSF2, PSF3). CDC45 and GINS, like 
MCM2-7, are essential for elongation and colocalise at the replication fork, to form a complex 
called CMG (CDC45, MCM2-7, GINS) which is the replicative helicase (Moyer et al., 2006, 
Tanaka et al., 2007). Cryo-EM structures of double CMGs indicate that each MCM2-7 at an origin 
develops into a CMG prior to MCM separation, perhaps maintaining the CMGs in close proximity 
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may ensure coupled activation (Costa et al., 2014). Reconstitution of S. cerevisiae replication 
initiation with purified proteins demonstrated that the minimal set of proteins required for the pre-
initiation complex (pre-IC) are Mcm2-7, Cdc45, GINS, Sld2, Sld3/7, Dpb11 and pol ε, which were 
all necessary and sufficient (Yeeles et al., 2015). MCM10 is not required for CMG formation in this 
in vitro system, but is required for recruitment of the ssDNA binding protein RPA (replication 
protein A), which coats ssDNA to stabilise and protect it from degradation, implying that MCM10 
is required for CMG helicase activity (Yeeles et al., 2015). In addition to facilitating the recruitment 
of pre-IC components, MCM phosphorylation by DDK is thought to convert MCM2-7 from an 
inactive state in G1 to an active conformation in S phase. For example, the S. cerevisiae MCM5 
mutant bob1 (P83L) bypasses the requirement of DDK activity for activation of helicase activity, as 
proline is not a post-translation modification site and is often required for backbone structure in a 
peptide. bob1 mimics a conformational change in MCM2-7 that is normally caused by DDK 
activity (Hardy et al., 1997). 
 
1.2.7) Elongation 
Transitioning from the pre-IC to the RPC (replisome progression complex) requires melting of the 
origin DNA and switching MCM2-7s substrate from dsDNA to ssDNA, clamp loading of PCNA by 
RFC, recruitment of pol ɑ, checkpoint mediator MRC1, fork stabilisers TOF1 and CSM3, a 
homotrimer of CTF4, MCM10, topoisomerase I and FACT. 
 
The mechanism of DNA melting in eukaryotic origins is not known. A recent cryo-EM structure of 
a S. cerevisiae MCM2-7 double hexamer purified from G1 chromatin, with a resolution of 3.8 Å, 
reveals that the central channels of each hexamer are offset and twisted relative to one another, and 
are likely to cause a kink in the DNA that initiates melting of the duplex (Li et al., 2015). Whether 
MCM2-7 translocates dsDNA or ssDNA to facilitate unwinding was unknown, with several models 
proposed (Takahashi et al., 2005), but an experiment in Xenopus egg extract demonstrated that 
strand-specific fork obstruction stopped the progression of MCM2-7 on the translocation strand 
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(corresponds to the leading strand) but not on the excluded strand (corresponds to the lagging 
strand), favouring the 'steric exclusion' model over the 'ploughshare' model, and defining MCM2-7 
as a 3'-5' ssDNA translocase (Fu et al., 2011). How a salt-resistant MCM2-7 hexamer wrapped 
around dsDNA develops into a 3'-5' ssDNA translocase is not clear, but the authors speculate that 
following melting of dsDNA the MCM2/5 gate reopens during S phase and opposite ssDNA 
molecules are extruded from each hexamer, perhaps aided by MCM10, and the binding of CDC45 
and GINS at the MCM2/5 gate (as seen in cryo-EM structures (Costa et al., 2014)) closes the gate 
and activates the helicase (Fu et al., 2011). 
 
A number of components of the RPC were identified by mass spectrometry of proteins that were 
pulled out of S. cerevisiae cell lysate with purified GINS. Other than components of the CMG, 
TOF1, CSM3, MRC1, CTF4 and FACT were precipitated, with low levels of topoisomerase I and 
MCM10 (Gambus et al., 2006). CTF4 forms a homotrimer, and each molecule contains a domain 
that binds a motif found in multiple proteins called CIP-box (CTF4 interacting peptide), one 
valency of the trimer binds GINS and the other two can recruit multiple factors to the fork, crucially 
pol ɑ (Villa et al., 2016, Gambus et al., 2009). CTF4 is also important for establishing cohesion 
between sister-chromatids (Hanna et al., 2001). 
 
Once the two RPCs of an origin are established, leading and lagging strand synthesis can take place, 
as described previously, and the forks progress away from the origin bidirectionally, expanding the 
replication bubble. MCM2-7s on chromatin, that remain inactivated, are displaced from DNA by a 
replication fork from a nearby origin, a process known as passive replication (Yekezare et al., 2013, 
Santocanale and Diffley, 1996). 
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1.2.8) Termination 
The complicated DNA structure at converged replication forks must be resolved into two separate 
duplexes of DNA. A precise, and elegant, mechanism for eukaryotic termination has only recently 
been proposed. 
 
Firstly, experiments in S. cerevisiae and Xenopus egg extract revealed that polyubiquitylated 
MCM7 is enriched at the end of S phase and results in rapid disassembly of CMG, which is 
dependent on the activity of CDC48/p97 segregase (Moreno et al., 2014, Maric et al., 2014). In 
yeasts, ubiquitylation of Mcm7 was found to be SCFDia2-dependant, which was only visible in vivo 
after AID-degron-mediated depletion of Cdc48, indicating that MCM7 proteolysis is rapid 
following ubiquitylation (Maric et al., 2014). dia2Δ yeast cells, and blocked ubiquitylation of 
MCM7 in Xenopus egg extract could not dissemble their CMGs, which accumulated at the end of S 
phase (Moreno et al., 2014, Maric et al., 2014). It was previously shown that SCFDia2 is tethered to 
the RPC via a domain that facilitates binding to CTF4 and MRC1 (Morohashi et al., 2009), so it is 
not clear how SCFDia2 is regulated to target only terminated CMGs for degradation. 
 
Secondly, experiments in Xenopus egg extract on plasmid constructs with site-specific replication 
fork barriers revealed that converging CMGs pass each other without slowing, as opposed to 
colliding, and continue until the strand along which they translocate interfaces with the excluded 
strand of the other fork (Dewar et al., 2015). The CMGs do not dissociate from the DNA until the 
gaps between the leading strand of one fork is ligated to the last Okazaki fragment of the other fork, 
implying that MCM2-7 is unloaded from dsDNA (Dewar et al., 2015). This is consistent with in 
vitro experiments where purified MCM2-7 was capable of translocating along a 3' ssDNA overhang 
and continued when MCM2-7 encountered dsDNA (Kang et al., 2012). Dewar et al. 2015 speculate 
that MCM2-7 on dsDNA is the substrate for SCFDia2-mediated ubiquitylation, differentiating 
terminated CMGs from active CMGs. 
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1.2.9) Dormant origins. 
A series of observations demonstrate that origin licensing does not always conform to the model 
described above, and are collectively termed the 'MCM paradox' (Hyrien et al., 2003). The number 
of MCM2-7 double hexamers loaded onto chromatin in S. cerevisiae, Xenopus egg extract and 
human cells is well in excess of the number of initiation events at origins (Blow and Dutta, 2005, 
Burkhart et al., 1995, Lei et al., 1996, Mahbubani et al., 1997). MCM2-7 double hexamers were 
also observed to be distributed at significant distances away from the ORC. In vitro experiments in 
Xenopus egg extract revealed that the quantity of MCM on synthetic DNA molecules with one ORC 
increased linearly with the length of DNA, up until ~3 kbp (~35 double hexamers) (Edwards et al., 
2002). Immunoprecipitation of crosslinked nucleoproteins with MCM antibodies, followed by 
shearing and fractionation, revealed that MCM can be on DNA up to ~1 kbp away from an ORC in 
HeLa cells (~10 double hexamers) (Ritzi et al., 1998). Additionally, sites of DNA synthesis only 
contain a fraction of the chromatin-bound MCM complexes (Blow and Dutta, 2005, Dimitrova et 
al., 1999, Krude et al., 1996, Madine et al., 1995). Xenopus egg extract can support a normal 
replication rate after reducing the availability of MCMs to ~1-2 per active origin (Blow and Dutta, 
2005, Edwards et al., 2002, Mahbubani et al., 1997, Woodward et al., 2006), and the affinity of 
CDC6 for origins is reduced once they are licensed (Oehlmann et al., 2004). Together, these 
observations indicate that a significant proportion of MCM2-7 is loaded onto chromatin but are 
rarely activated. It is estimated that ~30% of licensed origins are stochastically activated in a given 
S phase (Blow and Ge, 2009, Blow et al., 2011, Ge et al., 2007, Ibarra et al., 2008, Woodward et 
al., 2006). 
 
It was hypothesised that the excess origins could be activated in response to insufficient replication 
from the ~30% of origins that are normally activated (Hyrien et al., 2003, Edwards et al., 2002, 
Blow and Dutta, 2005). Supplementing Xenopus egg extract with increasing concentrations of the 
CDT1 inhibitor geminin can be used to limit licensing up until replication dynamics are affected, a 
state termed 'minimal licensing' (Oehlmann et al., 2004, Woodward et al., 2006). Minimally 
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licensed extracts exhibited a normal frequency of origin activations but are unable to complete 
replication when treated with low doses of replication inhibitors such as aphidicolin and the ATR 
(ataxia telangiectasia and rad3 related protein) inhibitor caffeine, where normally licensed extracts 
could (Woodward et al., 2006). In human cells, a ~50% depletion of licensed origins had no 
significant effect on the frequency of origin activations compared to control cells. When treated 
with HU, depleted cells did not activate dormant origins, had a reduced nucleotide incorporation 
rate and were hypersensitive compared to control cells (Ge et al., 2007). 
 
Taken together, CDC6 has the potential to load multiple copies of MCM2-7 at one ORC. Within an 
origin cluster, each origin has the potential to be stochastically activated, and when one is it 
supresses the activation of neighbouring origins by passive replication. When faced with replication 
stress, and fork progression is slowed or stopped, then other origins within the cluster stochastically 
activate (Alver et al., 2014, Blow and Ge, 2009). Disruption of replication forks causes a 
decoupling of the CMG and the polymerases, which increases the exposure of RPA-coated ssDNA 
that is threaded between them, and is the substrate for ATR recruitment and activation (Branzei and 
Foiani, 2009). ATR activates CHK1 DNA damage checkpoint kinase, which inhibits the activation 
of new replication factories but permits the activation of new origins within already activated 
factories (Alver et al., 2014, Ge and Blow, 2010). As discussed in Blow and Ge, 2009, this model 
makes evolutionary sense as licensing inefficient dormant origins, that will only be activated where 
needed and after the majority of replication has already taken place, is less demanding on cellular 
resources than the addition of efficient origins at the relevant sites (Blow and Ge, 2009). This is 
supported by experiments in human cells where inhibition of ATR caused unrestrained origin 
activation which caused depletion of the cellular pool of RPA, and thus the unprotected ssDNA at 
replication forks developed into DNA damage (Toledo et al., 2013). RPA is rate-limiting on the 
number of replication forks that can be active at once, so dormant origins which only become active 
if a nearby efficient origin stalls, will not significant contribute to the total rate. 
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1.3) The licensing system 
The licensing system is an elegant solution to ensure complete replication of the genome without 
replicating any section more than once (Blow and Laskey, 1988). This is achieved by strictly 
separating the biochemistry that drives origin licensing from origin activation. The first step is to 
load MCM hexamers onto chromatin from late mitosis and throughout G1. The second step begins 
at the G1/S transition, where the loading of MCMs is strictly halted and origins are activated. These 
two steps must not overlap as the cell would have nothing to biochemically differentiate an origin 
that requires MCM2-7 for activation, and an origin that has already been replicated. If licensing 
were permitted to take place in S phase then replicated origins will be relicensed and re-replicated. 
However, although the licensing system effectively prevents re-replication, it creates additional 
challenges to ensure that all of the genome is duplicated. As licensing cannot take place in S phase, 
the origins that are licensed must be sufficient to support replication of the entire genome. In the 
event of replication stress, no new replication factors can be recruited to rescue replication. The 
loading of MCM2-7 at an origin licenses it for activity, and when that origin is activated the MCM 
complexes elongate away from the origin as part of the replicative helicase CMG, thus when S 
phase begins the origin loses its license, which cannot be regained until after the following mitosis 
(Blow and Laskey, 1988).  
 
The licensing system is tightly regulated at multiple levels by the cell cycle. Licensing is limited to 
late mitosis and early G1 largely by the regulation of ORC, CDC6 and CDT1, as they are required 
for licensing, but not for replication (Blow and Dutta, 2005). The mechanism by which licensing is 
limited to late mitosis and G1 varies between lower and higher eukaryotes. In yeasts, CDK activity 
is high from the G1/S transition through to late mitosis, and phosphorylates MCM, ORC1, CDC6 
and CDT1 (Arias and Walter, 2007, Blow and Dutta, 2005). Phosphorylation of CDC6 signals it for 
proteolysis via ubiquitylation by SCFCdc4, and causes it to form a stable association with mitotic 
CDKs, disabling its licensing activity, additionally, CDK inhibits CDC6 transcription by blocking 
the nuclear import of transcription factor Swi5 (Arias and Walter, 2007). Phosphorylation of 
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MCM2-7 by CDK results in its export from the nucleus (Liku et al., 2005), along with CDT1, due 
to their association (Tanaka and Diffley, 2002). CDK phosphorylation of Orc2 and Orc6, inhibits 
ORC function, and the yeast S phase Cyclin Clb5 binds directly to Orc6 after origin activation, 
inhibiting the formation of a pre-RC (Arias and Walter, 2007, Wilmes et al., 2004). Inhibition of 
any one of these six processes is not sufficient to cause significant re-replication, nor is inhibition of 
different combinations of two or three, only when most, or all but one, are inhibited does re-
replication take place (Nguyen et al., 2001). The unit of re-replication is the number of origins that 
are relicensed and activated. In S. cerevisiae, there are ~500 origins, so if relicensing is supressed 
with a 99% efficiency then re-replication will occur from ~5 origins. The redundancy of inhibition 
of pre-RC components during yeast S phases not only makes repression of re-replication robust, but 
also combine together to repress even a single origin of re-replication from occurring. For example, 
two mechanisms that each repress re-replication with a 99% efficiency would combine together to 
suppress re-replication with a 99.99% efficiency. 
 
In metazoans, licensing is largely restricted to late mitosis and G1 by the inhibition of CDT1 
activity. This is achieved by the degradation of CDT1 and inactivation by the coiled-coil protein 
geminin. The synthesis of CDT1 remains relatively constant throughout the cell cycle but protein 
levels decline during S phase (Nishitani et al., 2001). Proteolysis of CDT1 is mediated by two 
different E3 ubiquitin ligases. CDT1 binds to chromatin-bound PCNA via its PIP (PCNA-
interacting protein) box, restricting this process to S phase, and is then bound by CUL4-DDB1CDT2 
which ubiquitylates CDT1, targeting it for destruction (Arias and Walter, 2007, Blow and Dutta, 
2005). CDT1 is also phosphorylated by CDK activity in S and G2 phase, which targets it for 
ubiquitylation by SCFSKP2, and thus proteolysis (Takeda et al., 2005). Geminin binds CDT1 to 
physically block its interactions with MCM2-7 (Lee et al., 2004, Xouri et al., 2007). Geminin is 
marked for proteolysis, or inactivation, by the APC/C, which means that geminin activity is reduced 
in late mitosis and early G1, thus CDT1 is able to function as a licensing factor following mitosis 
and up until the transition to S phase (Arias and Walter, 2007, Blow and Dutta, 2005). Proteolysis 
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of CDT1 by SCFSKP2 is blocked when geminin binds CDT1, and CUL4-DDB1CDT2 activity is 
switched off after S phase, so CDT1•geminin complexes accumulate from G2 through to mitosis 
(Arias and Walter, 2007). The APC/C mediates the destruction of geminin, which means that a free 
pool of CDT1 is immediately available for licensing as cells exit mitosis (Arias and Walter, 2007). 
 
1.3.1) Over-replication 
Unprogrammed re-replication can be highly deleterious in eukaryotic cells by increasing gene 
dosage, causing DNA damage, and reducing genomic stability. Overexpression of licensing factors 
is a hallmark and prognostic of many cancers (Blow and Gillespie, 2008), but it is not clear whether 
that is what drove tumorigenesis or is a consequence of a deregulated proliferation. A study of 
CDT1 and CDC6 expression levels of lung, colon and head-and-neck cancers found no correlation 
between the >4-fold overexpression of CDT1 and CDC6 with the proliferation marker Ki-67, 
leading the authors to hypothesise that in the absence of functional p53, re-replication caused the 
DNA damage and genomic instability that resulted in tumorigenesis (Karakaidos et al., 2004, 
Liontos et al., 2007). 
 
A mutant S. cerevisiae cell line, where CDK regulation of Orc2, Orc6, Mcm2-7 and Cdc6 is 
blocked, undergoes re-replication and its chromosomes become fragmented (Green and Li, 2005). 
A Rad9-dependent and Mrc1-independent checkpoint is activated by re-replication, indicating that 
DNA damage has been caused, rather than stalled forks and replication stress (Green and Li, 2005). 
Similar experiments in mammalian cells which are geminin, DDB1 or CDT2 mutants (so CDT1 
levels remain high in S phase and beyond) exhibit increased ɣ-H2AX foci (double strand breaks, 
DSBs) and activate CHK1 and CHK2 which downregulate CDK1 and thereby entry into mitosis 
(Zhu and Dutta, 2006, Lovejoy et al., 2006, Jin et al., 2006, Zhu et al., 2004, Melixetian et al., 
2004). Inhibition of CHK1 in these experiments forced cells to enter mitosis and resulted in mitotic 
catastrophe and apoptosis. 
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A similar experiment shows that Xenopus egg extract supplemented with purified CDT1 causes re-
replication and CHK1 activation (Li and Blow, 2005). One way in which re-replication has been 
proposed to cause DSBs is a head-to-tail collision between a re-replicative fork and the replicative 
fork from the same origin (Davidson et al., 2006). 
 
1.3.2) Under-replication 
In contrast to over-replication, where licensing overlaps with S phase, under-replication can occur 
when S phase begins before a sufficient number of origins are licensed. Under-replication directly 
causes genomic instability as fork structures in the DNA are unstable, and can indirectly contribute 
to genome instability by physically linking sister-chromatids, a structure that must be resolved for 
errorless segregation during anaphase. A MCM4 hypomorphic mouse model exhibited increased 
chromosome breaks and micronuclei when treated with aphidicolin, had a reduced ability to activate 
dormant origins, and were prone to adenocarcinomas (Shima et al., 2007). A similar study found 
that mice with reduced MCM2 levels also exhibited increased frequencies of micronuclei and ɣ-
H2AX (Pruitt et al., 2007). Overexpression of CyclinE causes a reduction in licensing in human 
cells (Ekholm-Reed et al., 2004), genomic instability and tumorigenesis in mice (Loeb et al., 2005, 
Spruck et al., 1999) and triggers the DNA damage response (DDR) and eventual senescence in a 
primary human cell line (Bartkova et al., 2006). 
 
1.4) Replication fork stalling 
In addition to insufficient origin licensing, under-replication can be caused by slowed or stopped 
replication fork progression. 
 
1.4.1) Fork stalling 
The progression of replication forks can be stalled. However, origins are licensed in excess to levels 
that reduce the impact of fork stalling. Firstly, as previously mentioned, many more origins are 
licensed than are typically used in a given S phase, and otherwise dormant origins can be 
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stochastically activated to rescue a replicon from fork stalls. Secondly, more origins are activated, 
even in the absence of replication stress, than are strictly necessary to complete replication within 
the time constraint of S phase. For example, initiation events in human cells are a mean of ~100 kbp 
apart (Conti et al., 2007, Jackson and Pombo, 1998), so the mean number of bases a fork replicates 
is ~50 kbp, yet each fork can potentially replicate DNA in the order of megabases (Blow and Ge, 
2008, Newman et al., 2013). The excess initiation events reduce the total time for complete 
replication of the genome, but will also mean that a fork stall from one origin can still terminate 
with the corresponding fork from the neighbouring origin. 
 
There are multiple causes of replication fork stalling, including DNA adducts, single strand breaks, 
collision with transcription factors, DNA-bound proteins, ssDNA secondary structures and torsional 
and topological stress (Mankouri et al., 2013). Additionally, exogenous reagents can be used to stall 
replication forks. Commonly used examples include, aphidicolin, a pol ɑ inhibitor, and 
hydroxyurea, an inhibitor of ribonucleotide reductase, which results in the depletion of the pool of 
dNTPs. 
 
1.4.2) Checkpoint signalling 
If a sufficient number of replication forks stall, this will be detected by cell cycle checkpoints that 
either protect the cell from exacerbating damage by transmitting it through complex cellular 
processes such as S phase and mitosis, irreversibly hold the cell in a state of senescence or activate 
apoptosis. The two main checkpoint sensors are ATR and ATM (ataxia telangiectasia mutated), 
both of which belong to the phosphatidylinositol 3-kinase-related kinase family, which 
phosphorylates S/TQ motifs. Targets of these kinases include transducers CHK1 and CHK2 which 
acts upon effectors such as p53, DDK, and CDC25, which can trigger cell cycle arrest prior to S 
phase, mid-S phase and mitosis, respectively (Sancar et al., 2004, Blackford and Jackson, 2017). 
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ATR-mediated checkpoint activation is associated with replication stress. The main phenomenon 
detected by the ATR pathway is long tracks of ssDNA coated by RPA. As mentioned previously, 
decoupling of the replicative helicase, CMG, from the DNA polymerases within a fork cause the 
ssDNA between the two to become extruded, exposing a track of RPA-coated ssDNA (Branzei and 
Foiani, 2009). Tracks of RPA recruit ATRIP (ATR-interaction protein) which in turn recruits ATR 
to ssDNA (Cortez et al., 2001). RPA is also bound by RFCRAD17, which clamp-loads the PCNA-like 
heterotrimeric 9-1-1 complex (RAD9, HUS1, RAD1), which activates RPA-recruited ATR. ATR 
activates RPC-component MRC1, which recruits RAD17 and together facilitates phosphorylation of 
CHK1 (Blackford and Jackson, 2017). Activated CHK1 stabilises MRC1 at the RPC, completing a 
positive feedback loop that amplifies ATR signalling at a stalled fork. Once activated by 
phosphorylation, CHK1 is released from the fork and transduces the stress signal to p53, CDC25 
and DDK (among others) (Blackford and Jackson, 2017). ATR and CHK1 is in constant feedback 
with fork progression, and is required for normal fork progression in unperturbed S phases 
(Petermann et al., 2006). Depletion of ATR activity is mouse embryonic lethal and stops 
proliferation of cells or cell death in the absence of induced replication stress or DNA damage (de 
Klein et al., 2000, Brown and Baltimore, 2000). 
 
ATM-mediated checkpoint activation is associated with DSBs. A proportion of stalled replication 
forks collapse, forming a DSB, either by endonucleolytic cleavage of replication intermediates or if 
the fork encounters a ssDNA lesion (Yeeles et al., 2013, Berti and Vindigni, 2016). One of the first 
responders to a DSB is the MRN complex (MRE11, RAD50, NBS1), which binds the DSB ends, 
and stabilises them at the break. ATM is recruited to the break by MRN, and upon activation 
phosphorylates local modified histone H2AX, forming ɣ-H2AX. MDC1 binds ɣ-H2AX, which 
facilitates the recruitment of more MRN complexes which further recruits and activates ATM 
(Sancar et al., 2004, Blackford and Jackson, 2017). This positive feedback loop at DSBs amplifies 
ATM signalling to enhance activation of a DNA damage checkpoint. ɣ-H2AX functions as a 
docking site for many DNA damage repair factors, including 53BP1, BRCA1/2 and RAD51 
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(Sancar et al., 2004, Blackford and Jackson, 2017). One of the other targets of ATM 
phosphorylation is CHK2, which targets a variety of substrates, including some that overlap with 
CHK1. 
 
1.4.3) Resistance and recovery of replication forks under stress 
In addition to the redundancy in the number of activated origins, another mechanism that reduces 
the impact of replication fork stalls is fork restart, whereby some stalled replication forks can be 
restarted by ATR-mediated fork repriming, upregulation of dNTP concentrations or fork 
remodelling (Berti and Vindigni, 2016). 
 
Base modifications on one strand of the DNA do not block the progression of the replicative 
helicase, but can physically block polymerases, causing them to uncouple and expose a long track 
of ssDNA. Due to the dynamic nature of lagging strand synthesis, a modified base is tolerated there 
and causes a ssDNA lesion approximately the size of 1 or 2 Okazaki fragments (Yeeles et al., 
2013). However, a modified base on the leading strand is not so easily tolerated. When a fork 
encounters a leading strand DNA lesion, pol ε is blocked and a specialised, yet low-fidelity, 
polymerase can be recruited to use the lesion-containing DNA as a template, and once the lesion is 
bypassed pol ε can resume. The specialised polymerases are known as lesion-bypass DNA 
polymerases, which include pol η, κ, ι, ν, θ and REV1, 3L/7 (Sale et al., 2012), and the process in 
which they function is known as translesion synthesis (TLS). Recruitment of lesion-bypass 
polymerases is facilitated by ubiquitylation of PCNA by RAD6 and RAD18. It was initially thought 
that leading strand DNA synthesis is continuous and could only be primed at origins. However, the 
ssDNA lesions seen in the replicated strand after forks encounter a lagging strand lesion can also be 
seen in the leading strand when forks encounter a leading strand lesion (Lopes et al., 2006), 
implying that repriming can take place on the leading strand as an alternative to TLS. Repriming is 
facilitated by PrimPol, originally discovered in archaea and only more recently discovered in 
eukaryotes, and is the only known eukaryotic polymerase that can prime its own synthesis or prime 
	 36	
with DNA (Garcia-Gomez et al., 2013, Mouron et al., 2013). PrimPol can also function as a TLS 
polymerase (Mouron et al., 2013). The ssDNA lesions in the replicated DNA, caused by leading or 
lagging strand base modifications, are repaired by homology-directed repair, or by TLS (Yeeles et 
al., 2013, Berti and Vindigni, 2016). 
 
TLS is categorised as a DNA damage tolerance (DDT) mechanism. Another DDT mechanism is 
fork reversal. When the progression of a fork is blocked on the leading strand, the newly 
synthesised DNA of both the leading and lagging strand can anneal, causing the fork to form a 
‘chicken foot’ structure that resembles a Holliday junction (Neelsen and Lopes, 2015). Sub-lethal 
doses of topoisomerase I inhibitor do not cause DSBs in eukaryotes, previously thought to be a 
direct consequence of topoisomerase I inhibition, but instead cause large amounts of replication 
fork reversal (Ray Chaudhuri et al., 2012). Additionally, combining the topoisomerase treatment 
with inactivation of PARP1 (poly(ADP-ribose) polymerase 1), an essential fork reversal factor, 
increases DNA breaks, indicating that fork reversal protects genomic stability against aberrant 
replication (Ray Chaudhuri et al., 2012). Fork reversal is not unique to topoisomerase I inhibition, 
and has been identified as a global responder to replication stress in human cells (Zellweger et al., 
2015). Additionally, fork reversal is a physiological process that occurs at a low frequency in 
unperturbed and untransformed human cells (Zellweger et al., 2015, Ray Chaudhuri et al., 2012, 
Neelsen and Lopes, 2015). It is not fully understood how replication forks are reversed. In vitro 
experiments reveal that a series of DNA translocases can support fork reversal, as well as a few 
helicases, including RECQ family members BLM (Bloom syndrome protein) and WRN (Werner 
syndrome protein) (Berti and Vindigni, 2016). Also implicated in fork reversal are DSB-
independent roles for recombination factors, especially RAD51 (Petermann et al., 2010, Zellweger 
et al., 2015, Berti and Vindigni, 2016). It is thought that RAD51 is recruited to stalled forks and 
replaces RPA at the leading strand ssDNA lesion, causing the leading strand template to re-anneal 
to the lagging strand template (opposite of helicase activity, reversal). The newly synthesised 
strands are then free to anneal, forming the Holliday junction, and RAD51 may be recruited again to 
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the ssDNA overhang of the newly annealed duplex, and facilitate strand invasion to the 
corresponding homologous sequence in front of the reversed fork (see figure 3A of Neelson and 
Lopes, 2015) (Zellweger et al., 2015, Neelsen and Lopes, 2015). An alternative pathway to 
restarting reversed forks involves the helicase activity of RECQ1, as regulated by PARP1, which 
inhibits RECQ1 until the DNA damage that caused the fork to stall is repaired (Berti et al., 2013, 
Berti and Vindigni, 2016). Another pathway includes the DNA2 nuclease and WRN helicase which 
function together to resect the annealed newly synthesised DNA, creating a 3’ overhang, which is 
the preferential substrate for the SWI/SNF-related translocase SMARCAL1, which can convert 
Holliday junctions into functional replication forks (Betous et al., 2013, Berti and Vindigni, 2016). 
 
Replication forks can also be restarted after uncoupling between the CMG and polymerases without 
reversing first. The long track of RPA-coated ssDNA in the leading strand can be primed by pol ɑ-
primase, which requires the replication initiation factor TOPBP1 (Yeeles et al., 2013), both of 
which promote the recruitment of the 9-1-1 complex, and thus contribute to the activation of ATR 
(Yan and Michael, 2009). 
 
1.4.4) ‘Double fork stalling’ 
Despite the measures taken to reduce the impact of fork stalling, it is still theoretically possible that 
two converging replication forks from neighbouring origins may both irreversibly stall, with no 
intervening dormant origins, a phenomenon termed a ‘double fork stall’ (DFS). Figure 1 is a simple 
schematic of how a DFS may occur. Four replication origins (W, X, Y and Z) are on a generic 
section of DNA, and are licensed with MCM2-7 double hexamers (blue). Upon the onset of S 
phase, MCMs are activated and forks progress (pink). Origins W, Y and Z are activated, and X 
remains dormant. The right-hand fork of origin W (WR) and the left-hand fork of origin Y (YL) both 
stall, however, dormant origin X is stochastically activated and completes replication of its replicon. 
YR and ZL also stalled, but in the absence of a dormant origin or fork restart, the intervening  
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Figure 1: Double fork stalling. Cartoon depicting how replication forks that 
irreversibly stall can result in a double fork stall. Four replication origins have been 
licensed as indicated by the blue double hexamers (W, X, Y and Z). Elongating 
replication forks are coloured pink. Irreversible fork stalling is indicated by red crosses.
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segment of DNA remains unreplicated. If left intact through to mitosis, the unreplicated DNA will 
physically link sister-chromatids and interfere with chromosome segregation in anaphase. 
 
1.5) Replication origin mapping 
As mentioned previously, S. cerevisiae origins were discovered to have an AT-rich 11-17 bp 
consensus sequence termed ACS (ARS consequence sequence). There are ~12000 ACSs in the ~11 
Mbp haploid S. cerevisiae genome, but only ~500 are functional replication origins (Nieduszynski 
et al., 2007, Siow et al., 2012). ACSs require cis-acting sequence elements which include three 
other domains (B1, B2 and B3), together spanning a ~200 bp domain comprising the ARS. 
Additionally, transcription ablates origin activation, and chromatin structure can aid ORC 
recruitment (Nieduszynski et al., 2007, Siow et al., 2012). S. cerevisiae origins were then confirmed 
or dismissed by assays including 2D-gel electrophoresis, that detects intermediate replication DNA 
structures at specific origins, and genome-wide approaches that either detect origin-associated 
proteins or DNA synthesis (Nieduszynski et al., 2007, Siow et al., 2012). 
 
In human cells, but also generally applicable to higher-eukaryotes, there is no origin consensus 
sequence as there are in yeasts. A small number of well-studied efficient human origins are 
restricted to specific genomic loci, but with no identifiable commonality that might function to 
promote pre-RC formation. More recently, genome sequencing technologies have provided 
comprehensive surveys of origin activation (Prioleau and MacAlpine, 2016). Origin mapping has 
also been attempted by chromatin immunoprecipitation of pre-RC components such as ORC and 
MCM. However, not all ORC binding sites are replication origins, and not all licensed origins are 
activated, so, although these methods may identify where origins potentially form, they are not 
informative of where replication forks will be activated. With respect to DFSs, active origins are 
more relevant so genome-wide sequencing techniques that detect active replication are summarised 
below. 
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Sequencing of short nascent strands (SNS) is designed to capture the 5’ region of the leading strand, 
which corresponds to the DNA that is first replicated at each activated origin. In summary, this is 
usually achieved by heat denaturation of genomic material followed by sucrose gradient 
fractionation. The fraction that contains ~0.5-2.5 kbp DNA fragments is selected and digested with 
excess λ-exonuclease, purified and sequenced using next-generation Illumina technology. The 
sequenced reads are then mapped to a reference genome of the relevant cell type. Nascent strands 
feature a ~20 bp RNA primer at their 5’ end, but includes Okazaki fragments in addition to the 
leading strand. Selecting for >500 bp fragments after heat denaturation will enrich leading strand 
fragments, and select against Okazaki fragments. λ-exonuclease is a 5’ to 3’ DNA exonuclease, and 
will digest DNA fragments without an RNA primer, and is used in excess as the enzyme has a bias 
against certain DNA sequences, such as G-quadruplexes, that would cause the inclusion of false 
positives (Foulk et al., 2015). SNS sequencing is able to resolve origins to less than1000 bp 
(Prioleau and MacAlpine, 2016). Genome-wide SNS sequencing in a variety of human cells, 
including HeLa and IMR-90, identified 80,000-250,000 replication origins (Cayrou et al., 2015, 
Besnard et al., 2012, Martin et al., 2011, Picard et al., 2014). In one study, the origin positions were 
compared between multiple human cell lines and it was found that a third of the total mapped 
origins overlapped between cell lines (Besnard et al., 2012, Picard et al., 2014). These origins are at 
well-defined positions and are associated with CpG islands and DNase hypersensitive chromatin 
(open chromatin) (Cayrou et al., 2015, Besnard et al., 2012, Martin et al., 2011). CpG islands are 
more commonly associated with promotion of transcription, but may have a dual role. Although a 
significant proportion of origins are associated with CpG islands and open chromatin, these features 
are neither necessary nor sufficient to define a genomic locus as an origin (Prioleau and MacAlpine, 
2016). 
 
Low percentage agarose can be used to trap replication intermediate bubble-structures	(Mesner et 
al., 2006). Prior to bubble trapping, the chromosome must be fragmented by restriction digestion, 
which limits the resolution of origin position to the positions of restriction sites (Prioleau and 
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MacAlpine, 2016). In human cell line GM06990, whole-genome bubble-seq identified ~120,000 
origins, which largely occupy initiation zones, and revealed that they are enriched at DNase 
hypersensitive chromatin, and early origins are associated with actively transcribed genes, in partial 
concordance with the SNS-seq experiments (Mesner et al., 2013). 
 
At replication origins, there is a sharp transition on each individual DNA strand between the 
continuously (leading) and discontinuously (lagging) synthesised DNA fragments. Genome-wide 
mapping of Okazaki fragments in S. cerevisiae cells was facilitated by inactivation of DNA ligase I 
(Smith and Whitehouse, 2012). Replication origins largely corresponded to the transition of 
Okazaki fragments mapping to one strand and then the other (Smith and Whitehouse, 2012). The 
same technique was applied to human cells where only 66 origins could be identified by a sharp 
transition that occurred within a 5 kbp window. However, broad initiation zones were identified, 
and were on average ~30 kbp in length (Petryk et al., 2016). As with SNS- and bubble-seq, the OK-
seq initiation zones corresponded to CpG islands and expressed genes (Petryk et al., 2016, Prioleau 
and MacAlpine, 2016). Additionally, OK-seq revealed that the direction of replication is co-
orientated with the direction of transcription, potentially to reduce the frequency of head-to-head 
collision between replicative and transcriptional machinery (Petryk et al., 2016, Prioleau and 
MacAlpine, 2016). 
 
Collating the origin mapping data of human cells using the methods described above highlights the 
stochastic nature of origin positioning and activation, and how this contrasts to yeasts, where the 
genomic positions of most origins are known at base pair-resolution and the efficiency of many 
origins characterised. There is a low level of concordance in origin positions in human cells from 
inter- or intralab-datasets, which is likely due to the stochastic nature of human origin licensing and 
activation, innate biases of the different techniques used and differences between the cell lines used. 
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1.6) Common fragile sites and mechanisms for responding to under-replication 
The first results chapter will open with theoretical approaches to predicting the frequency of DFSs 
in a given human cell S phase. The rest of the results presented in this thesis will first provide 
evidence for the validity of the model (chapter 3), and then follow-up with other cellular responses 
(chapter 4). Candidates for factors involved in the response to DFSs were inspired by research into 
CFSs (common fragile sites), which will be introduced here. 
 
CFSs are specific genomic loci, of which there are ~90 throughout the genome of cultured human 
somatic cells (Durkin and Glover, 2007), where breaks occur in chromatid arms, observable in 
metaphase chromosomes (Glover et al., 1984). These sites are hyper-sensitive to replicative stress, 
such as treatment with a low concentration of the replicative polymerase inhibitor aphidicolin, after 
which they reliably develop into breaks, which was how a large proportion of these sites were 
defined (Glover et al., 1984). More recently, in work largely carried out by Professor Ian Hickson 
and colleagues, it was discovered that a subset of CFSs can become connected between sister-
chromatid arms during anaphase, forming a structure termed an ultrafine anaphase bridge (Chan et 
al., 2007) (UFB). These structures are undetectable by DAPI staining, and do not contain histones; 
distinguishing them from previously described ‘bulky’ anaphase bridges that are often lagging 
chromosome arms (Chan et al., 2007). UFBs are detected by proteins that coat the structure: BLM 
helicase complex, which includes BLM helicase (Bloom’s syndrome protein), topoisomerase IIIɑ, 
RMI1 and RMI2 (RecQ-mediated genome instability 1 and 2), and PICH (PLK1-interacting 
checkpoint helicase) (Baumann et al., 2007, Chan and Hickson, 2009, Chan et al., 2007). This 
composition of repair proteins maintains genome stability, and can facilitate branch migration in the 
resolution of Holliday junctions and disentangle DNA catenanes (Bachrati and Hickson, 2009, 
Bizard and Hickson, 2014, Chan et al., 2007, Karow et al., 2000, Mankouri and Hickson, 2007). 
BLM is a RecQ-like helicase that can unwind a variety of DNA substrates (Brosh et al., 2001, 
Karow et al., 1997, Mohaghegh et al., 2001, Sun et al., 1998). BLM is defective in sufferers of 
Bloom syndrome, who are prone to tumours, retarded growth and light sensitivity. BLM syndrome 
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cells exhibit an increased frequency of micronuclei (segments of chromosomes that are broken 
away and not segregated correctly during anaphase; their presence is a sign of genomic instability) 
(Chan et al., 2009, German, 1993, Rosin and German, 1985). It has been proposed that the BLM 
complex functions to resolve segregation of genomic loci that are sensitive to replication stress 
(Chan et al., 2007, Chan et al., 2009, Liu et al., 2014). Cells that lack BLM were less able to restart 
replication forks following treatment and release from aphidicolin (Davies et al., 2007).  
 
The frequency of UFBs increases in cells treated with low concentrations of aphidicolin (Chan et 
al., 2009). The frequency of UFBs stained by PICH increases in a BLM-deleted cell line ,and BLM 
is only recruited to bridges in anaphase that are coated by PICH in metaphase (Chan et al., 2007). 
There are two types of UFB bridges described which are distinguished by the presence or absence 
of a FANCD2/I foci at the termini of each bridge (Chan et al., 2009). FANCD2 and FANCI are two 
members of nineteen in the Fanconi anaemia complex (FA complex) which has a well described 
role in DNA repair, especially repair of inter-strand cross-linked (ICL) DNA (Moldovan and 
D'Andrea, 2009). A mutation in any of these nineteen genes causes Fanconi anaemia, a disease with 
characteristics that overlap with Bloom’s syndrome, that include cancer predisposition and retarded 
growth (Kee and D'Andrea, 2012). Five FA complex components (A, F, G, C and E), RPA and 
topoisomerase IIIɑ were pulled down by immunoprecipitation of BLM, and together were defined 
as a functional complex termed BRAFT (BLM, RPA, FA and topoisomerase IIIɑ) that is involved 
in DNA repair by DNA-unwinding (Hemphill et al., 2009, Meetei et al., 2003). Cells from FA 
patients are hyper-sensitive to reagents that cause ICLs (such as cisplatin or mitomycin-C) and also 
present chromosomal abnormalities that are exacerbated by replicative stress (treatment with 
aphidicolin) (Kee and D'Andrea, 2010, Naim and Rosselli, 2009, Schlacher et al., 2012). More 
recently, it was discovered that depletion of FANCD2 is similar to the depletion of BLM, as well as 
the double-depletion, with respect to fork restart after replicative stress, indicating that they function 
in the same pathway to facilitate fork restart (Chaudhury et al., 2013). FANCM detects stalled 
replication forks and recruits the FA core complex, resulting in the monoubiquitylation of FANCD2 
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and FANCI (Deans and West, 2009, Garcia-Higuera et al., 2001, Smogorzewska et al., 2007). 
FANCD2Ub localises to the stalled fork and recruits DNA repair factors FAN1 (Fanconi-associated 
nuclease 1) and SLX 4 (FANCP, a Holliday junction resolvase) (MacKay et al., 2010, Yamamoto et 
al., 2011). FAN1 and SLX4 facilitate recruitment of HR-mediated DNA damage repair factors 
BRCA2 (FANCD1), PALB2 (FANCN) and BRIP1 (FANCJ) (Wang, 2007). An alternative pathway 
for fork restart by FANCD2 has been discovered. The FA core complex was found to be 
dispensable for fork restart by FANCD2, and a monoubiquitylation-dead mutant of FANCD2 still 
localised to stalled forks as induced by aphidicolin and facilitated fork restart (Raghunandan et al., 
2015). From this it was proposed that the ubiquitylation status of FANCD2 defined the DNA 
damage response downstream of the FA pathway, ICL-specific repair requires FANCD2Ub but is 
dispensable for fork restart (Raghunandan et al., 2015). Additionally, it was found that FAN1 is 
dispensable for ICL repair, but is vital for fork restart (Lachaud et al., 2016).  
 
UFBs that lack adjacent FANCD2/I foci link centromeric loci, and constitute ~55% of all UFBs. 
They are thought to occur because centromeres are replicated late in S phase and are the last region 
of a metaphase chromosome where cohesin complexes are removed (Chan et al., 2007) and are 
proposed to contain unresolved catenanes (Wang et al., 2010). UFBs flanked at each end by 
FAND2/I foci are products of replication stress as treatment with aphidicolin increases UFB 
frequency overall, and this increase is largely in the FANCD2-positive population of UFBs (Chan et 
al., 2009, Naim and Rosselli, 2009). It was also observed that FANCD2 foci are frequently 
localised in pairs, from G2 through to prophase until segregating symmetrically during anaphase, 
and are at a similar frequency in each daughter telophase nucleus (Chan et al., 2009, Naim and 
Rosselli, 2009). It has more recently been shown that the structure-specific endonuclease, MUS81, 
is required for genomic stability at CFS loci (Ying et al., 2013). MUS81 requires a partner protein, 
EME1, to function, and was originally thought to process recombination intermediates, as S. pombe 
cells with defective MUS81 or EME1 exhibited meiotic defects (Boddy et al., 2001). Since then, 
however, it was found that the heterodimer more efficiently (~75 x) cleaves replication fork 
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structures and 3’-flaps (Ciccia et al., 2003), and deletion of MUS81 in yeasts results in 
hypersensitivity to replicative stress (treatment with hydroxyurea/camptothecin), and is proposed to 
have an important role in replication fork restart (Bastin-Shanower et al., 2003, Doe et al., 2002, 
Hanada et al., 2007, Whitby et al., 2003). MUS81-depleted human cells exhibit an increased 
frequency of stalled replication forks, micronuclei, bulky anaphase bridges and UFBs. Additionally, 
MUS81 foci colocalise with CFSs in early-mitosis as detected by FISH (fluorescence in situ 
hybridisation) (Ying et al., 2013). From this, it is proposed that MUS81-EME1 cleaves 
incompletely replicated CFSs in early-mitosis to stop anaphase bridging and the resultant DNA 
break is repaired in the following cell cycle, and that this pathway is preferable to uncontrolled 
breakages caused by tension during chromosome segregation, or aneuploidy (Ying et al., 2013). 
 
To summarise, CFSs are sensitive to replicative stress and can develop into UFBs that link sister-
chromatids. DNA repair factors are recruited to these sites before, during and after bridge formation 
in an attempt to conserve genomic stability, whether by fork restart (FANCD2, BLM, MUS81 etc), 
bridge decatenation (BLM, topoisomerase IIIɑ) or post hoc DNA damage repair (caused by 
MUS81-mediated excision).  
 
Whether UFBs are processed by MUS81-EME1-mediated cleavage or BLM helicase unwinding, 
the unusual DNA structures created by this process are inherited by each daughter cell, where they 
are processed or repaired. In G1, there exist nuclear bodies that contain a large accumulation of a 
protein called 53BP1 (Harrigan et al., 2011, Lukas et al., 2011). They are present in unperturbed 
cells, but increase in frequency in response to replicative stress as caused by treatment with a low 
concentration of aphidicolin (Harrigan et al., 2011, Lukas et al., 2011). It was also observed that 
53BP1 (p53-binding protein 1) nuclear bodies are frequently (~70%) symmetrical in number and 
morphology between sister-daughter cells (Lukas et al., 2011). ChIP-qPCR revealed that 53BP1 is 
enriched at the FRA3B and FRA16D CFSs (the best studied and most fragile CFSs) (Lukas et al., 
2011). Additionally, depletion of MUS81 or BLM increases the frequency of 53BP1 nuclear bodies 
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in the following G1 phase (Lukas et al., 2011, Ying et al., 2013). Taken together, it seems possible 
that unreplicated DNA transmitted through mitosis results in the inheritance, by each daughter cell, 
of unusual DNA structures that correspond to CFSs and are coated with 53BP1. 
 
53BP1was discovered by its binding to p53 in a yeast-2-hybrid screen (Iwabuchi et al., 1994). 
Domain analysis revealed that 53BP1 contains tandem BRCT (BRCA1 C-terminal) domains, 
implicating a function in the DNA damage response (Bork et al., 1997, Callebaut and Mornon, 
1997). At its N-terminus are (S/T)Q motifs which were found to be hyperphosphorylated by ATM 
in response to DNA damaging agents, which is necessary for the rapid relocalisation of 53BP1 to 
damaged DNA sites (Anderson et al., 2001, Rappold et al., 2001, Schultz et al., 2000, Xia et al., 
2001). As little as 30 minutes after irradiation (X-ray, infra-red or ɣ-), 53BP1 relocalises to nuclear 
loci that also contain previously known double strand break repair proteins ɣ-H2AX and MRN 
(Anderson et al., 2001, Rappold et al., 2001, Schultz et al., 2000). 53BP1-deficient mice models are 
hypersensitive to irradiation and prone to tumour development (Morales et al., 2003, Ward et al., 
2003b). 53BP1 has no known enzymatic activity, but is thought to bind to chromatin and act as a 
scaffold and signal transducer for other DNA repair factors (Panier and Boulton, 2014). As detailed 
in Panier and Boulton’s comprehensive review, 53BP1 accumulates at damaged chromatin by 
binding to histones displaying H4K20me2 (via tandem tudor domains) and H2AK13/15Ub (via a 
ubiquitylation-dependent recruitment domain) modifications (Panier and Boulton, 2014). E3 
ubiquitin ligases RNF8 and RNF168 prime histones for binding by 53BP1 by facilitating the 
ubiquitylation of L3MBTL1 and JMJD2A (marking them for deactivation or proteolysis), which 
mask H4K20me2, and ubiquitylation of H2AK13/15. RNF8-RNF168 activity is promoted at 
damaged sites by a positive feedback loop between ATM, MDC1 and MRN. DSBs are recognised 
by MRN which recruits autophosphorylated ATM. ATM phosphorylates histone variant H2AX to 
produce ɣ-H2AX, which recruits MDC1. MDC1 recruits further ATM and MRN to the damaged 
chromatin where activated ATM phosphorylates MDC1 which finally recruits RNF8-RNF168 
(Panier and Boulton, 2014). 53BP1 binding to chromatin requires ɣ-H2AX (Ward et al., 2003a) and 
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ɣ-H2AX foci span ~1 Mbp around a DSB (Rogakou et al., 1999). 53BP1 functions as a key 
determinant of DSB repair pathway choice between homologous recombination (HR) or non-
homologous end-joining (NHEJ) (Bouwman et al., 2010, Bunting et al., 2010, Chapman et al., 
2012). HR requires a homologous section of DNA elsewhere in the genome which can be used as a 
template for strand invasion by resected DSB ends, and facilitates high-fidelity repair even if the 
DNA damage has caused a significant deletion of genetic material (Heyer et al., 2010). NHEJ 
merely rejoins broken DNA ends and can result in significant loss of genetic material (Lieber, 
2010). 53BP1 is phosphorylated at DSBs by ATM which triggers the recruitment of RIF1 and PTIP 
which repress DNA end resection and BRCA1, and thereby HR (Bothmer et al., 2010, Bunting et 
al., 2010, Callen et al., 2013, Chapman et al., 2013, Feng et al., 2013, Zimmermann et al., 2013). 
BRCA1-deficient cells exhibit genetic instability associated with promoted levels of NHEJ, but this 
phenotype is rescued by also deleting 53BP1 (Bouwman et al., 2010, Bunting et al., 2010). 
Conversely, promotion of NHEJ by 53BP1 is inhibited by BRCA1, as loss of BRCA1 function 
causes RIF1 to accumulate at DSBs in S/G2 phase (NHEJ extends from G1 into the rest of 
interphase) and inhibits DNA end resection and thereby HR (Chapman et al., 2013, Escribano-Diaz 
et al., 2013, Feng et al., 2013). Based on these experiments, it is clear that 53BP1 and BRCA1 
function antagonistically to ensure that NHEJ and HR are mutually exclusive at any single DSB. 
The DSB repair pathway that prevails is highly dependent on cell cycle regulation, NHEJ is mostly 
confined to G1 and HR to S and G2. The repression of BRCA1 function, by 53BP1, is inhibited in S 
and G2 phase by S phase CDK activity. CDK2 phosphorylates CtIP which promotes its binding to 
BRCA1, and BRCA1-CtIP inhibits the interaction between 53BP1-RIF1, thereby enabling resection 
and HR (Escribano-Diaz et al., 2013). CtIP promotes DNA end resection and is recruited to DSBs 
by the MRN complex (Sartori et al., 2007). Cell cycle regulation of DSB repair is necessary, as HR 
cannot take place in G1 since there is no sister-chromatid that can be used as a template for strand 
invasion and high-fidelity repair. CDK2 is required for the G1/S transition and is active up until the 
end of G2 phase, during which period template DNA will be made available for HR by DNA 
replication from the beginning of S phase. 
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Recently, a novel form of DNA synthesis was discovered to take place in mitosis in response to 
replicative stress (Minocherhomji et al., 2015). It was observed that punctate foci of EdU 
incorporation are present in prophase and prometaphase cells but only at a low frequency unless 
replicative stress is induced by treatment with a low concentration of aphidicolin. These foci 
(termed MiDAS, mitotic DNA synthesis) colocalise with FISH probes for FRA3B and FRA16D 
CFSs, and a majority colocalise with FANCD2 twin-foci, additionally indicating associations with 
CFSs (Chan et al., 2009). MiDAS foci are also associated with a majority of DNA breaks in 
metaphase chromosome spreads. Incorporation of EdU was found to be restricted to prophase and 
prometaphase, as releasing cells from a nocodazole synchronisation into EdU yielded very few foci. 
A major event in early-mitosis is the condensation of chromatin into discretely identifiable 
chromosomes, a process which requires a ring-shaped complex called condensin. Depleting cells of 
SMC2, a member of the condensin complex, supresses chromatin condensation, as well as MUS81 
recruitment to CFSs, and EdU incorporation at CFSs in early-mitotic cells. Depletion of MUS81 
nuclease activity reduces the recruitment of POLD3 (a non-catalytic subunit of DNA pol δ) to 
chromatin, and reduces the frequency of MiDAS foci. Depletion of POLD3, but not POLD4 (a 
catalytic subunit of DNA polymerase δ), reduces the frequency of MiDAS foci. In human cancer 
cells synchronised at the G1/S boundary, POLD3 is dispensable for canonical DNA synthesis and 
fork speed is unaffected, although cells progress through S phase slowly (Tumini et al., 2016), 
however, POLD3 is haploinsufficient in mice (Murga et al., 2016). POLD3 is the human orthologue 
to S. cerevisiae Pol32, which is required for BIR (break-induced replication) and ALT (alternative 
lengthening of telomeres; telomere elongation in the absence of telomerase) (Lydeard et al., 2007). 
BIR is a repair pathway initiated by a single recombination strand invasion event, followed by up to 
100 kbp of DNA synthesis (Malkova et al., 2005), and reinitiates DNA synthesis at damaged 
replication forks and repairs one-ended DSBs in yeasts (McEachern and Haber, 2006), by extension 
of a migrating D-loop (Donnianni and Symington, 2013). BIR requires CMG (CDC45, MCM2-7, 
GINS) as well as CDC7 and CDT1, but not ORC or CDC6 (Lydeard et al., 2010) and facilitate 
conservative replication (Donnianni and Symington, 2013, Saini et al., 2013). Minocherhomji et al. 
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2015, also discovered that suppression of MiDAS by aphidicolin increased non-disjunction, UFBs, 
DNA breaks in metaphase chromosome spreads, 53BP1 nuclear bodies in the following G1 and 
reduced cell survival. Taken together, the authors propose a model whereby stalled replication forks 
at CFSs are excised by MUS81-EME1 nuclease to create a single-ended DSB which is resected for 
strand invasion. A D-loop is formed and migrates with BIR-like POLD3-dependant conservative 
replication, which reinitiates replication at that locus. MUS81 recruitment requires chromosomal 
condensation, so the authors speculate whether the mechanical forces of condensation expose 
unreplicated DNA as a template for DNA repair synthesis. Successful gap filling by DNA repair 
synthesis reduces the amount of unreplicated DNA transmitted through anaphase. Follow up work 
from the same group found that RAD52 is required for MiDAS foci formation, independently of 
ATR, RAD51 and BRCA2 (Bhowmick et al., 2016), implicating a novel role for RAD52 which so 
far has been thought to be backup in RAD51-depleted cells. The authors propose that RAD52 plays 
a specialised role in mitosis to facilitate microhomology-mediated BIR, a class of BIR which can 
occur independently of RAD51, by annealing a small overhang at a one-ended DSB (created by 
MUS81-EME1 nucleolytic cleavage at a stalled fork) to a microhomology in the unreplicated DNA. 
From there, POLD3-dependant DNA synthesis conservatively replicates the previously unreplicated 
DNA (Bhowmick et al., 2016). 
 
A number of the experiments carried out on MiDAS have used aphidicolin to cause CFS 
expression, and the CDK1-inhibitor RO-3306 to synchronise cells at the G2/M boundary, in an 
attempt to ensure that the DNA synthesis they observe takes place in mitosis, and not in G2. In 
human cells, CDK1 primarily regulates the G2-M phase transition. RO-3306, a small molecule 
inhibitor of CDK1, functions as an ATP-competitor at the ATP binding pocket of CDK1 (Vassilev 
et al., 2006). CDK1 and CDK2 are highly structurally similar, so inhibitors of CDK1 also inhibit 
CDK2, but RO-3306 has, so far, the greatest selectivity for CDK1 over CDK2 (~10 fold) (Vassilev, 
2006, Vassilev et al., 2006). CDK2 promotes the G1/S phase transition, as well as progression 
through S phase. Although RO-3306 is described as a strong synchroniser of cells at the G2/M 
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boundary, which can then be efficiently released into mitosis, the synchronisation is not absolute. 
Minocherhomji et al. 2015 show in figure S2C the dynamics of RO-3306 release in U2OS cells, and 
see that 5 minutes after release ~one third of cells are still in G2 and 20 mins after release 10% of 
cells are in G2. The authors incubate U2OS cells in EdU for 30 mins after release from RO-3306, so 
one sixth of the incubation time takes place when between ~33-100% of cells are in G2 and one half 
of EdU incorporation takes place when 10-33% of cells are in G2. It is likely that a majority of the 
MiDAS foci the authors observed were de novo DNA synthesis in mitosis, however, it is also 
possible that a significant proportion of MiDAS foci are from late replication in G2 (estimated to be 
~1% of the genome) (Widrow et al., 1998) or DNA repair synthesis including fork restart in G2, 
translesion synthesis (Diamant et al., 2012) or homologous recombination. Additionally, combining 
a polymerase inhibitor (aphidicolin) with a molecule that also inhibits CDK2 activity is highly 
unphysiological. 
 
Taken together, it is proposed that FANCD2 and MUS81 are recruited to stalled replication forks 
that are associated with unreplicated segments of DNA, and facilitate unlinking of sister-chromatids 
before anaphase. If unsuccessful, UFBs form and either BLMs helicase facilitates unwinding or 
mis-segregation events take place. Whether MUS81 endonuclease activity excises unreplicated 
DNA, or BLM helicase unwinds unreplicated DNA into stretches of ssDNA, the resultant DNA 
damage is largely inherited symmetrically by each daughter cell (Lukas et al., 2011). It has also 
been proposed that, in an alternative process, that MUS81 and FANCD2 facilitate POLD3- and 
RAD52-dependent BIR at unreplicated segments of DNA in early-mitosis (Bhowmick et al., 2016, 
Minocherhomji et al., 2015). Depletion or repression of BLM, FANCD2, MUS81, MiDAS, POLD3 
and RAD52 increase the frequency of G1-specific 53BP1 nuclear bodies (Bhowmick et al., 2016, 
Bourseguin et al., 2016, Lukas et al., 2011, Minocherhomji et al., 2015, Ying et al., 2013). Lukas et 
al. 2011 proposed that CFS breaks are caused by tension from chromatin condensation in early-
mitosis, based on the increase in UFB frequency and the reduction in 53BP1 nuclear body 
frequency caused by SMC2 depletion, indicating that condensation caused the breaks that 53BP1 
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eventually coats, and if not, would form a UFB as a safer alternative. However, Ying et al. 2013 
observe that depletion of MUS81 reduces the frequency of chromosome breaks but an increase in 
UFBs and segregation defects (bulky bridges, micronuclei), and counter-propose that breaks seen in 
early-mitosis are caused by MUS81 nuclease, not by mechanical forces from condensation, and are 
preferable to forming UFBs. Additionally, in figure S5B and S5C, Minocherhomji et al. 2015 show 
that 53BP1 nuclear bodies increase in frequency after SMC2 depletion. Either way, both 
possibilities are likely to result in DSBs. Alternatively, it is proposed that unreplicated DNA in 
UFBs is unwound by helicase activity, considering the presence of BLM helicase and 
topoisomerase IIIɑ at UFBs, which together could facilitate decatenation of hemicatenated DNA, 
and find in support of this the presence of BrdU after partial DNA denaturation, indicating ssDNA, 
across the length of UFBs (Chan et al., 2007), as well as RPA (Chan and Hickson, 2009). However, 
the absence of detectable ssDNA in G1-specific 53BP1 nuclear bodies, whether by BrdU in non-
denaturing conditions or RPA (Harrigan et al., 2011, Lukas et al., 2011), throws doubt on this 
possibility. 
 
Research into CFSs is a good foundation for potential DFS responses. They are considered origin-
poor regions. A DNA fibre study of forks at FRA3B and FRA16D (the two most studied and highly 
expressed CFSs) showed that the fork speed and fork stall rate were the same in the CFSs as 
elsewhere in the genome, but found at FRA3B a ~700 kbp region of DNA that contained no 
initiation events, with consistent results at FRA16D (Letessier et al., 2011) and FRA6E (Palumbo et 
al., 2010). It is this category of CFSs that are expected to overlap with genomic loci that are prone 
to spontaneous DFSs, as opposed to CFSs that are expressed at large genes (making a collision with 
transcription factors probable). A large amount of CFS research has been based on colocalisation 
experiments specifically between FRA3B and FRA16D (as probed by FISH), and DNA damage 
responders including FANCD2, UFBs, MUS81 and 53BP1 (Chan et al., 2009, Lukas et al., 2011, 
Ying et al., 2013).
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1.7) Aims of this thesis 
In collaboration with the Blow lab, the DFS model published in Newman et al. 2013 has been 
applied to origin mapping data in human cells by the same group (Al Mamun et al., 2016, Moreno 
et al., 2016). 
 
The first aim is to find a biological marker for DFSs, or their consequences, and use it to emulate 
precise predictions made by the DFS model, which is presented in chapter 3. 
 
The second aim is to use research into CFSs as a foundation to identify further candidates of the 
DFS response, which is presented in chapter 4.  
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Chapter 2 
 
Materials and methods 
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2.1) Tissue culture & cell lines 
Human cell lines HeLa (ATCC CCL-2), U2OS (ATCC HTB-96) and IMR-90 (ATCC CCL-186) 
were obtained from the American Type Culture Collection (ATCC) and used for experiments at no 
more than 20 population doublings. All cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM; 41966, Gibco) supplemented with 10% v/v fetal bovine serum (FBS; 10270106, 
Gibco), 100 Units/ml penicillin and 100 µg/ml streptomycin (15140, Gibco). Cultures were 
maintained in incubators set to 37 °C, 5% CO2 and in a humid environment. For culture 
maintenance and assay preparation, all cell lines were washed with Dulbecco’s phosphate buffered 
saline (DPBS; 14190, Gibco) and suspended with 0.25% Trypsin-EDTA (25200, Gibco). Where 
appropriate, cells were counted by trypsinising culture dishes of cells and mixing a small aliquot of 
suspended cells in DMEM with 0.2% v/v trypan blue (T10282, Life Technologies) and transferring 
them to a Countess Chamber Slide (C10283, Invitrogen). Alive cells, that excluded the dye, were 
automatically counted by a Countess II Automated Cell Counter (AMQAX1000, Life 
Technologies). HeLa cells were split 1:~10, ~3 times per week, meaning that their doubling time 
was ~16 hours. 
 
2.2) Cell synchronisation 
2.2.1) Release into S phase 
HeLa and U2OS cells were synchronised in early S phase by double thymidine block. Cells were 
incubated in 2.5 mM thymidine (T1895-10G, Sigma-Aldrich) in DMEM for 16 hours and then 
released by DPBS washes followed by an incubation in DMEM for 8 hours. Cells were then 
incubated in 2.5 mM thymidine for 16 hours. Finally, DPBS washes released cells into S phase. 
 
2.2.2) Release into G1 
HeLa cells were synchronised by a double thymidine block. They were released for 4 hours by 
DPBS washes and then treated with 50 ng/ml nocodazole (M1404, Sigma-Aldrich) for 4 hours. To 
release cells from metaphase, they were washed with DPBS. 
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2.3) RNAi & siRNAs 
Transfection of short interfering RNA (siRNA) was carried out using the Lipofectamine 
RNAiMAX system in accordance with the manufacturer’s instructions. Two mixtures were 
prepared in parallel; siRNA solution in Opti-MEM (31985, Gibco) and Lipofectamine RNAiMAX 
(137780, Invitrogen) in Opti-MEM, which were combined before addition to DMEM (with 10% 
FBS but without antibiotics) on cultured cells. Lyophilised siRNAs were solubilised in 5x siRNA 
Buffer (B-002000-UB, Dharmacon) diluted to 1x in Molecular Grade RNase-free water (B-003000-
WB, Dharmacon). Transfection efficiency using this system is ~90% as measured by transfection of 
siGLO Green Transfection Indicator (D-001630-01, Dharmacon) using the manufacturers 
instructions. 
 
Given the abundance and slow turnover of MCMs, a regime of transfections was developed to 
significantly deplete the cellular pool of MCM5. HeLa cells were transfected twice consecutively 
over a 32 hour period, such that the cells in the final sample will have been in transfection reagent 
for a total of 64 hours. During this regime, samples were harvested at 16 hour intervals starting after 
the first transfection, such that a variety of depletions of MCM5 can be quantified. U2OS cells were 
transfected for a 24 hour period twice consecutively, and so were transfected for a total of 48 hours. 
 
 
 
 
Table 1: siRNA sequences and the concentrations at which they were used. 
Target transcript Sequence (starting from 5’ sense) Concentration Product code 
Control UAGCGACUAAACACAUCAA - D-001210-01-50 
53BP1 GAAGGACGGAGUACUAAUAUU 20 nM Custom order 
CDT1 SMARTpool 
CCAAGGAGGCACAGAAGCA 
GCUUCAACGUGGAUGAAGU 
UCUCCGGGCCAGAAGAUAA 
GGACAUGAUGCGUAGGCGU 
20 nM M-003248-02 
MCM5 GGAUCUGGCCAGCUUUGAUUU 50 nM Custom order 
All from Dharmacon. 
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2.4) Immunoblotting 
2.4.1) Sample preparation 
Preparation for immunoblotting was the same for each cell line. For an unfractionated ‘whole cell’ 
lysate, cell pellets were lysed by ice-cold incubation with radioimmunoprecipitation assay buffer 
(RIPA, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% v/v IGE-pal CA-630, 0.5% w/v Na-
deoxycholate, 1mM EDTA, supplemented with 1 mM PMSF, 1 mM Na-OV, 10 µg/ml leupeptin, 10 
µg/ml aprotinin and 10 µg/ml pepstatin). Lysates were sonicated and centrifuged to break-up and 
clear genomic material. The protein concentration of each lysate was quantified by the Bradford 
assay. Lysates were mixed with Bio-Rad Protein Assay Dye Reagent (5000006, Bio-Rad) and 
absorbance measured at 595 nm wavelength with FLUOstar Omega plate reader (BMG Labtech). 
10 µg of protein was heated to 70 °C with NuPAGE LDS Sample Buffer (NP0007, Novex) 
supplemented with 25 mM dithiothreitol (DTT, 443853B, VWR) before loading into a NuPAGE 4-
12% Bis-Tris Protein Gel (NP0322, Invitrogen). Samples were run alongside PageRuler Plus 
Prestained Protein Ladder, 10-250 kbp (26619, Thermo Scientific). Gels were run at 80 V for 30 
minutes followed by 200 V for 30 minutes. Proteins were transferred onto nitrocellulose membrane, 
0.2 µm pore size (10600001, Amersham) in transfer buffer (12.5 mM tris, 96 mM glycine, 10% v/v 
ethanol) at 40 V for 15 hours. Membranes were stained with Ponceau S Stain (K793-500ML, 
AMRESCO), which was used with the protein ladder to dissect the membrane. Ponceau stain was 
washed away with tris-buffered saline (TBS, 50 mM tris, 150 mM NaCl, pH 7.6) and membranes 
were blocked in 5% powdered milk w/v (Original dried skimmed-milk, Marvel) in TBS + 0.1% v/v 
Tween 20 (TBST, BP337-500, Fisher Scientific) for 1 hour. Primary antibodies (detailed in table 2) 
were diluted in 3% bovine serum albumin (BSA, A9647-100G, Sigma) and 0.01% v/v Na-azide 
(786-299, G-Biosciences) in TBST and membrane was incubated in this mixture overnight (~15 
hours) at 4 °C. The membrane was washed in TBST followed by incubation in secondary antibodies 
(detailed in table 2) diluted in block solution for 1 hour at room temperature. The blots were washed 
with TBST and then transitioned into TBS. Fluorescence intensity was acquired with an Odyssey 
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CLx Imaging System (LI-COR) at 700 nm and 800 nm excitation wavelengths at a resolution of 84 
µm pixels. 
 
To isolate the chromatin-bound fraction of proteins, pellets of cells were incubated in ice-cold CSK 
extraction buffer (10 mM HEPES pH 7.4, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2 
supplemented with 1 mM PMSF, 1 mM Na-OV, 10 µg/ml leupeptin, 10 µg/ml aprotinin and 10 
µg/ml pepstatin) with 0.5% v/v Triton X-100 (BP151-500, Fisher Scientific) for 10 minutes on ice. 
Extracted nuclei were centrifuged and the pellets washed with ice-cold CSK extraction buffer 
(without Triton) twice. For comparison between the soluble and chromatin-bound fractions of 
53BP1, the CSK + Triton fraction was retained and loaded proportionally to the chromatin-bound 
fraction, otherwise they were discarded. The final pellet of extracted chromatin (and material from 
the nuclear lamina) was then prepared for immunoblotting, as described above. 
 
 
2.4.2) Sample acquisition & analysis 
Quantification of band intensity was carried out with Image Studio software (LI-COR). Background 
was automatically detected from the signal surrounding each region of interest (ROI, effectively 
each band) and subtracted per-pixel. Intensity was then normalised against the loading control. 
Finally, relative intensity was normalised against the negative controls, which were assigned an 
arbitrary value of 1. 
 
Table 2: primary and secondary antibodies used for immunoblotting. 
Antibody Source Manufacturer Product code Dilution 
53BP1 Rabbit - polyclonal Bethyl A300-272A 1:5000 
ɑ-tubulin Mouse - monoclonal Sigma-Aldrich T6199 1:20000 
GAPDH Mouse - monoclonal Abcam ab9484 1:1000 
Lamin B1 Rabbit - polyclonal Abcam ab16048 1:1000 
MCM5 Mouse - monoclonal Santa Cruz sc-136366 1:1000 
IRDye 680 anti-mouse Donkey - polyclonal LI-COR 926-68072 1:15000 
IRDye 680 anti-rabbit Donkey - polyclonal LI-COR 926-68073 1:15000 
IRDye 800 anti-mouse Donkey - polyclonal LI-COR 926-32212 1:15000 
IRDye 800 anti-rabbit Donkey - polyclonal LI-COR 926-32213 1:15000 
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2.5) Flow cytometry 
2.5.1) Sample preparation 
Preparation for flow cytometry was the same for each cell line. Immediately before harvesting cells 
they were incubated with 40 µM 5-ethynyl-2’-deoxyuridine (EdU, C10634, Invitrogen) added 
directly to the DMEM for 30 minutes. Pellets of live cells were incubated in ice-cold HEPES-CSK 
buffer (1% w/v BSA, 1mM EGTA, 0.2% v/v Triton X-100, 1mM DTT, 10 mM HEPES pH 7.4, 300 
mM sucrose, 100 mM NaCl, 3 mM MgCl2 supplemented with 1 mM PMSF, 1 mM Na-OV, 10 
µg/ml leupeptin, 10 µg/ml aprotinin and 10 µg/ml pepstatin) for 10 minutes on ice. Extracted nuclei 
were washed with 1% w/v BSA in DPBS (14190-250, Gibco) and then fixed with 2% v/v 
formaldehyde (28908, Thermo Scientific) in DPBS for 15 minutes at 37 °C and washed again. Cells 
were permeabilised with ice-cold 70% v/v ethanol in DPBS at -20 °C for 10 minutes and then 
washed as above. Cells were then incubated in anti-BM28 antibody (mouse monoclonal, 1:500, 
610701, BD Biosciences) in 1% BSA w/v DPBS for 2 hours and then washed. Cells were incubated 
with Alexa Fluor 488 anti-mouse secondary antibody (1:1000, A11029, Molecular Probes) diluted 
in 1% BSA w/v in DPBS for 1 hour and then washed. To conjugate a fluorophore to the 
incorporated EdU, a Click-iT reaction (C10634, Invitrogen) cocktail was prepared by mixing 219 µl 
DPBS, 5 µl 100 mM Cu(II)SO4, 1 µl 1mM Alexa Fluor 647 picolyl azide and 25 µl ‘Reaction 
Buffer Additive’ (~5 mM ascorbic acid) for a final volume of 250 µl per sample. This reaction 
mixture was made fresh and immediately added to cells for 30 minutes, followed by a wash with 
1% BSA w/v in DPBS. Finally, cells were stained with 50 µg/ml propidium iodide (PI, P4864-
10ML, Sigma-Aldrich) in 1% BSA w/v in DPBS and 50 µg/ml RNase A (EN0531, Thermo Fisher).
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2.5.2) Sample acquisition & analysis 
Events were recorded using a BD FACS Canto II flow cytometer (BD Biosciences) with 
FACSDIVA software (BD Biosciences). Six parameters were recorded: forward scatter (peak area), 
side scatter (peak area), PI (peak width and area), Alexa Fluor 488 (peak area) and Alexa Fluor 647 
(peak area). Detector voltages were adjusted for each parameter with the negative control for each 
experiment. Additionally, events with a chromosome content of 2n (diploid G0/G1 cells) were 
adjusted to 50,000 arbitrary intensity units on the PI-area scale, thus events with a chromosome 
content of 4n (G2/M cells) would have an arbitrary intensity of ~100,000 units. 
 
Flow cytometry data was analysed using FlowJo software (FlowJo, LLC). Plotting events using the 
forward scatter and side scatter values provided a qualitative diagnostic of the quality of the cells 
and sample preparation. Populations of apoptotic cells, cell debris or general debris (undissolved 
BSA, for example) as well as doublets (cells that have clumped together during sample preparation) 
can be identified in this plot. Plotting events using PI peak width (PI-W) against PI peak area (PI-A) 
allowed the identification of cycling cells separate from apoptotic cells, doublets and debris, which 
were all gated out for all further analysis. To analyse chromatin-bound MCM2 immunofluorescence 
in early S phase cells, early S phase cells were defined as events that had above-background levels 
of EdU fluorescence (where background was defined by cells that had no EdU incorporation but 
were treated with the Click-iT reaction) but had not significantly increased their total DNA content 
beyond 2n (50,000 arbitrary units of PI fluorescence intensity. To quantify the average intensity of 
chromatin-bound MCM2 in early S phase cells, the Alexa Fluor 488 intensity values (MCM2 on 
chromatin) in all events that were defined as early S phase were averaged by calculating the 
geometric mean. Using these mean values background was removed by subtracting the mean 
intensity of Alexa Fluor 488 in cells that were not incubated with anti-BM28 primary antibody. 
After correcting for background, abundance of MCM2 on chromatin in early S phase cells was 
quantified relative to cells transfected with control siRNA which were assigned the arbitrary value 
of 100%. 
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2.6) Microscopy 
2.6.1) Sample preparation 
Sample preparation for microscopy was the same for each cell line. Thickness #1.5 coverslips (631-
0156, VWR) were sterilised in 70% v/v ethanol before being placed into empty culture dishes. 
Suspended cells were aliquoted and incubated in these dishes until fully adhered, and seeded at a 
density such that prior to fixing the cells they were at ~80% confluency. For experiments requiring 
fluorescent staining of nucleotide incorporation, cells were incubated with 40 µM EdU for 30 
minutes up until fixation. To fix cells, the coverslips were removed from culture dishes and washed 
with DPBS, followed by incubation in 4% v/v formaldehyde in DPBS (28908, Thermo Scientific) 
for 10 minutes. After washing with DPBS, cells were permeabilised with 0.2% v/v Triton X-100 in 
DPBS for 10 minutes. Cells were washed with 0.1% v/v Tween in DPBS (PBST) and blocked in 
0.5% v/v fish skin gelatine (G-7765, Sigma) in PBST (FSG-PBST) for 1 hour. Primary antibodies 
(detailed in table 3) were diluted in FSG-PBST, and cells were incubated in antibody at 4 °C 
overnight (~15 hours). Following washes with PBST, cells were incubated in secondary antibodies 
(indicated in table 3) also diluted in FSG-PBST for 1 hour. Cells were then washed with PBST 
which was transitioned into PBS. If cells were incubated with EdU then the Click-iT reaction 
mixture was prepared as follows: 215 µl DPBS, 10 µl 100 mM Cu(II)SO4, 1 µl 1mM Alexa Fluor 
555 picolyl azide and 25 µl ‘Reaction Buffer Additive’ (~5 mM ascorbic acid) for a final volume of 
250 µl per sample (C10338, Invitrogen). Cells were treated with this mixture for 30 minutes and 
then washed with DPBS. Finally, cells were incubated in 0.1 µg/ml 4’,6-diamidino-2-phenylindole 
(DAPI, D9542, Sigma) in DPBS for 5 minutes and then washed with DPBS. Coverslips were 
mounted onto slides (Superfrost, Thermo Scientific) in VectaShield (H-1000, Vector Laboratories) 
and sealed with nail varnish. 
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The cells used to quantify the proportion of 53BP1 in nuclear bodies were a gift from Professor Jiri 
Lukas and express a GFP-53BP1 fusion protein, with more details in Bekker-Jensen et al. 2005. 
 
2.6.2) Image acquisition 
Images were acquired with a DeltaVision Elite (GE Healthcare) widefield fluorescence microscope, 
using a Coolsnap HQ (Roper Scientific) CCD camera and solid-state illumination. Most 
experiments were imaged with a 40x/1.3 Oil Plan Fluor APO objective (Olympus), except when 
imaging EdU foci in mitotic cells and FANCD2, where a 100x/1.4 Oil Super-Plan APO objective 
(Olympus) was used. The entire camera sensor chip was used for each image (1024x1024) and the 
exposure time and transmission were adjusted for each experiment to ensure that the most intense 
pixel of fluorescence was detected in the linear range of the sensor. Excitation light was filtered 
with the following filter set: DAPI, FITC, TRITC and Cy5, which correspond to fluorescent 
staining with DAPI, Alexa Fluor 488, Alexa Fluor 555 and Alexa Fluor 647 respectively. All 
experiments required imaging of the cell nuclei only and so required a z-section range of 10-12 µm, 
with sections taken every 1 µm. Z-sections were deconvolved using softWoRx Constrained Iterative 
Deconvolution with the Enhanced Ratio protocol for 10 cycles. 
 
2.6.3) Image analysis 
Image analysis was carried out with Volocity (Perkin Elmer). Foci were identified with a 
minimally-biased approach using the following sequential programme consisting of Volocity 
analytical functions: 1) Find Objects Using Signal Intensity (threshold set to intranuclear 
background), 2) Clip Objects to ROI (ROI is drawn around nucleus using DAPI signal), 3) Remove 
Table 3: primary and secondary antibodies used for immunofluorescence microscopy. 
Antibody Source Manufacturer Product code Dilution 
53BP1 Rabbit - polyclonal Novus NB100-904 1:2000 
γ-H2AX Rabbit - polyclonal Cell Signalling 2577 1:1000 
CyclinA Mouse - monoclonal Abcam ab16726 1:200 
FANCD2 Rabbit - polyclonal Santa Cruz Sc-28194 1:200 
p-H3 Rabbit – polyclonal Cell Signalling 9701 1:1000 
RPA Mouse - monoclonal Abcam ab2175 1:300 
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Noise From Objects (Median Filter), 4) Separate Touching Objects (Minimum Object Size Guide = 
1 µm3), 5) Exclude Objects by Size (Exclude Objects < 0.1 µm3). In practice, the protocol finds 
signal intensity above background in a specified channel, separates objects that may be overlapping 
and excludes small objects, all bound within the volume defined by DAPI signal. 
 
Colocalisation analysis was carried out using the built-in colocalisation tools in Volocity. The two 
channels of interest were selected and each threshold was set to their respective intranuclear 
backgrounds. ROIs were defined by the volume occupied by DAPI signal, and within each ROI 
(each nucleus) Pearson’s Correlation Coefficient and Manders’ Overlap Coefficient was calculated. 
Additionally, colocalisation was calculated by a third method where foci of two separate channels 
(for example, ‘A’ and ‘B’) were identified as foci described above and categorised as either foci ‘A’ 
only, foci ‘B’ only or co-localised if foci from both channels overlapped by a single voxel or more. 
 
2.7) Clonogenic assay 
HeLa cells were transfected with siRNAs targeted against MCM5 and 53BP1 transcripts and a 
scramble control, as described above. Following transfection, cells were seeded into culture dishes 
at a density of 500 cells per 100 mm diameter petri dish. After allowing the cells to adhere for 24 
hours, they were incubated in hydroxurea (HU, H8627-5G, Sigma-Aldrich) at the indicated 
concentrations in DMEM for 48 hours. After washing away HU with DPBS and adding fresh 
DMEM, colonies were allowed to grow for 10-12 days. Colonies were fixed with ice-cold 100% 
methanol for 20 mins at -20 °C. Colonies were stained with crystal violet solution (25% v/v 
methanol, 0.5% v/v crystal violet (HT90132, Sigma-Aldrich) in water) for 20 minutes and then 
washed with water and counted. Colony counts were normalised against the untreated counts in 
each transfection set, which were assigned an arbitrary value of 1.
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2.8) Mathematical & computer simulated modelling 
All theoretical modelling was carried out by Dr Mohammed Al Mamun, Dr Luca Albergante and 
Professor Timothy Newman. This work is detailed in Moreno et al. 2016 and Al Mamun et al. 2016 
and the concept first published in Newman et al. 2013. 
 
2.9) CDC6 overexpression HBEC cell line 
This cell line was developed by Eirini-Stavroula Komseli and Professor Vassilis Gorgoulis as 
detailed in Petrakis et al. 2016. The experiments using this cell line presented in this thesis were 
carried out by Dr Alberto Moreno. Details of the cell line can be found in Moreno et al. 2016. 
 
2.10) 53BP1 ChIP sequencing 
The ChIP seq (chromatin immunoprecipitation sequencing) experiment presented in this thesis was 
carried out by Dr Alberto Moreno. The data was analysed by Dr Luca Albergante and Dr 
Mohammed Al Mamun. Details of both procedures can be found in Moreno et al. 2016. 
 
2.11) Immunofluorescence staining of ultrafine anaphase bridges 
Ultrafine anaphase bridges (UFBs) were stained and quantified by Dr Alberto Moreno using the 
anti-BLM primary antibody (sc-7790, Santa Cruz). More details can be found in Moreno et al. 
2016.  
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Chapter 3 
 
Double fork stalls frequently occur in 
unperturbed cells, and are marked by G1-
specific 53BP1 nuclear bodies in the 
following cell cycle 
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3.1) Predicting the Frequency of Double Fork Stalls in Unperturbed Human Cells 
There has long been a low level of consistency in human cell origin mapping datasets. Origin 
mapping of the same cells lines would produce highly variable estimates for the number and 
distributions of replication origins. Bubble-seq performed with the human GM06990 cell line 
proved to be a relatively robust and experimentally independent method to validate SNS-seq 
datasets (Mesner et al., 2013). The authors compared their dataset with a separate groups SNS-seq 
dataset of the same cell line and found that ~45% of the SNS calls fell within bubble-containing 
EcoR1 fragments (the unit of resolution in bubble-seq analyses) (Mesner et al., 2013). Picard et al. 
2014 used these two sequencing technologies in parallel on several human cell lines, including 
HeLa and IMR-90 cells, and found that ~65% of SNS calls were validated by bubble-seq (expected 
to be ~6% with randomised datasets) (Picard et al., 2014). Analysis of the Picard dataset finds that 
there are ~180,000 replication origins in the diploid human genome of ~5.65 Gbp, which means that 
the mean replicon size is ~31 kbp in both HeLa and IMR-90 cells (Al Mamun et al., 2016, Picard et 
al., 2014). In any individual unperturbed human cell, it is estimated that ~30% of origins are 
activated in a S phase (Ge and Blow, 2010, Ge et al., 2007, Ibarra et al., 2008, Kunnev et al., 2015), 
and DNA fibre analysis shows that origin activations are an average of ~100 kbp apart (Conti et al., 
2007, Jackson and Pombo, 1998). So, if ~30% of origins are ~100 kbp apart in an individual cell, 
then all origins within a population of cells are estimated to be an average of ~33 kbp apart, which 
is consistent with the frequency of origins detected by Picard et al. 2014. Although the total number 
of origins seem to be a good fit to independent experiments, it should be noted that the largest 
replicons within a dataset has a disproportionate influence on the predicted frequency of DFSs (Al 
Mamun et al., 2016), and it is possible that a single false-negative origin could as much as half the 
size of the largest replicon. 
 
The theoretical model, published by Newman et al. 2013, that predicts the probability of at least one 
DFS event in a given eukaryotic S phase was developed with the assumption that the largest 
replicon is significantly smaller than the estimated median number of base-pairs a replication fork 
	 66	
replicates before irreversibly stalling (Al Mamun et al., 2016, Newman et al., 2013). The S. 
cerevisiae genome conformed to this constraint as the largest replicon is 60 kbp and the median stall 
distance is ~10 Mbp (Newman et al., 2013, Siow et al., 2012). However, analysis of the HeLa 
origin mapping data published by Picard et al. 2014 revealed that the distribution of replication 
origins is highly irregular compared to yeasts (Al Mamun et al., 2016). A measure of regularity is 
given by the coefficient of variation (R, standard deviation/mean) which for absolutely equal 
replicon sizes is 0 and for random replicon lengths is 1. Replicon lengths in the S. cerevisiae 
genome have an R-value of ~0.7 (more uniform than random) and in the HeLa genome it’s ~1.5 
(more irregular than randomly distributed origins) (Al Mamun et al., 2016, Newman et al., 2013, 
Picard et al., 2014). This irregularity is also illustrated in figure 2A, the frequency distribution of 
HeLa replicons, where the mean replicon length (red) of ~31 kbp is more than two orders of 
magnitude smaller than the largest replicons (Al Mamun et al., 2016, Picard et al., 2014). In fact, 
the HeLa genome contains an unexpectedly high frequency of very large replicons, the largest of 
which is ~6 Mbp (which would be ~0.3 Mbp if origins are distributed randomly) (Al Mamun et al., 
2016, Picard et al., 2014). 
 
Given the presence of very large replicons in the HeLa origin mapping dataset, which approach the 
expected median stall distance, a general model, termed the “central equation”, was developed from 
the same principals used to develop the DFS model published by Newman et al. 2013 (Al Mamun 
et al., 2016) (figure 2B). The central equation does not contain the approximations that were used in 
the previous DFS model and so appears more complicated. However, both models share the same 
key parameters each of which have similar properties. For example, inputting the parameters of S. 
cerevisiae origin-mapping data into both versions of the model yields the same predicted 
probability of DFSs of ~0.1% (Al Mamun et al., 2016, Newman et al., 2013, Siow et al., 2012). The 
key parameters in both models are the genome size (Ng), median stall distance (Ns), median replicon 
length/origin number (Nl or K) and the origin distribution (R). The average replicon length is 
equivalent to origin number within a dataset: Nl ≈ Ng/(K+1). The coefficient of variation, R, is 
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reflected by the sum of Ni (length of the ith origin) over K origins, for example, huge replicons will 
increase the standard deviation (and thereby R) and reduce the magnitude of the summation on the 
right-hand side of the central equation (figure 2B), both of which result in increased predicted 
probabilities for DFSs. The only poorly-known parameter is the average number of bases replicated 
by a fork before it irreversibly stalls, Ns (median stall distance). However, Newman et al. 2013 used 
a variety of approaches to estimate the value of Ns, including by quantifying the frequency of fork 
stalling in DNA fibre assays published by Maya-Mendoza et al. 2007. A particular pattern in the 
fluorescently labelled incorporated nucleotides can be identified as fork stalls and occur in ~0.16% 
of DNA tracks, where each track is ~25 kbp. Therefore, the per nucleotide stall rate can be 
calculated as 0.0016/25000 bp to be ~6 x 10-8 bp-1. Using an intermediate equation in the 
development of the earlier DFS model, Newman et al. 2013 derived Ns from the per nucleotide stall 
rate to be ~10 Mbp (Ns ≈ ln(2)/ ~6 x 10-8 bp-1), but stressed that this should be considered a rough 
estimate. The DNA fibre assays were carried out with MRC5 cells, but the median stall rate of ~10 
Mbp was found to be well conserved with the estimated S. cerevisiae fork stall rate derived by 
theoretical methods. Newman et al. 2013 estimated the theoretical fork stall rate by making the 
assumption that the frequency of DFS at telomeres should be approximately equal to the rest of the 
genome. These regions are considered separately in the theoretical model as a single fork stall in a 
telomeric region is equivalent to a DFS in a replicon. The probability of single fork stalls at all S. 
cerevisiae telomeres is therefore modelled as a function of Ns, as opposed to Ns2 in replicons. 
Assuming the probability of single fork stalls at telomeres to be similar to DFSs in all replicons 
means that the equation can be rearranged to solve for Ns (see equation 9 in Newman et al. 2013). 
Inputting the parameters from the S. cerevisiae origin mapping data into this equation outputs an 
estimate for Ns as ~12.7 Mbp (per nucleotide stall rate of 5.4 x 10-8 bp-1) (Newman et al., 2013). A 
value of 10 Mbp for the median stall distance was also consistent with the increase in chromosome 
loss when replication origins were systematically deleted, it was observed that synthetically creating 
a ~160 kbp origin-less region, by the removal of five efficient origins, increased the chromosome 
loss rate by ~6 x 10-5 (Theis et al., 2010). A simulation of a replicon of the same size and with a 
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median fork stall distance of 10 Mbp failed to complete replication at a rate of ~6.1 x 10-5 (Newman 
et al., 2013). 
 
Analysis of replicon sizes in Arabidopsis, Drosophila and human cells by Mamun et al. 2016 
further test the likely value of Ns. Mamun et al. point out that the largest replicon sizes are likely to 
be bounded by the median stall distance, consistent with an Ns value of 10 Mbp in human cells. 
Parameter scanning of Ns reveals that a value of 5 Mbp or less saturates the frequency of a cells 
with at least one DFS (figure 8A of Mamun et al. 2016). There are diminishing returns from 
increasing Ns beyond 10 Mbp, even up to 30 Mbp a DFS would still occur in 20% of S phases. 
Interestingly, the probability of one, two or three DFSs occurring showed a very pronounced 
maximum for Ns around 10 Mbp (Al Mamun et al., 2016), consistent with the idea that metazoans 
have acquired mechanisms for dealing with only a small number of DFSs. Given the similarity of 
these estimates derived by independent methods, and the conservation of the DNA replication 
biochemistry from budding yeast to human cells, Ns shall be considered as ~10 Mbp in human cells. 
 
In both models there exists a ‘hierarchy of contribution’, where certain parameters have a greater 
effect on the predicted probability of DFSs than others. As indicated in figure 2B, Ng is the greatest 
contributor to the frequency of DFSs and presents a significant barrier to increasing genome sizes 
from megabases (S. cerevisiae) to gigabases (human cells), even if the frequency of origins is 
maintained. Origin number is the next greatest contributor (equivalent to decreasing Nl in the earlier 
DFS model and increasing K in the central equation), but has limited ability to compensate for 
increasing genome sizes. For example, using the earlier DFS model, fully compensating for the 
increase in size from the diploid S. cerevisiae genome (~22 Mb) to the diploid human genome (~5.6 
Gbp) by addition of origins alone would require ~250 fold more licensed origins than already exist 
in human cells, which would mean the average replicon size would become ~100-200 bp, a similar 
frequency to histones. Finally, origin distribution is the smallest contributor. The S. cerevisiae 
origin mapping dataset has a coefficient of variation of ~0.7 and so (1 + R2) = 1.49, meaning that 
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the significant investment in perfectly spacing origins would only reduce DFSs by approximately a 
third (Newman et al., 2013). 
 
Mamun et al. 2016 hypothesise that as genome sizes increase from megabases to gigabases the 
effect of optimising origin distribution is significantly diminished. So, while yeast origin 
distributions with a coefficient of variation that is biased towards order (<1), human cells have a 
coefficient of variation that is more disordered than randomly positioned origins (>1), as there is no 
evolutionary benefit realised by optimising origin distribution. The diploid human genome (~5.6 
Gbp) is ~250 fold larger than the diploid S. cerevisiae genome (~22 Mb) and yet has a similar 
frequency of origins (one origin for every ~31 kb, to S. cerevisiae’s ~14 kb) which are more 
disordered (R = ~1.5 to S. cerevisiae’s ~0.7) (Al Mamun et al., 2016, Newman et al., 2013). This 
seemingly counterintuitive disparity implies that higher eukaryotes have acquired cellular 
mechanisms that are able to resolve unreplicated segments of DNA, as even a single DFS in an S 
phase can potentially cause mis-segregation during the following anaphase. Such mechanisms 
would relieve the evolutionary pressure from compensating for gigabase genomes by licensing 
origins at a similar frequency to histones, or optimising origin distribution, and explain why there is 
no increase in origin frequency or order in human cells when compared to yeast. 
 
The predicted frequency of DFSs in human cells is calculated by the central equation (figure 2B) 
using the origin-mapping data for HeLa and IMR-90 cells from Picard et al. 2014. Centromeric 
regions, which correspond to the largest replicon in each chromosome in both datasets, are 
disregarded due to the technical problems associated with sequencing those regions (Al Mamun et 
al., 2016). IMR-90 cells are a human female primary fibroblast that are stable and untransformed, 
with a diploid karyotype of 2n = 46 (Nichols et al., 1977), and are included in this analysis to 
illustrate that the theory applies equally to normal and cancer-derived cells. According to the central 
equation, the predicted frequency of DFSs in a HeLa cell S phase is ~1.5 (figure 2C, ‘100% 
replication origins’). This is more than three orders of magnitude greater than the frequency 
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predicted for S. cerevisiae cells (~1 in 1000) and if left unresolved would mean that human cells 
risk mis-segregation in most cell cycles. The predicted frequency of DFSs is similar between IMR-
90 and HeLa cell line origin-mapping datasets (figure 2C).  HeLa cells are highly transformed and 
have a super-triploid karyotype, but despite these chromosomal rearrangements have maintained a 
similar genome size, origin number and order compared to the primary cell line IMR-90 (table S2 
of Mamun et al. 2016). DFSs are not expected to be unique to cancer cells, and they are equally 
likely to occur in unperturbed, normal cells. In this chapter, in vivo experiments are carried out with 
HeLa cells in concordance with the high-quality HeLa origin mapping data published in Picard et 
al. 2014, but chapter 4 begins with a brief analysis in IMR-90 cells that indicates that the theory is 
indeed appropriate for human cancer and normal human cells alike. 
 
The central equation is used to predict the frequency of DFSs in response to randomly adding or 
removing origins from the HeLa and IMR-90 origin-mapping datasets (figure 2C). The number of 
origins in wild type cells are defined as ‘100%’ (~180,000 from both data sets). Intuitively, 
randomly removing origins causes the predicted frequency of DFSs to increase, as this will cause 
the replicons to increase in average length and so the remaining replication forks will be required to 
replicate more base pairs of DNA before irreversibly stalling (figure 2C, left-hand side). However, 
randomly removing a significant number of origins has only a modest effect on the predicted 
frequency of DFSs. For example, randomly removing 40% of origins (from ~180,000 to ~108,000) 
will only increase the predicted frequency of DFSs from ~1.5 to ~2. This is likely due to the 
relationship between the average replicon size of ~31 kbp and the median fork stall rate of ~10 Mbp 
(Ns), hypothetically one replication fork could replicate a median of ~330 replicons-worth of DNA. 
This redundancy of licensed origins allows cells to tolerate replication stress caused by blockers of 
fork progression, whether caused by proteins tightly bound to the DNA, DNA damage or collisions 
with transcriptional machinery, as well as by activating origins that would otherwise remain 
dormant (Blow and Ge, 2009, Ge et al., 2007, Ibarra et al., 2008, Woodward et al., 2006). The 
excess of origins, when considering the estimate fork stall rate of ~10 Mb, also protects the genome 
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against under-licensing, as seen in figure 2C. There is a marked increase in the predicted frequency 
of DFSs, from ~2 to ~3 when the proportion of randomly removed origins transitions from 40% to 
60%, possibly as the system reaches a state of minimal licensing, as the ~30% of origins that are 
normally activated must now be sufficient for complete replication of the genome. 
 
Conversely, as origins are added at random positions in the HeLa and IMR-90 origin-mapping 
datasets, the frequency of predicted DFSs decreases (figure 2C, right-hand side). Again, the 
reduction is modest and illustrates how compensating for gigabase genomes by extraordinary 
licensing is inefficient. Licensing an additional 50% origins (from ~180,000 to ~270,000), which 
reduces replicon length from ~31 kbp to ~21 kb, only reduces the predicted frequency of DFSs by 
approximately a half, which is still orders of magnitude greater than in a typical megabase genome 
such as S. cerevisiae. 
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Figure 2: Predicting the frequency of double fork stalls in unperturbed human 
cells. A) Frequency distribution of ~90,000 replicon lengths (kbp) in HeLa cells, derived 
from the origin mapping data from Picard et. al. 2014, analysed by Dr Mohammed Al 
Mamun and Dr Luca Albergante. The average replicon length of ~31 kb is indicated by 
the red bar. B) The double fork stall model updated for use with HeLa origin mapping 
data. Ng = genome size (bp), Nl = average replicon length (bp), Ns = median number of 
bases replicated before an irreversible replication fork stall (bp), K = number of 
replication origins in the dataset, Ni = size of particular replicon (bp), R = coefficient of 
variation. The hierarchy of contribution shows which parameters have the greatest 
effect on the predicted frequency of double fork stalls. Both models were developed by 
Prof. Timothy Newman with Dr Mohammed Al Mamun and Dr Luca Albergante. C) A 
graph of the effect of randomly adding or removing origins to the genomes of two 
human cell lines, one cancerous and highly transformed, HeLa, and the other a primary 
cell line, IMR-90, on the predicted frequency of double fork stalls. Orange squares 
represent the random addition and removal of replication origins from the HeLa origin 
mapping dataset (Picard et. al. 2014). Blue circles represent the random addition and 
removal of replication origins from the IMR-90 origin mapping dataset (Picard et. al. 
2014). Simulation carried out by Dr Mohammed Al Mamun and Dr Luca Albergante.
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3.2) G1-specific 53BP1 nuclear bodies: a potential marker for DFSs 
Now armed with the central equation and the well-defined hypotheses on the frequency of DFSs, 
and how that frequency changes with origin number, a biological marker for DFSs was required to 
validate the model. Ideally, DFSs would have a unique mark so that they could be stained in situ 
and imaged using fluorescence microscopy, so that their frequency could be quantified per cell. 
Indeed, there are a number of known proteins that are recruited to stalled replication forks 
(FANCD2, BLM, MUS81, etc.) but it was not clear whether these markers could be used to 
differentiate between reversible and irreversible stalls, or between single fork stalls and DFSs. In 
theory, the segment of unreplicated DNA within a DFS can range from less than the smallest 
replicon (<1 kb) up to the largest replicon (~6 Mb), although the probability distribution of DFSs is 
skewed towards larger replicons. So, within a DFS, the physical distance between one fork stall to 
the other could range from small enough to be unresolvable by wide-field microscopy, to being far 
apart enough to be undifferentiable from single fork stalls. Alternatively, a DFS could be 
distinguished by its segment of unreplicated DNA. However, identifying what could be a small 
segment of DNA amongst the entire genome presents a signal-to-noise ratio problem. For example, 
detecting unreplicated DNA by incorporation of fluorescently labelled nucleosides (such as 
bromodeoxyuridine) would act as a negative stain, however, this absence of signal would be 
swamped by the abundance of nucleotide incorporation that takes place during S phase. 
 
It has long been speculated that unreplicated DNA that persists through to the following anaphase 
will topologically link sister-chromatids and either cause mis-segregation or require excision or 
unwinding of the unreplicated DNA (Chan et al., 2007, Clarke et al., 1993). With little to 
biochemically distinguish a DFS from similar phenomena, quantifying the consequences of 
transmitting unreplicated DNA through mitosis may act as a good proxy.  
 
The rationale for investigating 53BP1 nuclear bodies as a potential marker for the frequency of 
DFSs was inspired by the proposition discussed in Harrigan et al. 2011 and Lukas et al. 2011 that 
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unreplicated segments of DNA are transmitted through mitosis and form UFBs. These UFBs are 
either broken or unwound by BLM helicase, and the resultant DNA damage is inherited by each 
daughter cell in the following G1. 
 
As mentioned in the introduction, under physiological conditions 53BP1 nuclear bodies are largely 
confined to G1 phase in human cells, as indicated by mutually exclusive immunofluorescence 
signal to CyclinA (Harrigan et al., 2011, Lukas et al., 2011). However, they have been observed at a 
lower frequency in early S phase and G2 (Lukas et al., 2011). Ensuring that 53BP1 nuclear bodies 
are quantified in G1 will limit interpretation to damaged DNA that has been inherited from the 
previous cell cycle, as opposed to breaks that are generated by internal cellular processes such as 
DNA replication. As in Harrigan et al. 2011 and Lukas et al. 2011, CyclinA is used to negatively 
identify G1 cells, but as its expression progressively builds from late G1 the distinction between G1 
and early S phase cells by CyclinA immunofluorescence is not sharp. Short pulse-incorporation of 
the modified thymidine EdU (5-ethynyl-2’-deoxyuridine) in live asynchronous cells, that can then 
be conjugated with a fluorophore, allows the identification of S phase cells with a sharp cut-off 
between G1 and S. This also means that the three stages of interphase can be easily distinguished 
under the microscope, without having to synchronise the cells, and will from now on be referred to 
as the ‘2-stain’ system. Mitotic cells are disregarded as 53BP1 nuclear bodies are rare in mitosis 
since chromatin condensation in mitosis represses ATM and DNA-PK activity and typical DSB 
repair factors such as BRCA1 and 53BP1 are not recruited to DSBs (Giunta et al., 2010, Nelson et 
al., 2009). Figure 3A is a representative image of asynchronous HeLa cells stained for 53BP1, 
CyclinA and EdU. As expected, 53BP1 nuclear bodies (green) can be seen in cells negative for both 
CyclinA and EdU, defining them as G1. To confirm the accuracy of the 2-stain system, it was used 
to quantify the frequency of each HeLa cell cycle stage (figure 3B). As indicated in figure 3A 
(‘Merge’ panel, white arrows), cells negative for both EdU and CyclinA signal are defined as G1, 
cells positive for EdU are defined as S, and cells positive for CyclinA only are defined as G2. ~60% 
of asynchronous HeLa cells are in G1, ~30% in S and ~10% in G2 (mitotic cells disregarded). The  
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Figure 3: 2-stain microscopy system to identify G1 cells in an asynchronous 
population. A) Representative microscopy image of 53BP1 nuclear bodies in the 
context of the 2-stain staging system. With 53BP1, asynchronous HeLa cells are also 
stained with EdU (orange) and CyclinA (red). G1 cells can be identified by the absence 
of both EdU and CyclinA staining. B) The proportion of asynchronous HeLa cells 
categorised as either G1 (EdU -ve/CyclinA -ve), S (EdU +ve) or G2 (EdU -ve/CyclinA 
+ve). Error bars represent S.E.M. of three biological replicates. C) Comparison 
between the 2-stain staging system and the approximate known lengths of the HeLa 
cell cycle stages. Mitosis is disregarded as mitotic cells were not categorised by the 
2-stain system. χ2 test (between observed 2-stain staging, and expected stage 
occupancy), p = 0.726.
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approximate HeLa cell cycle times are G1: 8 hours, S: 4 hours, G2: 2 hours and M: 2 hours for a 
total doubling time of ~16 hours (as calculated in Materials & Methods). Disregarding mitosis, the 
occupancy of asynchronous cells in each cell cycle stage can be calculated (figure 3C). For 
example, G1: ~8 h / (~8 h + ~4 h + ~2 h) x 100% = 57.1% of asynchronous cells are in G1. 
Comparing the observed cell cycle by the 2-stain system (top row of figure 3C) to the calculated 
occupancy of cell cycle stages by asynchronous HeLa cells (bottom row of figure 3C) indicates that 
the 2-stain system accurately identified HeLa cell cycle stages. 
 
As applies here and throughout the work presented in this thesis, 53BP1 nuclear bodies were 
identified for quantification using intranuclear background-corrected signal intensity with a 
minimum size guide of 0.1 µm3 (to distinguish nuclear bodies from punctate foci). The distribution 
of 53BP1 nuclear bodies throughout interphase was quantified by the 2-stain microscopy system in 
figure 4A. In G1 HeLa cells, the mean frequency of 53BP1 nuclear bodies is ~1. As previously 
mentioned, 53BP1 nuclear bodies are indeed present in S phase and more infrequently in G2. The 
frequency of predicted DFSs in unperturbed HeLa cells is ~1.5 (figure 2C, ‘100% origins’) and is 
well matched by the frequency of G1-specific 53BP1 nuclear bodies. The frequency distribution of 
G1-specific 53BP1 nuclear bodies is displayed in figure 4B. ~45% of G1 HeLa cells had no 53BP1 
nuclear bodies, so approximately half of all unperturbed G1 HeLa cells contain 53BP1 nuclear 
bodies, which is a significantly higher frequency than expected from unperturbed CFSs, which 
ranges from 1-5% of cells with observable breaks (Aula and von Koskull, 1976). The overall 
frequency of G1-specific 53BP1 nuclear bodies is used to construct a Poisson distribution, a 
distribution where the mean is equal to the variance, and so only requires one variable, λ. The ideal 
Poisson distribution is super-imposed as a black line over the observed frequency distribution 
(figure 4B). The observed frequency distribution is highly similar to the Poisson distribution, 
implying that the observable events are rare and independent. In the context of replication fork 
stalling, this is an accurate description of DFSs, as the diploid HeLa genome is estimated to contain 
~180,000 origins (Al Mamun et al., 2016, Picard et al., 2014) of which ~30% stochastically activate  
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Figure 4: G1-specific 53BP1 nuclear bodies are a potential marker for double fork 
stalls from the previous cell cycle. A) Mean frequency of 53BP1 nuclear bodies in 
cell cycle stages defined by the 2-stain staging system. Error bars represent S.E.M. of 
three biological replicates. B) Frequency distribution of G1-specific nuclear bodies in 
asynchronous HeLa cells. The mean frequency of nuclear bodies was assigned as the 
λ value to create a Poisson distribution (overlaid black line). Error bars represent 
S.E.M. of three biological replicates. χ2 test, p = 0.811.
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in a given S phase (Blow and Ge, 2009, Blow et al., 2011, Ge and Blow, 2010, Ge et al., 2007, 
Ibarra et al., 2008), so there are ~100,000 replication forks of which only 2, 4, 6 or 8 (HeLa cells 
were not observed to contain five or more 53BP1 nuclear bodies) converging forks stall in 
approximately half the cells. Additionally, in an unperturbed cell, a spontaneous DFS occurring at 
one genomic loci should have little-to-no influence on the probability of another DFS occurring 
elsewhere in the genome. So far, G1-specific 53BP1 nuclear bodies promisingly correlate well with 
the predicted frequency of DFSs, but further validation is required. 
 
3.3) The temporal distribution of 53BP1 nuclear bodies is constant throughout G1 and 
declines during S phase 
Whether G1-specific nuclear bodies facilitate NHEJ or suppress HR on the products of unreplicated 
DNA transmitted through mitosis until S phase remains unclear. NHEJ has been reported as a fast 
process, taking as little as 30 minutes in HCA2 human cancer cells (Mao et al., 2008a). If 53BP1 
facilitates NHEJ at 53BP1 nuclear bodies, then it would seem likely that they would appear in early 
G1 (Harrigan et al., 2011, Lukas et al., 2011) and disappear well before the end of G1, however, 
live microscopy shows that they linger from at least 80 minutes (Harrigan et al., 2011) to 150 
minutes (Lukas et al., 2011). 53BP1 nuclear bodies are predominantly specific to G1, but are 
present at a low frequency in S phase (Harrigan et al., 2011, Lukas et al., 2011). So, it seems likely 
that if a cell were to have at least one 53BP1 nuclear body, the body has the potential to appear in 
early G1 and dissolute in early S phase. To quantify the mean frequency of 53BP1 nuclear bodies 
across this timespan, HeLa cells were synchronised with the microtubule poison nocodazole, which 
holds the cells in metaphase (figure 5A). Cells were then released and samples harvested for flow 
cytometry and microscopy. Figure 5B is a representative example of cells synchronised at mitosis 
(‘0 h’), entering G1 (‘2 h’) and progressing through G1 until they synchronously enter S phase (’12 
h’). 30 minutes before harvesting, sample time-points were incubated in EdU to stage the cells 
through the cell cycle (figure 6A). At 0 hours from nocodazole release, a majority of the cells have 
a G2/M (4n) DNA content. 2 hours later a majority of the cells have entered G1, with a 2n total 
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DNA content. The very first cells start to enter S phase 6 hours after release and continue to do so 
until the final time-point. The cell cycle stages were defined as presented in the key, and the % 
frequency of cells were plotted against time after nocodazole release (figure 6B). A majority of cells 
are in G1 between 2 hours and 8 hours inclusive after release from nocodazole, and so were used 
for microscopy analysis to quantify 53BP1 nuclear bodies (figure 6C). G1-specific 53BP1 nuclear 
bodies were selected for by negative EdU and CyclinA staining, to ensure any stray S or G2 cells 
were not included in the quantification. The mean frequency of G1-specific nuclear bodies 
remained constant throughout G1 (figure 6C). Although there is a small decline, it is not statistically 
significant (χ2 test, p = 0.924). 
 
To quantify 53BP1 nuclear bodies through S phase, a double thymidine block was opted against as 
the synchronisation would not be precise during early S phase. Instead, the 10 and 12 hour time 
point releases from the nocodazole experiment were imaged and S phase cells were staged by the 
EdU incorporation morphology. The pattern of fluorescent nucleotide incorporation changes as cells 
progress through the replication timing programme. Five main morphologies of BrdU incorporation 
have been identified, and their order and timing discovered by releasing CHO cells from HU 
synchronisation and tracing the morphology frequency peaks through time, the same patterns were 
seen in HeLa cells (O'Keefe et al., 1992). In figure 7A are five representative images of each of 
these stages in HeLa cells incubated with EdU for 30 minutes. The ideal version of the patterns are 
displayed underneath and adapted from Gillespie and Blow, 2010. It should be noted that each stage 
is not equal in length, the pattern timing has been estimated in CHOC-400 cells, stage I: <5%, stage 
II: ~50%, stage III: ~25%, stage IV: ~12%, stage V: ~12% (Dimitrova and Gilbert, 1999). Figure 
7B is a representative image of a HeLa cell exhibiting a stage II EdU pattern, and a 53BP1 nuclear 
body. S phase-specific 53BP1 nuclear bodies were quantified according to the EdU staging pattern, 
which revealed that 53BP1 nuclear bodies gradually decline during S phase (figure 7C). The very 
low frequency of nuclear bodies in stage IV and V S phase cells is likely due to how short (and 
therefore infrequent) those patterns are, which when combined with an infrequent event probably 
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means that many hundreds of cells would have to be counted for a true reflection. 53BP1 nuclear 
bodies decline to almost zero during S phase, and the mean frequency of 53BP1 nuclear bodies 
increases up to ~0.2 per G2 nucleus again afterwards (figure 4A) as NHEJ is favoured over HR 
again in mid-to-late G2 (Mao et al., 2008b). 
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Figure 5: Synchronising HeLa cells for release into G1. A) Schematic of 
experimental design to synchronously release cells into G1 and track them through to 
S phase. B) Progression of cells released from nocodazole tracked by PI (total DNA) 
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Figure 6: The frequency of 53BP1 nuclear bodies remains constant throughout 
G1. A) PI intensity (total DNA) plotted against EdU intensity (nucleotide incorporation) 
at 2 hour intervals after nocodazole release. The key (bottom left) shows the gating 
used to track progression through the cell cycle after nocodazole release. B) % 
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bars represent S.E.M. of three biological replicates. χ2 test, p = 0.924.
C
0 
0.2 
0.4 
0.6 
0.8 
1.0 
2 4 6 8 
M
ea
n 
53
B
P
1 
bo
di
es
G1 (h after nocodazole release) 
A
I II III IV V Stage 
EdU
Ideal
Figure 7: The frequency of 53BP1 nuclear bodies declines during S phase. A) 
Representative EdU staining of S phase stages as described and defined in O’Keefe 
et. al. 1992. Ideal cartoon displayed underneath from Gillespie & Blow, 2010. B) 
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phase stage as indicated by EdU staining pattern. Error bars represent S.E.M. of three 
biological replicates. χ2 test, p = 4.99 x 10-4.
B C
5 μM
Merge
DAPI EdU
53BP1
I II III IV V
S phase stage (EdU morphology)
0 
0.2 
0.4 
0.6 
0.8 
1.0 
M
ea
n 
53
B
P
1 
bo
di
es
	 84	
3.4) Optimising the depletion of origin licensing by targeting MCM5 and CDT1 with RNAi 
The central equation presented in figure 2 not only predicts the frequency of DFSs in unperturbed 
HeLa cells, but also in cells with randomly added or removed replication origins from the HeLa 
origin mapping dataset. Intuitively, removing origins from the dataset increases the predicted 
frequency of DFSs, however, the model goes one step further and predicts the numerical increase 
with respect to the number of origins randomly removed. If G1-specific 53BP1 nuclear bodies are a 
good marker for DFSs from the previous cell cycle, then it would be expected that removing origins 
from HeLa cells in vivo would increase the frequency of G1-specific 53BP1 nuclear bodies 
numerically in line with the models predictions for DFSs. 
To reduce the number of origins available for S phase the licensing system was suppressed by 
depleting MCM5 or CDT1 protein levels. As previously discussed, 53BP1 is an early responder to 
DNA damage and forms nuclear bodies in response to ɣ-irradiation-induced DSBs (Anderson et al., 
2001), a process that is independent of DFSs and replicative stress that subnormal origin activity. 
This means that the method used to reduce origin usage should be precise and minimise the 
inhibition of replisome progression, so that any fork stalling detected by 53BP1 nuclear bodies in 
the following cell cycle should come as a consequence of subnormal origin activation and not 
directly caused by exogenous agents. This makes targeting the licensing system ideal as the effect 
will be limited to G1, and should not influence S phase. In contrast, for example, the AID-degron 
system developed in human cells by Professor Masato Kanemaki and colleagues to rapidly 
proteolyse MCMs during S phase (Natsume et al., 2016, Natsume et al., 2017) would not be 
adequate for our purposes as it would be impossible to differentiate 53BP1 nuclear bodies that have 
accumulated for DFSs from DNA damage caused by fork destabilisation. Targeting a member of 
the heterohexamer helicase, MCM5, for depletion should have an equivalent effect on licensing as 
depleting CDT1. The absence of any member of the heterohexamer MCM2-7 eliminates any 
replication licensing activity for that complex in Xenopus cell-free extracts (Prokhorova and Blow, 
2000) and elongation in S. cerevisiae (Labib et al., 2000). Depletion of MCM5 has previously been 
carried out in the Blow lab. As can be seen in figure 2D of Ge et al. 2007, partial depletion of 
	 85	
MCM5 results in a partial depletion of MCM2, MCM3, MCM6 and MCM7 in the chromatin 
fraction of U2OS cell lysate (Ge et al., 2007), indicating that fewer MCM2-7 complexes are 
licensed as a result of limited MCM5 supply. CDT1 promotes the formation of the pre-replicative 
complex and is required, with CDC6, for the recruitment of MCM2-7 to sites on chromatin marked 
by the ORC. S. pombe CDT1 null-mutants are unable to synthesise DNA (Hofmann and Beach, 
1994) and partially depleting CDT1 in S. cerevisiae cells blocks initiation of replication and MCM4 
(Cdc21) association with chromatin (Nishitani et al., 2000). Depleting either MCM5 or CDT1 result 
in the same consequence of reduced MCM2-7 on chromatin, and so should both increase the 
frequency of DFSs and potentially the G1-specific 53BP1 nuclear bodies in the following cell cycle. 
Additionally, their functional distinction will control for non-specific effects brought about by their 
depletion. Here, the depletion of MCM5 and CDT1 shall be facilitated by RNAi by transfection of 
siRNAs that are designed to duplex specifically with their target transcripts, thereby bringing about 
mRNA degradation and limiting their translation. RNAi can be used to produce a variety of 
depletions that can then be used to emulate the scatter graph of figure 2C (optimal or hemi-
depletion alone would be unsatisfactory as they would only be one data point). 
 
As mentioned above, MCM5 depletion has previously been carried out in the Blow lab and was also 
facilitated by RNAi. The siRNA sequence for MCM5 used in experiments presented in this thesis is 
identical to the sequence primarily used in Ge et al. 2007 (MCM5-2i). A second sequence was 
analysed in parallel to MCM5-2i in Ge et al. 2007 (MCM5-1i) that achieved a similar depletion of 
MCM5 protein (~50%) and a similar effect on total nucleotide incorporation and proliferation. 
Additionally, cells transfected with either siRNA exhibited similar hypersensitivity to HU, but 
differed slightly on their effect on intra-cluster origin spacing (Ge et al., 2007). The CDT1 siRNA 
used in experiments presented in this thesis is a SMARTpool (Dharmacon); an equal mixture of 
four different siRNAs targeted against CDT1 transcripts. 
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It is necessary to produce a wide variety of origin licensing reductions to emulate the theoretical 
predictions represented in the scatter graph of figure 2C. In Ge et al. 2007, they achieved a total 
depletion of ~25% MCM5 with 2 nM siRNA transfected, which resulted with a ~50% reduction of 
MCM2-7 components in the chromatin-bound fraction of U2OS cell lysate (Ge et al., 2007). As can 
be seen in figure 8A, a similar depletion of ~30% is achieved with 5 nM MCM5 siRNA transfected 
for 24 hours. However, returns diminish as the concentration of MCM5 siRNA transfected is 
increased up 20 nM (figure 8A). It seems clear that the concentration of siRNA molecules 
transfected is not limiting, and it is likely that MCM5 proteins have a long half-life. It is reported 
that HeLa cell MCM3 and MCM4 have a half-life of ~20 hours (Ishimi et al., 2003, Musahl et al., 
1998), which at approximately one HeLa cell cycle implies very little degradation of the protein has 
occurred and the pool of protein has just been split in two upon cell division. Alternatively, ~50% 
depletion of an MCM might represent an impenetrable ceiling beyond which transfected cells die, 
meaning that the cells left for the analysis have been transfected inefficiently. However, this is 
extremely unlikely: a) a depletion of ~50% of MCM5 in U2OS cells (that also lack an intact 
licensing checkpoint) has very little effect on S phase dynamics and proliferation rate (Ge et al., 
2007), b) ~30% of licensed origins are used in a given S phase (Blow and Ge, 2009, Blow et al., 
2011, Ge and Blow, 2010, Ge et al., 2007, Ibarra et al., 2008) and these cells are otherwise 
unperturbed, c) the theoretical model presented in figure 2C indicates that a significant reduction in 
licensed origins only has a modest effect on replicative stress. It could not be explained by 
activation of a licensing checkpoint, as expression of E6 protein from the HPV-18 genome 
integrated into the HeLa genome means that they lack p53 activity. This means that the potent CDK 
inhibitor p21 remains inactive and allows constitutive CDK4/6 and CDK2 phosphorylation of Rb 
(retinoblastoma protein) which means that the E2F transcription factor facilitates expression of S 
phase cyclins irrespective of licensing status (Blow and Gillespie, 2008, Feng et al., 2003, 
Montagnoli et al., 2004, Nevis et al., 2009, Shreeram et al., 2002, Teer et al., 2006). In case 
lipofectamine was the limiting factor, increasing volumes of lipofectamine were mixed with MCM5 
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siRNAs prior to transfection (figure 8B). Again, a depletion of ~50% was the maximum depletion 
of MCM5 achievable in 24 hours (figure 8B). 
 
Given the reported slow turnover of MCMs in HeLa cells (Ishimi et al., 2003, Musahl et al., 1998), 
and that ~50% depletion is seemingly the limit over a 24 hour period, the possibility that greater 
depletions could be achieved by waiting for cells to divide and share their non-growing pools of 
MCM5 protein was tested by the development of a transfection regime that covers ~4 HeLa cell 
cycles (figure 9A). HeLa cells were transfected with either control (non-targeted/scramble), MCM5 
or CDT1 siRNA twice over a period of 64 hours (twice, to maintain that the pool of transfected 
siRNAs within the cells). This regime also proved convenient for creating a variety of depletions, as 
samples taken every cell cycle (figure 9A) should have progressively less MCM5 protein. MCM5 
abundance in whole HeLa cell lysate is indeed progressively depleted after each cell cycle time-
point (figure 9B, top). Additionally, depletions beyond ~50% were made  possible, as after 64 hours 
of MCM5 RNAi there is an ~80% depletion of total cell MCM5 (figure 9B, top, right hand lane). 
However, the objective was to reduce MCM2-7 recruitment to DNA so it is more relevant to 
quantify depletions in a chromatin-bound fraction of HeLa cell lysate. Similar to the whole cell 
lysate, depletion of DNA-bound MCM5 is progressive with transfection time (figure 6B, bottom), 
and the maximal depletion is ~70% after 64 hours of MCM5 RNAi. A similar effect is achieved 
with CDT1 RNAi (see figure S2A of Moreno et al. 2016). 
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Figure 8: Optimising depletion of replication origins by MCM5 RNAi. A) 
Immunoblot of MCM5 depletion with increasing concentrations of transfected MCM5 
siRNA for 24 hours. Band intensities are normalised against the loading control, 
ɑ-tubulin. Abundance is band intensity relative to a sample transfected with control 
siRNA. B) Immunoblot of MCM5 depletion with increasing volumes of lipofectamine 
used on HeLa cells transfected in 100 mm diameter plates. Band intensities are 
normalised against the loading control, ɑ-tubulin. Abundance is band intensity relative 
to a sample transfected with control siRNA.
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Figure 9: Transfection regime to produce a variety of depletions of MCMs on 
chromatin. A) Schematic of the experimental design used to create a variety of 
depletions of MCMs on chromatin. HeLa cells were transfected twice consecutively for 
32 hours each, and samples taken every 16 hours until the final sample at 64 hours 
after the first transfection. B) Immunoblots of MCM5 depletion at regular time points for 
up to 64 hours of RNAi, as described by figure 9A. Band intensities are normalised 
against the loading controls; GAPDH for whole cell and LaminB1 for the chromatin 
bound fraction. Abundance is band intensity relative to each equivalent time-point 
transfected with control siRNA.
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3.5) HeLa cells still enter S phase after sever depletion of licensing. 
Now that a maximal ~70% depletion of MCMs on chromatin has been achieved in HeLa cells they 
are somewhat nearing a state of minimal licensing, given that ~30% of licensed origins are used in a 
given S phase (Blow and Ge, 2009, Blow et al., 2011, Ge and Blow, 2010, Ge and Blow, 2009, 
Ibarra et al., 2008). This depletion proved to be a second ceiling that was impossible to exceed with 
RNAi, causing concern that, beyond this level of depletion, HeLa cells were entering S phase, 
grossly under-replicating and causing large amounts of DNA damage and eventually initiating 
apoptosis (Blow and Gillespie, 2008, Feng et al., 2003, Shreeram et al., 2002). If this was the case 
then the cells remaining would be inefficiently transfected, skewing the apparent depletion to be an 
underestimate. To rule-out this possibility, a flow cytometry technique, developed by Dr Emma 
Haagensen, designed to observe MCM licensing dynamics through the cell cycle was used to 
quantify chromatin-bound MCMs specifically in early-S phase cells (the technique was published 
for the first time in Moreno et al. 2016). The basis of the technique is to combine into one sample: 
total DNA fluorescence (PI), MCM2 immunofluorescence and a 30 minute pulse of EdU 
fluorescence, in asynchronous HeLa cells with soluble proteins extracted (leaving behind a largely 
chromatin-bound fraction). Extraction of soluble proteins is necessary as immunofluorescence of 
MCM2 proteins that are not members of a licensed MCM2-7 heterohexamer, such as a MCM2 
homodimer or MCM2, MCM4, MCM6 and MCM7 heterotetramer (Prokhorova and Blow, 2000), 
will be in excess in MCM5 and CDT1 depleted cells and thereby obscure the immunofluorescent 
signal from MCM2 as part of a licensed origin. 
 
In figure 10A (top panel), total DNA content is plotted against chromatin-bound MCM2 
immunofluorescence intensity in asynchronous HeLa cells transfected with control siRNA for 32 
hours (second cell cycle, see figure 9A) and then with EdU for 30 minutes prior to harvesting. 
G1/G0 phase cells are aligned above an arbitrary intensity of PI (‘2n’) and G2/M phase cells are 
thus aligned at approximately twice that intensity (‘4n’), with S phase cells situated in between as 
they progressively increase their total DNA content. Chromatin-bound MCM2 intensity in G1/G0 
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cells ranges from unlicensed cells (bottom of column) to sufficient licensing to enter S phase (top of 
column). It is likely that cells with significant chromatin-bound MCM2 intensity signal intensity are 
G1 cells, as opposed to G0, as quiescent cells do not license origins (Blow and Hodgson, 2002). 
G2/M cells have little to no chromatin-bound MCM2, as geminin activity strongly inhibits licensing 
upon the onset of S phase through until the end of mitosis and MCM2-7 helicases (CMGs) 
dissociate from the DNA as converging forks meet and terminate, which is why MCM2 signal 
decreases as cells progress through S phase. Background MCM2 signal intensity is slightly higher 
in G2/M events compared to background intensity in G1/G0 events as the data is uncompensated 
and there is minor overlap between the emission spectra of PI and Alexa Fluor 488 (MCM2), as 
well as PI and Alexa Fluor 647 (EdU). In figure 10A (bottom panel) are the same cells but total 
DNA fluorescence intensity is plotted against EdU fluorescence intensity. Like the MCM2 plot, the 
G1/G0 and G2/M, both exhibiting background levels of EdU signal intensity, are aligned at the ‘2n’ 
and ‘4n’ total DNA signal intensities. Cells in the midst of S phase (the peak of the arch shape) are 
incorporating EdU at the fastest rate, and cells in early and late S phase incorporate EdU at a slower 
rate (vertical components of the arch. Additionally, cells that enter or exit S phase during the 30 
minute EdU pulse will be quantified with a low intensity of EdU as they will have had less exposure 
to EdU whilst incorporating nucleotides in S phase. 
The effect of depleting MCM5 by RNAi for 32 hours can be seen in figure 10B. In the G1 phase 
population of cells, the peak of chromatin-bound MCM2 immunofluorescence is decreased 
compared to control. Additionally, the threshold of licensing seemingly required to enter S phase 
has been reduced. This is likely because of the absence of a licensing checkpoint in HeLa cells (as 
mentioned previously, the licensing checkpoint does not function in the absence of p53 activity 
(Montagnoli et al., 2004, Nevis et al., 2009)). MCM5 depletion has not had a significant effect on 
peak EdU incorporation (figure 10B, bottom panel) as is the case in Ge et al. 2007. This is likely 
because the depletion of origins, although striking in the top panel of 10B, has not pushed the cells 
into a state of sub-minimal licensing and the ~30% of origins that are used in a given S phase are 
able to support a normal rate of nucleotide incorporation in these MCM5 depleted cells. 
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Interestingly, depletion of CDT1 by RNAi for 32 hours does not phenocopy MCM5 depletion 
(figure 10C, top panel). Rather than a population of cells with a discrete intensity of chromatin-
bound MCM2 transitioning from G1 to S phase (figure 10A and 10B, top panels), cells enter S 
phase with a variety of MCM2 intensities. Speculatively, this could be explained by the difference 
in how MCM5 and CDT1 are regulated. One MCM5 molecule is required for the licensing of one 
MCM2-7 helicase, whereas one CDT1 molecule can license multiple origins. Unlike MCM2-7, 
CDT1 is degraded during S phase and G2 in every cell cycle. Although the depletion of CDT1 is 
strong (see figure S2A in Moreno et al. 2016), it cannot be very high otherwise cells would fail to 
license a sufficient quantity of MCM2-7, and thus enter S phase and apoptose (Shreeram et al., 
2002). The kinetics of CDT1 licensing activity may exaggerate the difference between the most and 
least efficiently transfected cells. In the less efficiently transfected cells a small number of CDT1 
molecules can facilitate normal levels of licensing, and in the efficiently transfected cells a near-
zero quantity of CDT1 molecules can only license a small number of origins. The peak rate of EdU 
incorporation has been slightly diminished in CDT1-depleted HeLa cells (~75% signal compared to 
control and MCM5-depleted cells, figure 10C, bottom panel). This is probably because a depletion 
of licensing has resulted in a sufficiently limiting number of replication forks to affect overall 
incorporation of EdU. 
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With the flow cytometry system established, it could then be used to quantify the relative depletions 
of licensed origins in asynchronous early-S phase HeLa cells transfected with either MCM5 or 
CDT1 siRNA. The EdU flow cytometry profile can be used to separate the asynchronous HeLa cell 
cycle stages, as illustrated in the left panel of figure 11A. The red population of cells have a 2n 
content of total DNA (PI) and background levels of EdU fluorescence intensity, defining them as 
G1/G0 cells. The green population have a 4n content of DNA and background EdU signal, and so 
are defined is G2/M cells. The blue and orange populations are both S phase cells, defined by EdU 
signal intensity above the background. The blue population has been distinguished from the rest of 
S phase cells by gating for cells that are incorporating EdU but have not significantly increased their 
total DNA content, and defined as early-S phase cells (so the interface between early-S phase cells 
and late-S phase cells is defined by the right-side extreme of the G1/G0 cells). The same events are 
replotted with chromatin-bound MCM2 immunofluorescence intensity against total DNA in figure 
11A, right panel, maintaining populations defined by the EdU plot. G1/G0 cells (red) exhibit a 
range of MCM2 intensity, from background levels of licensing at the bottom of the column to 
sufficiently licensed at the top. Early-S phase cells (blue) are situated at the top of the column, 
having just entered S phase with a sufficient number of licensed origins. Presented in figure 11B is 
a schematic of how the flow cytometry system is used to quantify chromatin-bound MCM2 
intensity in early-S phase cells. The left panel re-illustrates the gate used to define early-S phase 
cells, and the events contained within this gate are re-plotted with MCM2 intensity in the middle 
panel (corresponds to the blue population in figure 11A). The right panel contains the same events 
as the middle panel, but the MCM2 intensities are plotted as a linear scale. This shows that cells 
normally enter S phase with a tightly-defined quantity of DNA-bound MCM2. 
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Figure 11: Visualising MCMs on chromatin in ‘Early’ S phase cells. A) Flow 
cytometry plots presenting the same events with either EdU intensity or chromatin- 
bound MCM2 intensity against PI (total DNA). The left plot indicates the cell cycle 
divided into four categories: G1 (red), ‘early’ S (blue), ‘late’ S (orange) and G2/M 
(green). These same events and their categories are displayed in the right plot. B) 
Control example of selecting ‘early’ S phase cells for chromatin-bound MCM2 intensity 
analysis. ‘Early’ S phase is defined by the gate in the left panel: events that are EdU 
positive yet not significantly increased in total DNA signal. Middle: ‘early’ S chromatin- 
bound MCM2 signal. Right: as with the middle panel but chromatin-bound MCM2 signal 
intensity is plotted on a linear scale.
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The relative immunofluorescence intensity of chromatin-bound MCM2 in early-S phase HeLa cells 
decreases as they are depleted of MCM5 and CDT1 over a period of 64 hours (figure 12). 
Asynchronous HeLa cells were transfected with siRNAs twice over a period of 64 hours and 
samples were harvested every 16 hours, as described in the schematic of figure 6A. The difference 
between depleting MCM5 and CDT1 is seen here, as in figure 10B and 10C. MCM5-depleted early-
S phase cells exhibit a tight cluster of MCM2 signal that steadily decreases to background levels 
over 64 hours of transfection (figure 12A). In contrast, the effect of depleting CDT1 for 16 hours 
does not significantly reduce the modal intensity of MCM2, but quickly produces a population of 
cells with background levels of MCM2 signal. The modal signal does not significantly decrease 
until 48 hours of transfection with CDT1 siRNA. However, taking the geometric mean shows that 
using either method to reduce origin licensing has an equivalent effect on early-S phase MCM2 
signal intensity. 
 
3.6) Origin number is inversely proportional to the frequency of G1-specific 53BP1 
nuclear bodies 
With an accurate system to quantify licensing depletion in a population of cells, the cellular 
response to under-replication can be quantified as the frequency of G1-specific 53BP1 nuclear 
bodies. After serial transfections with either control, MCM5 or CDT1 siRNA over a period of 64 
hours, samples were harvested for flow cytometry and microscopy (figure 9A). Flow cytometry was 
used to quantify licensing depletion (figure 12), and from the same population of cells 
immunofluorescence microscopy was used to quantify G1-specific 53BP1 nuclear bodies (figure 
3A). In figure 13A and 13B, each data point represents one such population of cells. The cells 
transfected with control siRNA are defined as having 100% replication origins, and depletions are 
relative to the corresponding control within a replicate. The mean frequency of G1-specific 53BP1 
nuclear bodies in control transfect cells (‘100%’) is 1.49 ± 0.24 (S.D.), and is slightly higher than 
untreated cells (figure 4A), likely due to stresses associated with transfection. Depletion of MCM5 
is proportional to the frequency of G1-specific 53BP1 nuclear bodies. The maximal depletion 
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achieved, as measured by relative immunofluorescence intensity of chromatin-bound MCM2 is 
~60%, in which cases cells exhibit a mean of ~2.5 G1-specific 53BP1 nuclear bodies, up from ~1.5 
in the control cells figure 13A). The effect of CDT1 depletion on the frequency of G1-specific 
53BP1 nuclear bodies is subtly greater compared to MCM5 depletion, where the gradient (‘M’) of 
the regression is 0.025 compared to 0.019. This is likely due to experimental or biological variation. 
However, it could also be caused by the heterogeneity of MCM2 loading that is caused by treatment 
with CDT1 siRNA (figure 12), but could also be a consequence CDT1’s alternative function in 
mitosis. CDT1 was pulled-down by HEC1 (Highly Expressed in Cancer 1), a member of the 
NDC80 kinetochore-microtubule attachment complex (Varma et al., 2012). As HeLa cells were 
asynchronous when transfected with CDT1 siRNA, it could be that both under-licensing and mis-
segregation events have contributed to the frequency of G1-specific 53BP1 nuclear bodies. 
 
Validation of the theoretical prediction on how origin number influences DFSs (figure 2C) would 
be significantly strengthened by showing that over-licensing reduces the frequency of G1-specific 
53BP1 nuclear bodies. Inducing over-licensing in vivo presents a greater technical challenge 
compared to under-licensing. The licensing system strictly confines licensing to late-M and G1 
phase to eliminate the possibility of re-licensing of replicated origins in S phase, which would cause 
re-replication. Re-replication is disastrous for genomic stability, with defects including mis-
segregation/aneuploidy, gene amplification and chromosome translocations (Hook et al., 2007). 
Overexpression of licensing factors CDT1 and CDC6 induces re-replication and DNA damage in S. 
cerevisiae (Green and Li, 2005), human cancer cells (Vaziri et al., 2003), and makes mice cancer-
prone (Munoz et al., 2017). Re-replication is usually only permitted in the absence of p53 activity 
(Galanos et al., 2016, Vaziri et al., 2003). Professor Vassilis Gorgoulis and colleagues developed a 
HBEC (Human Bronchial Epithelial Cell) immortalised cell line with a Tet-On doxycycline-
inducible promotor for CDC6 overexpression (Petrakis et al., 2016), and gifted the cell line to the 
Blow lab. Dr Alberto Moreno carried out an experiment where chromatin-bound MCM5 was 
quantified before and after induction of CDC6 overexpression with doxycycline (figure 14A).  
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Figure 12: MCMs on chromatin in ‘early’ S phase cells decrease progressively 
through the RNAi regime. A) Chromatin-bound MCM2 in early S phase HeLa cells 
with increasing depletions of MCM5 (see ‘early’ S population of events in figure 11A, 
and transfection protocol in figure 9A). B) As with figure 12A, but the transcript targeted 
for depletion is CDT1.
	 99	
Overexpression of CDC6 has increased the relative amount of chromatin-bound MCM5. Dr Alberto 
Moreno quantified the frequency of G1-specific 53BP1 nuclear bodies in doxycycline-induced 
HBEC cells and, as with the experiments presented in figure 13, quantified the relative amount of 
chromatin-bound MCM5 in the same population of cells. 
 
To verify the theoretical predictions on how origin number affects the frequency of DFSs (figure 
2C), calculated licensing reductions (figure 12), and additions (figure 14A), are assumed to be 
equivalent to the random origin removal and addition to the HeLa origin mapping dataset carried 
out in silico, and the quantified frequency of G1-specific 53BP1 nuclear bodies are treated as a 
proxy for DFSs. So in figure 14B, the data from figure 13 and 14A is superimposed over figure 2C. 
On the left-hand side of the ‘100%’ axis are the experiments presented in figure 13, MCM5 RNAi 
depletions are in red and CDT1 RNAi depletions are in green. The clusters of data points were 
averaged at every 10% depletion to reduce clutter on the graphs. On the right-hand side is the CDC6 
overexpression experiment carried out by Dr Alberto Moreno (light blue). The immortalised HBEC 
overexpression cell line exhibit ~1 G1-specific 53BP1 nuclear body, and this frequency is reduced 
to ~0.75 when there’s a surplus of ~30% additional MCMs on chromatin. Overall, the three 
experiments are in excellent concordance with the theoretical predictions. 
 
3.7) 53BP1 preferentially binds to chromatin associated with large replicons 
If 53BP1 does accumulate at genomic loci that inherit DNA damage caused by the transmission of 
unreplicated DNA through mitosis, then it would be expected that these sites would correspond to 
the largest replicons in the HeLa genome. The probability of a DFS taking place in a given replicon 
is proportional to its length squared (Newman et al., 2013), which means that they should occur at a 
disproportionally high frequency at the largest replicons. The increase of chromosome breakage at 
CFSs caused by aphidicolin treatment is consistent with the idea that a major contributor to their 
fragility is that they are origin-poor (or where large replicons exist). It was shown by ChIP-qPCR 
that fragile sites FRA3B and FRA16D are pulled down by 53BP1 and ɣ-H2AX (Lukas et al., 2011).  
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Figure 13: Depletion of MCMs on chromatin increases the frequency of 
G1-specific 53BP1 nuclear bodies. A) Scatter plot of the depletion of MCM5 as 
measured by flow cytometry (figure 12) against the frequency of G1-specific 53BP1 
nuclear bodies as quantified by fluorescence microscopy (figure 3 and 4). Each data 
point represents one experiment where both measurements are taken as separate 
samples of the same population of cells. The line represents the trend using the ‘least 
squares’ method (R2), M is the gradient of the line. B) As with figure 13A but depletion 
of MCMs on chromatin is facilitated by CDT1 RNAi.
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Figure 14: Replicon length is proportional to the frequency of G1-specific 53BP1 
nuclear bodies. A) Immunoblots of CDC6 over-expression HBEC cell line before and 
after induction by addition of 5 μg/ml doxycycline. Induction and blot carried out by Dr 
Alberto Moreno. B) Figure 2C superimposed with the data and trend lines from figures 
13A (red) and 13B (green) in addition to G1-specific 53BP1 nuclear bodies quantified in 
HBEC cells after induction of CDC6 (blue).
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This interaction between 53BP1 and ɣ-H2AX with the two CFSs required a treatment with 
aphidicolin. In unperturbed cells there was no significant enrichment for the fragile sites (Lukas et 
al., 2011). G1-specific 53BP1 nuclear bodies colocalise with ɣ-H2AX foci, which were shown to 
bind to ~1 Mbp-worth of chromatin around a DSB (Rogakou et al., 1999). A fraction of the nuclear 
pool of 53BP1 molecules is bound to chromatin in the absence of DNA damage, although this 
interaction is transient (Bekker-Jensen et al., 2005). Any regions of chromatin enriched by 53BP1 
immunoprecipitation can be sequenced and compared to the distribution of origins from the HeLa 
origin mapping data, and thereby the distribution of 53BP1 chromatin-binding can be determined 
relative to small or large replicons. 
 
To confirm this hypothesis with a more holistic approach, where the entire genome can be analysed, 
Dr Alberto Moreno carried out a ChIP-seq experiment using an anti-53BP1 antibody and IgG (non-
specific) control antibody to pull down 53BP1 in unperturbed and asynchronous HeLa cells 
(Moreno et al., 2016). The precipitated DNA was sequenced and then analysed by Dr Luca 
Albergante (in Professor Timothy Newman’s lab, at the time). The 53BP1/IgG binding ratio is 
proportional to replicon length (figure 15A). The very largest replicons are few in number (figure 
2A), and so the associated 53BP1/IgG binding ratios are relatively noisy (shaded white 
proportionally to the number of replicons). The correlation between replicon length and 53BP1/IgG 
is very highly significant (p < 10-15), however, the dynamic range of the 53BP1/IgG binding ratio is 
very small. This could be caused by the high level of stochasticity of pulling down an event that 
only occurs ~1-2 times per cell cycle and which could potentially occur anywhere in the genome. 
Alternatively, the high level of background could be caused by the fraction of 53BP1 that is bound 
to chromatin but not part of a nuclear body. Consistent with this, the genomic coverage of both anti-
53BP1 and IgG antibodies are comparable (Moreno et al., 2016). 1 kbp regions of the genome with 
high 53BP1/IgG binding ratios (p < 10-3) were identified, and if one or more these regions fell 
within a replicon it was defined as a ‘53BP1+’ replicon (Moreno et al., 2016). The average 
‘53BP1+’ replicon is three times longer than the average ‘53BP1’- replicon (figure 15B). 
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Figure 15: 53BP1 preferentially binds at large replicons. A) Scatter plot of 
53BP1/IgG binding ratio per kilobase against replicon size. Replicon sizes were 
grouped and each data point represents the mean of each group. The shade of each 
datapoint represents the number of reads in that replicon size group (the largest 
replicons have very few reads and are thus noisy). Spearman, ρ = 0.91, p < 10-15. 
ChIP-seq carried out by Dr Alberto Moreno, and analysis by Dr Luca Albergante. B) 
Mean length of replicons with (53BP1+) or without (53BP1-) significant 53BP1/IgG 
binning ratios. t-test, p < 10-15. ChIP-seq carried out by Dr Alberto Moreno, and analysis 
by Dr Luca Albergante.
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To better our understanding of the nature of the binding of 53BP1 to chromatin, cells were 
fractionated to determine the proportion of 53BP1 that is chromatin-bound, and microscopy was 
used to quantify the intensity of 53BP1 nuclear body signal compared to total nuclear signal. U2OS 
cells were used for these experiments as Professor Jiri Lukas and colleagues have developed a well-
characterised and validated U2OS cell line that expresses a GFP-53BP1 fusion protein at near-
physiological expression levels; the amount of total protein is equivalent between fusion and 
endogenous and the fusion protein retained physiological functions (Bekker-Jensen et al., 2005, 
Jullien et al., 2002). The rationale for using this cell line, as opposed to immunofluorescently 
labelling endogenous 53BP1, is that the ratio between the fluorescent molecule, GFP, and the 
ectopic 53PB1 is 1:1, which is not necessarily the case for immunofluorescence, meaning that 
quantification of GFP fluorescence should be in the linear range. Firstly, U2OS cells were 
fractionated, producing a chromatin-bound insoluble lysate and a soluble lysate (figure 16A). 
Equivalent volumes of each lysate were loaded so that abundances of 53BP1 in the chromatin-
bound fraction could be quantified relative to the 53BP1 abundance in the soluble fraction. 
LaminB1 and ɑ-tubulin were also blotted to verify the fractionation. LaminB1 is an intermediate 
filament protein that is insoluble and remains with the chromatin after fractionation, and ɑ-tubulin is 
a soluble protein that does not strongly associate with chromatin. The background-corrected signal 
intensities of the 53BP1 bands (in arbitrary units) are shown beneath the blot. ~80% of all 53BP1 is 
chromatin bound (figure 16A). Figure 16B is a representative image of the GFP-53BP1 U2OS cell 
line. When quantifying the fluorescence intensity of 53BP1, normal U2OS cells were imaged under 
the same conditions to obtain the intranuclear background. Software was used to find the volumes 
that corresponded to nuclear bodies and the entire nucleus, and background was removed on a per-
voxel basis. The relative intensity of GFP-53BP1 in nuclear bodies is ~1% when compared to the 
total nuclear signal (figure 16C). Taken together with the fractionation experiment (figure 16A), it 
seems that a majority of 53BP1 (~80%) is bound to chromatin without being part of a nuclear body 
in unperturbed U2OS cells (figure 16D). This is consistent with the 53BP1 ChIP-seq data that 
indicated 53BP1 had the potential to bind almost anywhere in the genome and probably explains  
Figure 16: A significant proportion of all 53BP1 proteins are bound to chromatin 
and not as part of nuclear bodies. A) Immunoblot of 53BP1 in either the 
chromatin-bound fraction or the soluble fraction, each fraction loaded at the same 
volume. B) Representative image of the GFP-53BP1 U2OS cell line. C) Sum voxel 
intensity of GFP signal in 53BP1 nuclear bodies in comparison the sum voxel intensity 
of GFP in the whole nucleus. Error bars represent S.E.M. of three biological replicates. 
t-test, p = 8.18 x 10-37. D) Pie chart of the nuclear localisation of 53BP1, summarising 
the results from figure 16A, B and C.
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why the dynamic range in figure 15A is small. Pan-nuclear chromatin-bound 53BP1 with sites of 
extreme 53BP1 accumulation and activity is reminiscent of the distribution of H2AX variant 
histone throughout the genome, but upon activation (phosphorylation) accumulates at the local site 
of damage and forms a nuclear body (Bewersdorf et al., 2006, Natale et al., 2017). It is possible that 
53BP1 is similarly poised throughout the genome to function with ɣ-H2AX to repair damaged 
DNA. 
 
3.8) Dormant origins and 53BP1 function synergistically to protect genomic stability 
against under-replication. 
53BP1 nuclear bodies protect unstable DNA structures inherited from the previous cell cycle 
(whether a long stretch of ssDNA generated by BLMs-mediated unwinding of a UFB or DSBs 
created by MUS81-mediated excision of stalled-fork structures at CFSs) by repressing BRCA1-
mediated HR. 53BP1-deficient mice are cancer-prone and exhibit stunted growth (Morales et al., 
2003, Ward et al., 2003b), and when depleted in BRCA1-/- mice this phenotype is rescued 
(Bouwman et al., 2010, Bunting et al., 2010), implying that inappropriate HR in G1 cells causes 
genomic instability. A partial-depletion of 53BP1 in HeLa cells could reduce HR inhibition at 
53BP1 nuclear bodies and increase genomic instability and cell death. However, the frequency of 
DFSs are predicted to be relatively infrequent (~1-2 per S phase (figure 2C)) and there may be 
redundant pathways that can protect or resolve a small number of DNA damage events. 
Unperturbed HeLa cells rarely exhibit four or more G1-specific nuclear bodies (figure 4B) and 
could indicate the low number of DFS events a HeLa cell can tolerate. Al Mamun et al. 2016 
speculate that if DFSs generate DSBs then the number of illegitimate end rejoinings increases 
disproportionately as the frequency of DFSs increases, reducing the probability of restoring the 
correct chromosomal structure. The number of possibilities for NHEJ recombination between DSB 
ends is approximate to the factorial of the number of DSBs. For example, 2 DSBs create 4 DSB 
ends that can be rejoined in 3 different ways, however 3 DSBs can be rejoined in 15 different ways 
and 4 DSBs in 105 different ways. If this is the case then it might be expected that increasing the 
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maximum frequency of DFSs in a single cell to beyond ~3, in combination with a partial-depletion 
of 53BP1, will additively increase genomic instability. However, DSB anchoring facilitated by ɣ-
H2AX, MRN, MDC1 and 53BP1 might ensure that DSB ends remain locally associated to preserve 
the structure of the genome, meaning that illegitimate end rejoining is less likely (Bassing and Alt, 
2004). 
 
To test this hypothesis, a clonogenic assay on asynchronous HeLa cells transfected with MCM5 and 
53BP1 siRNAs was carried out. Depletions of MCM5 and 53BP1 were confirmed (figure 17A) and 
the number of colonies that grew in increasing concentrations of HU were quantified (figure 17B). 
Partial-depletion of 53BP1 had no effect on HeLa sensitivity to HU treatment (figure 17B, green 
line), indicative of a toleration to replicative stress that is not dependent on high levels of 53BP1 
activity. Partial-depletion of MCM5 makes HeLa cells slightly more sensitive to replicative stress 
(figure 17B, red line, also see figure 5D of Ge et al. 2007) as fewer dormant origins are activated 
upon treatment with HU compared to the activation seen in cells with normal levels of origin 
licensing (Ge et al., 2007). The cells become most sensitive to HU when both MCM5 and 53BP1 
are partially-depleted (figure 17B, blue line). The sensitivity is well beyond the additive effect of 
individually reducing MCM5 and 53BP1, which implies a synergistic interaction between dormant 
origins and 53BP1 to promote genomic stability. Partial-depletion of replication origins increases 
the frequency of DFSs which are inherited as unstable sites or regions of DNA damage that would 
normally be protected from decay or inappropriate HR. HU treatment also increases the rate of fork 
stalling, DFSs, and, under normal conditions, the appearance of 53BP1 nuclear bodies. With the 
reduced abundance of 53BP1 at these loci, BRCA1-mediated HR is likely to take place at a higher 
frequency. Quantifying the number of colonies in the untreated conditions (by HU), without 
normalisation, shows that there is no significant difference in cell death after partial-depletion of 
MCM5, 53BP1, or both (figure 17C). 500 cells were seeded for each plate, which translates to ~300 
colonies quantified in the cells transfected with control siRNA, and does not significantly vary after 
the partial-depletions. This indicates that HU is required for the synergistic interaction to become 
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evident, likely because the induced increase in DFSs by MCM5 RNAi does not cause sufficient 
replicative stress to overwhelm the resultant DNA damage response, even if 53BP1 is partially 
depleted. It is also possible that alternative pathways that facilitate repair of under-replication do so 
before 53BP1 is required in the following G1 phase. These results are in concordance with an 
experiment where enrichment of TdT (indicates DSBs) at the origin-poor CFSs, FRA3B and 
FRA16D, only takes places when cells are both depleted of 53BP1 and treated with aphidicolin 
(Lukas et al., 2011).  
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Figure 17: Dormant origins and 53BP1 function synergistically to protect genome 
stability against under-replication. A) Immunoblot to confirm the depletion of both 
MCM5 and 53BP1 in HeLa cells used in the experiments presented in figure 17B-C. B) 
Clonogenic assay of HeLa cells depleted of either 53BP1, MCM5 or both. Colonies 
formed after treatment with increasing concentrations of HU were quantified and 
normalised to the untreated cells. Error bars represent S.E.M. of three biological 
replicates. K-S test, P = 1.00, P =  0.338, P = 0.0366, when comparing the ‘Control’ 
distribution to the ‘53BP1’, ‘MCM5’ and ‘MCM5 + 53BP1’ distributions respectively. C) 
Plating efficiency of cells for the clonogenic assay. Number of colonies of the control 
cells not treated with HU, pre-normalisation. Error bars represent S.E.M. of three 
biological replicates.
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Chapter 4 
 
Cellular responses to double fork stalls 
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4.1) G1-specific nuclear bodies in U2OS and IMR-90 cells 
The theoretical model predicts the average frequency of DFSs in a given HeLa S phase, and did so 
based on the genome size, origin mapping data, and an estimation for the median number of bases a 
replication fork replicates before irreversibly stalling. As described in Chapter 3, hypotheses that 
the model produced were confirmed by strong correlation with a candidate protein, 53BP1, that was 
already known to respond to replicative stress from the previous cell cycle (Harrigan et al., 2011, 
Lukas et al., 2011). 53BP1 also preferentially binds to large replicons and functions with dormant 
origins to protect genomic stability. None of these features depend on the cells in question to be 
cancerous. As long as the total genome size and number and distribution of replication origins are 
largely conserved between different types of human cells, then the frequency of DFSs should also 
be conserved. This can be seen in the small difference between the predicted frequencies of DFSs 
between HeLa and IMR-90 cells in figure 2C. However, there is a possibility that the characteristics 
of G1-specific 53BP1 nuclear bodies, with respect to the DFS model, presented so far in this thesis 
are unique to HeLa or cancer cells. HeLa cells are notoriously unstable and highly transformed, and 
exhibit cancer hallmarks such as gene amplification, deletions, chromosomal rearrangements and 
loss of heterozygosity (Frattini et al., 2015). The HeLa cells used in the experiments presented in 
this thesis were supplied from the ATCC (known as HeLa-CCL2) and are reported to have a modal 
chromosome number of 82, but can range from 70 to 164. However, a study reported that this cell 
line instead has a modal chromosome number of 78, which can range from 76 to 80 (Macville et al., 
1999). The instability is largely thought to be caused by aneuploidy which is characteristic of the 
HeLa cell line (Nicholson and Cimini, 2013). This instability and aneuploidies could cause DNA 
damage and activate 53BP1 accumulation at nuclear bodies, independent of DFSs.  
 
In order to test this idea, G1-specific 53BP1 nuclear bodies were quantified in U2OS and IMR-90 
cells to confirm that the basic characteristics were similar to those seen in HeLa cells. Human 
U2OS cells (osteosarcoma), like HeLa are highly transformed, exhibiting a modal chromosome 
number of ~68 (Janssen and Medema, 2013). However, U2OS cells are relatively stable when 
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compared to HeLa cells, with a chromosome number only slightly higher than when the cell line 
was first cultivated (ATCC). U2OS cells are null for the CDKN2A gene (CDK inhibitor 2a) which 
in normal cells has two gene products, p16INK4A and p14ARF. p16INK4A is an inhibitor of CDK4 and 
CDK6 activities, and its loss means that Rb is hyperphosphorylated and unable to repress E2F 
transcription factors (Serrano et al., 1993), promoting the expression of genes required for DNA 
replication. p14ARF (alternate reading frame) is expressed from the same locus and inhibits HDM2-
mediated (Mdm2 in S. cerevisiae) repression of p53. HDM2 is transcriptionally activated by p53 
and also represses p53, in a negative feedback loop by ubiquitylation which exports p53 to the 
cytoplasm for proteolysis (Zhang and Xiong, 2001). p14ARF binds to HDM2 to inhibit its E3 
ubiquitin ligase activity (Honda and Yasuda, 1999) and sequesters it to nucleoli (Weber et al., 
1999). So, in the absence of these two factors, U2OS cells lack regulated E2F-mediated 
transcription of S phase cyclins and this may therefore explain its lack of a licensing checkpoint, as 
with HeLa cells. 
 
Figure 18A is a representative image of U2OS cells stained as for HeLa cells in figure 3A. Dr 
Alberto Moreno quantified the frequency distribution of G1-specific 53BP1 nuclear bodies in U2OS 
cells. There are ~1.5 G1-specific 53BP1 nuclear bodies in U2OS cells (figure 18B), compared to ~1 
in HeLa cells (figure 3C). Despite the slightly higher frequency of G1-specific nuclear bodies in 
U2OS cells, their frequency distribution still conforms to a Poisson distribution (figure 18B, black 
line). A partial depletion of MCM5 (figure 18C) increased the mean frequency of G1-specific 
53BP1 nuclear bodies from ~1.5 to ~2.5 (figure 18D). There is no U2OS origin mapping data that 
these values can be compared to, but when compared to HeLa they are relatively similar, if not 
slightly higher, indicating that the link between the DFS predictions and 53BP1 nuclear bodies is 
valid in at least one other cancer cell line. 
 
IMR-90 cells, in contrast to HeLa and U2OS cells, are a primary fibroblast cell line cultivated from 
a 16-week old female foetus and are untransformed and stable with a normal chromosome number 
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of 46 (Nichols et al., 1977). Figure 19A is a representative image of IMR-90 cells stained as for 
HeLa cells (figure 3A) and U2OS cells (figure 18A). The frequency distribution of G1-specific 
53BP1 nuclear bodies was quantified (figure 19B). The overall mean is ~0.5 nuclear bodies and still 
fits well to a Poisson distribution (black line). Partial depletion of MCM5 (figure 19C) increases the 
mean frequency of G1-specific 53BP1 nuclear bodies to ~0.9 (figure 19D). Out of the three cell 
lines where G1-specific 53BP1 nuclear bodies have been quantified, IMR-90 has the lowest 
frequency. Although the sample size is small, it could be that the chromosomal rearrangements and 
hypertriploidy as seen in HeLa and U2OS cells causes an increase in G1-specific 53BP1 nuclear 
body frequency. 
 
4.2) Alternative responses to DFSs: MiDAS and FANCD2 
With respect to the cell cycle, there is a long period of time between a DFS in S phase and the 
accumulation of 53BP1 nuclear bodies in the following G1. It seems unlikely that 53BP1 is the first 
component of the DNA damage repair response that facilitates synthesis or repair at unreplicated 
segments of DNA. Although 53BP1 nuclear bodies accumulate rapidly and early in G1 (Lukas et 
al., 2011), a DFS-induced unreplicated segment of DNA must be preserved from the beginning of 
G2 through to anaphase where it may be excised by MUS81 endonuclease or form a UFB that is 
unwound by BLM helicase (Chan et al., 2007, Chan et al., 2009, Ying et al., 2013). Note, one of 
the core assumptions in the development of the original DFS model was that a population of 
replication forks stall irreversibly, and is built into the model by the median number of bases 
replicated before stalling (Ns	≈ 10 Mb) (Newman et al., 2013). Therefore, fork restart that 
successfully replicates a previously unreplicated segment of DNA and which can be resolved prior 
to mitotic entry, is disregarded as a response that is specific to DFSs.  
 
 Given the relevance of MiDAS to fork stalling and reducing the amount of unreplicated 
DNA transmitted through anaphase, it is potentially relevant to resolving DFSs. To test this,  
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Figure 18: G1-specific 53BP1 nuclear bodies in U2OS cells. A) Representative 
image of an asynchronous, unperturbed U2OS cell stained for 53BP1 (green), EdU 
(orange) and CyclinA (pink). B) Frequency distribution of G1-specific 53BP1 nuclear 
bodies in asynchronous, unperturbed U2OS cells. The mean frequency (1.62 nuclear 
bodies per G1 nucleus) is used to construct a Poisson distribution (black line). χ2 test, p 
= 0.651. 53BP1 nuclear bodies imaged and quantified by A.M. C) Immunoblot of MCM5 
depletion in U2OS cells for the experiment presented in figure 15D. Band intensities 
are normalised against the loading control, ɑ-tubulin. Abundance is band intensity 
relative to a sample transfected with control siRNA. D) Quantification of the mean 
frequency of G1-specific 53BP1 nuclear bodies in U2OS cells either transfected with 
control (scramble) or MCM5 siRNA. Error bars represent S.E.M. of three biological 
replicates. t-test, p = 1.4 x 10-12.
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Figure 19: G1-specific 53BP1 nuclear bodies in IMR-90 cells. A-D) As with figure 
18A-D, but with IMR-90 cells. χ2 test for figure 19B, p = 0.969. t-test for figure 19D, p = 
1.79 x 10-4.
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MiDAS foci frequency were quantified in response to MCM5 RNAi, for comparison with the 
numerical predictions generated by the DFS model.  
 
The introduction describes concerns about the use of the CDK inhibitor RO-3306 for assaying 
MiDAS. Figure 20A outlines a method to detect MiDAS where RO-3306 is not used. Instead, 
asynchronous U2OS cells are incubated in EdU for 30 minutes before fixation, and prophase and 
prometaphase cells are sought out using DAPI and p-H3 fluorescence morphology (similar to the 
method used for figure 1 of Minocherhomji et al. 2015). Meraldi et al. 2004 and Minocherhomji et 
al. 2015 show that U2OS cells take >30 minutes to reach prometaphase, and in figure 2A of Lukas 
et al. 2011 indicates that it takes ~ 1 hour. The intention of this method is that cells were fixed such 
that they had entered mitosis more than 30 minutes previously, so that EdU incorporation takes 
place exclusively in mitosis. Although this assumption could be challenged, the assay uses a more 
physiologically-true system than the use of RO-3306. Cells were treated with aphidicolin to 
compare to experiments in Minocherhomji et al. 2015. A representative image of an aphidicolin-
treated prophase U2OS cell is presented in figure 20B. In addition to fluorescently labelling EdU, 
FANCD2 is immunofluorescently stained, given the previously mentioned roles of FANCD2 in 
CFS resolution in mitosis, and the reported colocalisation between MiDAS foci and FANCD2 foci 
(Minocherhomji et al., 2015). FANCD2 foci are recruited to chromatin when ubiquitylated, and 
dissociate when deubiquitylated by USP1, after the damage is repaired (Garner and Smogorzewska, 
2011, Nijman et al., 2005). This means that in this experiment FANCD2 foci are a comparative 
snapshot of fork stalls, so mitotic EdU foci that colocalise with FANCD2 partially legitimises them 
as MiDAS foci. Inset into the ‘Merge’ panel of figure 20B shows some representative examples of 
colocalisation between MiDAS foci and FANCD2 foci. Quantification of FANCD2 and MiDAS 
foci in the experiment described in figure 20 is presented in figure 21. There is a mean of ~5 
FANCD2 foci in unperturbed prophase or prometaphase U2OS cells, which increases to ~35-40 
after a 24 hour treatment with aphidicolin (figure 21A), and is approximately in line with previously 
reported quantifications in metaphase nuclei in figure 1F of Chan et al. 2009. In unperturbed  
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Figure 20: Imaging MiDAS and FANCD2 foci in early-mitotic U2OS cells. A) 
Schematic of experimental design used in the experiments presented in figures 20, 21 
and 22. B) Representative image of a pro(meta)phase U2OS cell after a 24 hour 
treatment with 0.2 μM aphidicolin, stained for FANCD2 (green) and EdU (orange). 
White squares in ‘Merge’ pane indicate the context for the inset images.
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Figure 21: Aphidicolin increases the frequency of FANCD2 and MiDAS foci in 
early-mitotic cells. A) Quantification of the mean frequency of FANCD2 foci in 
prometaphase U2OS cells either untreated or incubated with aphidicolin for 24 hours. 
Error bars represent 95% confidence interval of one biological replicate. t-test, p = 4.87 
x 10-8. B) Quantification of the mean frequency of MiDAS foci in prometaphase U2OS 
cells either untreated or incubated with aphidicolin for 24 hours. Error bars represent 
95% confidence interval of one biological replicate. t-test, p = 5.52 x 10-7.
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prophase and prometaphase U2OS cells there is ~1 MiDAS focus, which increases to ~20 after 
aphidicolin treatment (figure 21B), which is similar to the quantification in figure 1B of 
Minocherhomji et al. 2015, where RO-3306 was not used either. Encouragingly, a mean frequency 
of ~1 MiDAS focus is in line with the theoretical prediction for the frequency of DFSs (although the 
origin number, distribution and genome size in U2OS may differ from HeLa, it is unlikely to differ 
by an order of magnitude). ~20 MiDAS foci after aphidicolin treatment is similar but slightly higher 
than the number of G1-specific 53BP1 nuclear bodies quantified in figure 1C of Lukas et al. 2011. 
As inhibiting nucleotide incorporation in mitosis increases the frequency of G1-specific 53BP1 
nuclear bodies, and MiDAS foci chased through to G1 infrequently colocalise with 53BP1 nuclear 
bodies, Minocherhomji et al. 2015 propose that when DNA is unsuccessfully repaired by MiDAS 
that loci is coated in 53BP1 in the following G1 phase. Both frequencies are comparable to the 
quantification in figure 1B of Minocherhomji et al. 2015. 
 
Colocalisation analysis of MiDAS foci and FANCD2 foci is presented in figure 22. In the context 
of image colocalisation analysis, Pearson’s correlation coefficient calculates the regression of a 
scatter graph of all pixel intensities of one channel against the intensities of the corresponding 
pixels of the other channel. It can range from -1 (anti-correlative) and 1 (perfect correlation), and 
works well for foci that are expected to be right on top of each other, and less well for complex 
structures (such as the inset images in figure 20B) or foci that are merely adjacent or partially 
overlap. Pearson’s correlation coefficient was calculated between MiDAS and FANCD2 foci 
(figure 22A). Manders’ overlap coefficient, designed for the purpose of quantifying colocalisation 
in biological samples, simply calculates the proportion of background threshold-adjusted voxels of 
one channel that overlap with the background threshold-adjusted voxels of the other, as well as the 
reciprocal (for example, there are 4 blue voxels, two of which overlap with red voxels, so Manders’ 
overlap coefficient for the blue channel is 0.5, and for the red channel its 1.0). Manders’ overlap 
coefficient ranges from 0 (not a single voxel overlaps), to 1 (all voxels of one channel overlap with 
voxels from the other. It is still weak for adjacent foci, but is superior for complex structures and 
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partially overlapping foci. Manders’ overlap coefficients for MiDAS and FANCD2 foci are 
presented in figure 22B. ‘FANCD2<EdU’ denotes the proportion of FANCD2 voxels that contain 
EdU voxels, and ‘EdU<FANCD2’ is the reciprocal. Finally, MiDAS and FANCD2 foci were 
defined by an unbiased visual approach and were then judged as either associated or unassociated. 
The percentage of FANCD2 foci that are associated with MiDAS foci is presented in figure 22C. 
Only ~5% of FANCD2 foci are associated with MiDAS foci in untreated cells. The average 
untreated cell has ~5 FANCD2 foci and ~1 MiDAS foci (figure 21), so the maximum expected 
proportion of overlap is ~20%, and therefore approximately one quarter of MiDAS foci are 
associated with FANCD2. When treated with aphidicolin, ~50% of FANCD2 foci contain MiDAS 
foci (figure 22C). The average aphidicolin treated cell contains ~40 FANCD2 foci and ~20 MiDAS 
foci, so the maximum expected overlap is also ~50%. This is not reflected as a perfect correlation or 
overlap coefficient in figure 22A and 22B since biological samples are noisy; when two foci 
colocalise does not necessarily mean every voxel they contain overlap. Overall, treatment with 
aphidicolin increases the frequencies of MiDAS and FANCD2 foci in early-mitotic U2OS cells 
(figure 21), but also disproportionately increases the extent of their colocalisation (figure 22). 
Speculatively, this could be explained by considering colocalised FANCD2 and MiDAS foci as 
sites of ongoing repair at severe damage. Without perturbation, isolated FANCD2 foci represent its 
function to protect and restart destabilised replication forks, which occur frequently in unperturbed 
cells, and MiDAS in isolation are sites of successful gap filling, potentially corresponding to a 
spontaneous DFS. Aphidicolin increases rates of fork stalling, creating large segments of 
unreplicated DNA that require BIR-like repair, as proposed by Minocherhomji et al. 2015 and 
Bhowmick et al. 2016, with extensive DNA synthesis. 
 
MiDAS foci were further tested for concordance with the DFS model. The experimental design is as 
before but the 24 hour treatment with aphidicolin is replaced with a 48 hour transfection period with 
MCM5 siRNA (figure 23A). Figure 23B is a representative image of a prometaphase U2OS cell 
transfected with control siRNA. MCM5 depletion was verified by immunoblotting, and ~80%  
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Figure 22: Aphidicolin increases colocalisation of FANCD2 and MiDAS foci. A) 
Mean Pearson’s colocalisation coefficients between FANCD2 foci and MiDAS foci in 
prometaphase U2OS cells either untreated or incubated with aphidicolin for 24 hours. 
Error bars represent the 95% confidence interval of one biological replicate. t-test, p = 
0.0167. B) Mean Manders’ overlap coefficient between FANCD2 foci and MiDAS foci in 
prometaphase U2OS cells either untreated or incubated with aphidicolin for 24 hours. 
‘FANCD2<EdU’ is shorthand for the proportion of FANCD2 signal that overlaps with 
EdU signal, and the inverse is labelled with ‘EdU<FANCD2’. Error bars represent 95% 
confidence interval of one biological replicate. t-test, p = 4.06 x 10-6, p = 5.33 x 10-4, 
respectively from left to right. C) Quantification of the proportion of FANCD2 foci that 
contained or overlapped with EdU foci in pro(meta)phase U2OS cells either untreated 
or incubated with aphidicolin for 24 hours. Error bars represent 95% confidence interval 
of one biological replicate. t-test, p = 3.14 x 10-6.
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Figure 23: Staining U2OS cells for MiDAS foci and FANCD2 foci after MCM5 
RNAi. A)  Schematic of experimental design for experiments presented in figures 23, 
24 and 25. B) Representative image of an unperturbed prometaphase U2OS cell 
stained with EdU (orange) and FANCD2 (green).
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depletion was achieved for each replicate: figure 24A is a representative example. The frequency of 
FANCD2 foci in early-mitotic cells transfected with either control siRNA or MCM5 siRNA was 
quantified (figure 24B). The frequency of FANCD2 foci increases from ~3 to ~6.5 after an ~80% 
depletion of total MCM5. The flow cytometry analysis used previously was not performed on this 
sample, so the actual reduction in DNA-bound MCM2-7 at S phase entry is unknown. In HeLa 
cells, an ~80% MCM5 depletion, as measured by immunoblotting whole cell lysate, results in a 
~50-60% depletion of DNA-bound MCM2-7 at S phase entry. This reduction of chromatin-bound 
MCM2-7 is predicted to cause 2-2.5 DFSs per cell, and is associated with a similar number of 
53BP1 nuclear bodies in each G1 cell (figure 14). Under these conditions there are twice as many 
MiDAS foci (~4) and three times as many FANCD2 foci. Most likely, 2-3 FANCD2 foci form for 
reasons other than a DFS and do not colocalise with MiDAS foci. Alternatively, it could be that 
FANCD2 foci are the true reflection of DFS frequency, and that G1-specific 53BP1 nuclear bodies 
are an underestimate. Minocherhomji et al. 2015 proposed that unsuccessful repair at MiDAS loci 
results in the inheritance of the DNA damage which is coated by 53BP1 in the following G1. It is 
possible that mitotic FANCD2 foci have a similar relationship with 53BP1 nuclear bodies in the 
following G1. Indeed, depletion of FANCD2 causes an increase in the frequency of cells that 
contain 53BP1 nuclear bodies (Bourseguin et al., 2016).  
 
Colocalisation analyses were carried out on MiDAS and FANCD2 foci in cells partially depleted of 
MCM5, as described above. Both Pearson’s correlation and Manders’ overlap coefficients increase 
after partial-depletion of MCM5 (figure 25A and 25B). This increase in colocalisation can also be 
seen in the populations of foci combinations. Foci in each channel were identified with an unbiased 
approach and were categorised as either ‘FANCD2 foci only’, ‘MiDAS foci only’ or ‘Colocalised’. 
Isolated FAND2 foci and MiDAS foci both increase after ~80% MCM5 depletion (figure 25C). 
However, the greatest change is seen in the colocalised population of foci (figure 25C, yellow 
columns), and, again, the frequencies of colocalised foci with and without MCM5 partial-depletion 
are in concordance with the DFS model (figure 2C). As speculated above, specifically colocalised  
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Figure 24: MCM5 RNAi increases the frequency of FANCD2 and MiDAS foci. A) 
Representative immunoblot of MCM5 depletion in U2OS cells used in the experiments 
presented in figures 21B and C. Band intensities are normalised against the loading 
control, ɑ-tubulin. Abundance is band intensity relative to a sample transfected with 
control siRNA. B) Quantification of the mean frequency of FANCD2 foci in 
prometaphase U2OS cells either transfected with control (scramble) or MCM5 siRNA. 
Error bars represent 95% confidence interval of three biological experiments. t-test, p = 
2.71 x 10-6. C) Quantification of the mean frequency of MiDAS foci in prometaphase 
U2OS cells either transfected with control (scramble) or MCM5 siRNA. Error bars 
represent 95% confidence interval of three biological experiments. t-test, p = 3.43 x 
10-8.
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Figure 25: MCM5 RNAi increases colocalisation of FANCD2 and MiDAS foci . A) 
Mean Pearson’s colocalisation coefficients between FANCD2 foci and MiDAS foci in 
prometaphase U2OS cells either transfected with control (scramble) or MCM5 siRNA. 
Error bars represent the 95% confidence interval of three biological replicates. t-test, p 
= 0.0172. B) Mean Manders’ overlap coefficient between FANCD2 foci and MiDAS foci 
in prometaphase U2OS cells either transfected with control (scramble) or MCM5 
siRNA. ‘FANCD2<EdU’ is shorthand for the proportion of FANCD2 signal that overlaps 
with EdU signal, and the inverse is labelled with ‘EdU<FANCD2’. Error bars represent 
95% confidence interval of three biological experiments. t-test, 2.63 x 10-5, 2.06 x 10-5, 
respectively from left to right. C) Quantification of frequency of FANCD2 foci only, 
MiDAS foci only and where both foci colocalise in prometaphase U2OS cells 
transfected with either control (scramble) or MCM5 siRNA. Error bars represent 95% 
confidence interval of three biological experiments. t-test, p = 1.05 x 10-6, for the 
‘Colocalised’ yellow columns.
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FANCD2 and MiDAS foci may be sites of a BIR-like DNA synthesis that fills long gaps of 
unreplicated DNA. Aphidicolin was shown previously to increase MiDAS foci frequency, 
implicating them as part of CFS repair (Minocherhomji et al., 2015), but here concordance with the 
DFS model implies that these sites of DNA synthesis are also a response to spontaneous DFSs in 
unperturbed cells, implicating a specific subset of CFSs that can contain large replicons (e.g. 
FRA3B and FRA16D). 
 
4.3) UFBs increase in frequency after MCM5 partial-depletion 
As mentioned previously, segments of DNA that remain unreplicated up until anaphase will 
physically link sister-chromatids and cause anaphase bridging, non-disjunction or mis-segregation. 
To test whether DFSs can cause UFBs, Dr Alberto Moreno imaged UFBs by immunolabelling 
BLMs helicase, and quantified their frequency in HeLa cells transfected with either control or 
MCM5 siRNA (figure 26). A representative image is presented in figure 26A, with two UFBs (red) 
bridging the anaphase gap. The mean frequency of UFBs in control cells is ~1.5, corresponding to 
the predicted frequency of DFSs and quantified frequency of G1-specific 53BP1 nuclear bodies, as 
well as previously reported quantifications in unperturbed human cells (Chan et al., 2007, Chan et 
al., 2009). Here, UFBs were not costained with FANCD2, so Dr Moreno’s quantification will 
include UFBs between centromeres, which are deemed to be of little relevance to CFS repair as 
they do not increase in frequency after aphidicolin treatment (Chan et al., 2009). It is reported that 
from ~20% (in unperturbed GM00637 cells) to ~60% (in unperturbed PSNF5 cells, BLM+ isogen to 
BLM- PSNF13) of UFBs are associated with FANCD2 foci (Chan et al., 2009). So, it is likely that 
Dr Moreno detected just under one UFB in the control transfected HeLa cells. The partial depletion 
of MCM5 increases the mean frequency of total UFBs to just over 2 (figure 26B). Again, these 
quantities are in concordance with the predicted frequencies of DFSs with a normal amount of 
licensing and partially depleted licensing (figure 2C). This claim has been used several times in this 
thesis so far, so it is worth restating here that it is not just that a cellular event occurs approximately 
once in an unperturbed cell cycle so must, therefore be a response to DFSs, but that the frequency of  
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Figure 26: Ultrafine anaphase bridges increase in frequency after MCM5 RNAi. A) 
Representative image of an anaphase HeLa cell, exhibiting an UFB stained with anti-
BLM antibody (red). UFBs imaged by Dr Alberto Moreno.  B) Quantification of the mean
 frequency of UFBs in anaphase HeLa cells either transfected with control (scramble) or
 MCM5 siRNA. Error bars represent S.E.M. of three biological replicates. t-test, p =
 0.0473. UFBs quantified by Dr Alberto Moreno.
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this event consistently increases to ~2-3 per cell cycle in response to a relatively gentle perturbation 
that otherwise is undetectable in the absence of induced replicative stress (figure 17 and Ge et al. 
2007). 
 
4.4) The state of the DNA contained within 53BP1 nuclear bodies inherited by sister-
daughter cells 
As previously mentioned, there are a few proposed causes of the DNA structures recognised by G1-
specific 53BP1 nuclear bodies that are inherited symmetrically by both daughter cells. So far, it has 
been proposed to be, or a combination of, a) pre-anaphase MUS81 (or other nucleases) nucleolytic 
cleavage at stalled or collapsed replication forks (Ying et al., 2013), b) DNA breaks caused by 
tension from chromatin condensation in early-mitosis (Lukas et al., 2011), or c) BLMs helicase 
unwinding of the unreplicated DNA, producing a segment of ssDNA (Chan and Hickson, 2009, 
Chan et al., 2007, Harrigan et al., 2011, Lukas et al., 2011). 
 
The DFS model favours the hypothesis of the inheritance of symmetrical ssDNA segments (option 
c), as it seems likely that this would be the best way to preserve genetic material for both daughter 
cells. DFSs are predicted to occur approximately once per unperturbed human cell cycle, and 
unreplicated DNA within a DFS has the potential to be in the order of Mbp in length, so it seems 
likely that persistent preservation of unreplicated DNA is mandatory for genomic preservation and 
stability. However, the creation of DSBs by MUS81 or other nucleases (option a) may be a possible 
consequence of DFSs, particularly for large unreplicated segments, if the unwinding of unreplicated 
DNA strands is not complete as chromatids are pulled apart in anaphase. We would therefore 
predict that many 53BP1 nuclear bodies generated by DFS events should contain significant 
amounts of ssDNA. 
 
To test this hypothesis, HeLa cells were immunofluorescently stained for 53BP1 and the ssDNA-
binding protein RPA. As previously reported, ssDNA is not readily detected in G1-specific 53BP1 
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nuclear bodies (Harrigan et al., 2011, Lukas et al., 2011). Lukas et al. 2011, found that <1% of 
53BP1 nuclear bodies contained RPA signal, and commented that the little that was found could be 
explained by the reincorporation of micronuclei, which contain highly damaged ‘pulverised’ 
chromatin (Crasta et al., 2012). Although micronucleation can be caused by replication stress or 
under-replication, reincorporated micronuclei were disregarded from the analysis as they can occur 
for several reasons, of which a DFS is unlikely. Figure 27A is a representative image of a G1-
specific 53BP1 nuclear body that contains what is considered ‘legitimate’ RPA signal. Examples of 
micronuclei reincorporation, as stained by 53BP1 and RPA, are in figure 27B, and are distinguished 
by the distinct lobed or fragmented appearance of the nuclear body. The proportion of G1-specific 
53BP1 nuclear bodies that contained ‘legitimate’ RPA signals was quantified in HeLa cells either 
transfected with control siRNA or MCM5 siRNA (figure 28). Depletion of MCM5 was confirmed 
by immunoblot (figure 28A). ~7% of 53BP1 nuclear bodies contained RPA signal (figure 28B). 
However, partial-depletion of MCM5 increases the proportion of G1-specific nuclear bodies that 
contain RPA foci to ~30% (figure 28B). The proportion of 53BP1 nuclear bodies colocalised with 
RPA in control cells is slightly higher here than was reported by Lukas et. al 2011, (<1%), and may 
be explained by sensitivity of the antibodies or microscopes, or the inclusion of false positives, 
given the subjective distinction between legitimate RPA signal and reincorporated micronuclei. 
More importantly is that even considering ~7% of 53BP1 nuclear bodies with ssDNA as real is still 
considerably less than predicted. Harrigan et al. 2011 speculate that if 53BP1 do contain significant 
stretches of ssDNA then it must either be coated in a yet-to-be discovered ssDNA binding protein or 
has adopted a secondary structure that is not bound by RPA or anti-BrdU antibodies. 
 
A speculative alternative is that MiDAS completes the replication of the vast majority of the 
unreplicated DNA in mitosis, allowing normal segregation of sister-chromatids, and these sites are 
then coated in 53BP1 in the following G1, and, like an epigenetic mark, designates the site as 
previously damaged or in need of further repair. If this is the case then these nuclear bodies would 
contain little to no ssDNA. If MiDAS partially replicates an unreplicated segment of DNA, for  
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Figure 27: RPA Indicates the Presence of ssDNA in a Proportion of G1-Specific 
Nuclear Bodies. A) Representative image of an unperturbed HeLa cell stained for 
53BP1 (orange) and RPA (green). B) Representative images of reincorporated 
micronuclei, 53BP1 (orange), RPA (green).
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Figure 28: The proportion of G1-specific 53BP1 nuclear bodies that contain RPA 
signal increases after MCM5 RNAi. A) Representative immunoblot of MCM5 
depletion of the HeLa cells used in the experiment presented in figure 28B. Band 
intensities are normalised against the loading control, ɑ-tubulin. Abundance is band 
intensity relative to a sample transfected with control siRNA. B) Proportion of 
G1-specific 53BP1 nuclear bodies that contain significant RPA signal in asynchronous 
HeLa cells either transfected with control (scramble) or MCM5 siRNA. Error bars 
represent S.E.M. of three biological replicates. t-test, p = 3.01 x 10-3.
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example if the unreplicated segment is particularly long, then segregation by BLM helicase or 
nucleolytic cleavage would still be necessary, and inherited DNA structures would contain partially 
filled gaps with MiDAS basepairs as well as ssDNA for RPA binding. Partial-depletion of licensing 
increases the frequency of DFSs, and also their length, which may explain the proportional increase 
in colocalisation between 53BP1 nuclear bodies and RPA.  
 
To gain a deeper insight into the colocalisation, or lack thereof, between MiDAS foci chased into 
G1 and G1-specific 53BP1 nuclear bodies, the colocalisation experiments presented in figures 20-
25 were used again on the experimental setup described in figure 29A. Asynchronous U2OS cells 
were incubated with EdU for 30 minutes followed by a mitotic shake-off, washed, re-seeded and 
allowing to adhere to a cover glass. A representative image of a pair of G1 cells, treated with 
aphidicolin, is presented in figure 29B. The mean frequency of 53BP1 nuclear bodies in untreated 
U2OS cells is higher than the control U2OS cells in figure 18D, probably caused by the stress of a 
mitotic shake-off (figure 30A). Aphidicolin treatment increases the frequency to ~10 nuclear bodies 
per G1 nucleus (figure 30A). The mean frequency of MiDAS foci in G1 (figure 30B) was ~3, 
similar to the frequency in early-mitotic cells, as quantified in figure 21. Aphidicolin treatment 
increases Pearson’s correlation and Manders’ overlap coefficients for EdU and 53BP1, compared to 
untreated cells (figure 31A and 31B). ~20% of 53BP1 nuclear bodies contain significant MiDAS 
foci in untreated cells (see inset images in 29B), which increases to ~50% after aphidicolin 
treatment (figure 31C). Minocherhomji et al. 2015 concluded from a similar experiment that the 
low level of colocalisation meant that either MiDAS or 53BP1 was sufficient to repair a particular 
locus of damage, however, they did not compare their colocalisation quantification with untreated 
cells. The disproportionate increase in colocalisation caused by aphidicolin has similar implications 
to those from figures 21 and 22. 53BP1 nuclear bodies or MiDAS foci in isolation could represent 
sites of less severe damage that are occur spontaneously in unperturbed cells, but when cells are 
treated with aphidicolin both mechanisms are required in the repair of the severe damage caused, 
and colocalisation in unperturbed cells could be the response to a DFS. 
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As mentioned above, 53BP1 nuclear bodies could reflect dsDNA breaks, either generated as a 
consequence of DFSs or by other means. The frequency of G1-specific ɣ-H2AX foci was quantified 
to test if under-replication would increase DSBs as detected by ɣ-H2AX in the following G1. As 
with figure 3A, G1 cells were identified in an asynchronous population by the absence of EdU and 
CyclinA signal (figure 32A). ɣ-H2AX foci are frequent in S phase (figure 32A, top left cell), and 
localise to sites of replication stress, and are disregarded. HeLa cells were partially depleted of 
MCM5 (figure 32B). There is no significant difference in frequency between G1 HeLa cells 
transfected with control siRNA or MCM5 siRNA (figure 32C). A more comprehensive 
colocalisation analysis with 53BP1 would be required to fully characterise the DNA content of 
53BP1 nuclear bodies in response to partial depletion of licensing, but this initial result indicates 
that there might be distinct pathways used by most CFS resolution and most DFS resolution. There 
are multiple ways in which CFSs are expressed by aphidicolin treatment that could develop into 
DSBs, perhaps a partial-depletion of licensing specifically exacerbates those CFSs that are 
contained within large replicons, and are less likely to produce DSBs come G1 phase.  
ADAPI 53BP1 EdU Merge
5 μm
24 hour 0.2 μM aphidicolin
30 min 40 μM EdU
Mitotic shake-off
Allow cells to adhere
Fix & stain
B
Figure 29: MiDAS foci from Early-mitosis are localised within G1-specific 53BP1 
nuclear bodies. A) Schematic of experimental design to observe the fate of 
pro(meta)phase MiDAS foci in G1 cells immunostained for 53BP1. B) Representative 
image of G1 U2OS cells treated with aphidicolin for 24 hours immunostained for 53BP1 
(green) and EdU incorporated in early mitosis (orange).
Figure 30: MiDAS foci and 53BP1 nuclear bodies both increase in frequency in 
G1 cells after treatment with aphidicolin. A) Quantification of the mean frequency of 
G1-specific 53BP1 nuclear in U2OS cells either untreated or incubated with aphidicolin 
for 24 hours. Error bars represent 95% confidence interval of one biological replicate. 
t-test, p = 6.07 x 10-5. B) Quantification of the mean frequency of MiDAS foci from 
pro(meta)phase in G1 U2OS cells either untreated or incubated with aphidicolin for 24 
hours. Error bars represent 95% confidence interval of one biological replicate. t-test, p 
= 7.07 x 10-7.
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Figure 31: MiDAS foci increase in colocalisation with G1-specific 53BP1 nuclear 
bodies after treatment with aphidicolin. A) Quantification of the proportion of 
G1-specific 53BP1 nuclear bodies that contained or overlapped with MiDAS foci 
incorporated in pro(meta)phase U2OS cells either untreated or incubated with 
aphidicolin for 24 hours. Error bars represent 95% confidence interval of one biological 
replicate. t-test, p = 2.80 x 10-3. B) Mean Pearson’s colocalisation coefficient between 
G1-specific 53BP1 nuclear bodies and MiDAS foci from pro(meta)phase in G1 U2OS 
cells either untreated or incubated with aphidicolin for 24 hours. Error bars represent 
he95% confidence interval of one biological replicate. t-test, p = 2.70 x 10-3. C) Mean 
Manders’ overlap coefficient between G1-specific 53BP1 nuclear bodies and MiDAS 
foci from pro(meta)phase in G1 U2OS cells either untreated or incubated with 
aphidicolin for 24 hours. ‘53BP1<EdU’ is shorthand for the proportion of 53BP1 signal 
that overlaps with EdU signal, and the inverse is labelled with ‘EdU<53BP1’. Error bars 
represent 95% confidence interval of one biological replicate. t-test, p = 9.51 x 10-8, p = 
5.55 x 10-4, respectively from left to right.
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Figure 32: MCM5 RNAi does not significantly increase G1-specific double strand 
breaks as marked by γ-H2AX foci. A) Representative of asynchronous HeLa cells 
stained with γ-H2AX (green), EdU (orange) and CyclinA (red). EdU and CyclinA 
staining are used to stage cells (white arrows) and G1 cells are used for the 
quantification in figure 32C. B) Representative immunoblot of the HeLa cells used in 
the experiment presented in figure 32C. Band intensities are normalised against the 
loading control, ɑ-tubulin. Abundance is band intensity relative to a sample transfected 
with control siRNA. C) Quantification of the mean frequency of G1-specific γ-H2AX in 
asynchronous HeLa cells transfected with either control (scramble) or MCM5 siRNA. 
Error bars represent 95% confidence interval of three biological replicates. t-test, p = 
0.716.
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Chapter 5 
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5.1) Summary of results 
Presented in this thesis is evidence that DFSs occur at a significantly higher rate in unperturbed 
human cells compared to yeasts, with which the DFS model was originally validated (Newman et 
al., 2013), and that the cellular responses to DFSs overlap with the cellular responses to CFSs. 
Firstly, given previous investigations and speculation as to the function of G1-sepcific 53BP1 
nuclear bodies (Harrigan et al., 2011, Lukas et al., 2011), they were tested as a candidate for 
responding to DFSs. The frequency of 53BP1 nuclear bodies in unperturbed cells, and in cells with 
partially depleted licensing, is in concordance with the predicted frequency of DFSs, and is likely 
applicable to primary cell lines. 53BP1 preferentially binds to chromatin associated with large 
replicons in unperturbed cells, and functions with dormant origins to protect genome stability 
against replication stress. Secondly, research into cellular responses to CFS expression has 
identified a series of factors that facilitates recovery from replication stress after the completion of S 
phase, and of those examined, were also found to largely concord with the predicted frequency of 
DFSs in unperturbed cells and cells partially depleted of licensing. These factors include FANCD2 
and MiDAS, as well as BLM-coated UFBs. Thirdly, after partial licensing depletion, the low 
frequency of G1-specific 53BP1 nuclear bodies that contain RPA (ssDNA) and MiDAS foci 
increases whilst the higher frequency that contain ɣ-H2AX (dsDNA) do not. 
 
This work builds on the original DFS model (Newman et al., 2013), and indicates that it is also 
applicable to higher eukaryotes, and therefore a conserved side-effect of the eukaryotic licensing 
system. Additionally, it is likely that cellular responses to DFSs are the same as those for some 
CFSs, which is consistent with the subset of CFSs that are associated with very large replicons, such 
as FRA3B and FRA16D (Letessier et al., 2011). It is also likely a significant proportion of DFSs 
occur at CFSs in unperturbed cells, but could also potentially occur anywhere in the genome.
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5.2) Model 
Collating the results presented here, as well as extensive research into CFSs, a model for the cellular 
responses to DFSs in unperturbed cells is presented in figure 33. From top to bottom is progression 
through the cell cycle from an arbitrary G1 to the S phase of the following cell cycle (stages are 
indicated in the left-hand margin). Starting with a duplex of unreplicated G1 DNA (blue), one or 
more DFSs occur in ~70% of all S phases. Theoretical modelling of the frequency distribution of 
DFSs in human cell S phases predicts that ~30% of S phases exhibit zero DFSs (see figure 6 of Al 
Mamun et al. 2016), which is reflected in the frequency distribution of G1-specific 53BP1 nuclear 
bodies in HeLa cells (figure 4B), where ~40% of G1 cells contain no 53BP1 nuclear bodies (figure 
33, ). 
 
A mean of ~1-2 DFSs are predicted per HeLa S phase (figure 2C and 4A). Mechanisms that can 
facilitate fork restart are acknowledged here, and can facilitate the complete duplication of the 
genome in response to under-replication (figure 33, ). For example, recent work published by 
Natsume et al. 2017, revealed the MCM8/9 can support progress through S phase via HR after 
induction of acute MCM2 destruction during S phase (Natsume et al., 2017). Similarly, the activity 
of MUS81 complexed with EME2 is restricted to S phase and promotes fork restart (Pepe and West, 
2014). However, one of the primary assumptions of the DFS model is that there is a per nucleotide 
probably of irreversible fork stalling, which is built into the estimation for Ns (Newman et al., 
2013), so fork restart or HR-mediated DNA synthesis that compensate for fork stalling in general 
are disregarded. 
 
FANCD2 is recruited to stalled forks, to stabilise and potentially facilitate restart (figure 33, ). 
However, where fork restart fails, MUS81-EME1 is recruited to stalled forks in mitosis and cleaves 
them to repress formation of UFBs. There is a mean frequency of ~3-5 FANCD2 foci per early-
mitotic U2OS cell (figure 21A and 24B), which is approximately double the predicted frequency of 
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DFSs (and UFBs, and 53BP1 nuclear bodies). This might indicate a function of these foci 
independent of DFSs, or might reflect the structure of a DFS, which is composed of two stalled 
forks but only causes one UFB and one 53BP1 nuclear body per sister-G1 cell (so two nuclear 
bodies total). Successful cleavage of stalled forks by MUS81-EME1 may result in the loss of the 
unreplicated segment of DNA, which is perhaps preferable to risking mis-segregation and UFBs. 
Each daughter cell inherits the DSB ends, which are maintained in local association by MRN 
scaffolding function, and localised activation of ɣ-H2AX promotes the recruitment of 53BP1 to 
chromatin ~1 Mbp around the DSB, and carries out its well described role in promoting NHEJ 
(figure 33, 	). Chromosome breaks are locally enriched with MDC1 (a direct sensor of ɣ-H2AX), a 
well characterised DSB marker, which persist from at least metaphase through to G1 and form 
symmetrical nuclear bodies in the daughter cells that colocalise with 53BP1. Additionally, ɣ-H2AX 
foci are symmetrical in number between segregated anaphase chromosomes and both of these 
phenomena occur at a low frequency in unperturbed cells, which increases after aphidicolin 
treatment (Lukas et al., 2011). This indicates that MUS81-type nuclease cleavage, or tension from 
chromosome condensation, creates DSBs in early-mitosis and account for a proportion of G1-
specific 53BP1 nuclear bodies. The function of these G1-specific 53BP1 nuclear bodies would then 
be in concordance with the genetic studies that identified 53BP1 as an inhibitor of HR and DNA 
end resection and a facilitator of NHEJ (Bothmer et al., 2010, Bouwman et al., 2010, Bunting et al., 
2010). 
 
In an alternative pathway, but not necessarily mutually exclusive, MUS81 cleavage could facilitate 
MiDAS upon chromosome-condensation in early-mitosis. The DSB ends created by MUS81-
mediated cleavage are resected and coated in RAD52 to facilitate microhomology-mediated BIR 
(Bhowmick et al., 2016), which results in the completion of replication at the previously 
unreplicated segment of DNA (figure 33,). The mean frequency of MiDAS foci in unperturbed 
early-mitotic U2OS cells is ~1 (figure 21B and 24C). BIR synthesis is highly inaccurate (Deem et 
al., 2011) which potentially explains why some segments of MiDAS are coated in 53BP1, 
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preventing end resection and HR, transcription (Harrigan et al., 2011), and protecting the 
mutagenised DNA until high-fidelity HR-dependant DNA repair can take place in S phase. 
However, in contradiction to this, BIR-type DNA synthesis is conservative (Donnianni and 
Symington, 2013, Saini et al., 2013), so to preserve genetic information one daughter cell would 
inherit a MiDAS duplex and the other the original unreplicated segment of DNA (figure 33, , 
top). Bhowmick et al. 2016, in the follow up to the model they presented in Minocherhomji et al. 
2015, prepared metaphase spreads and visualised MiDAS foci. Quantification revealed that ~45% 
of MiDAS foci were situated on one chromatid arm only, and ~35% were situated on both 
chromatid arms (~20% were uncategorisable), implying that there is more than one MiDAS 
mechanism or indeed that RO-3306 synchronisation and release is imperfect, as mentioned in the 
introduction, and semiconservative S/G2 synthesis has been visualised. It is not clear how an 
asymmetric process such as this would cause symmetrical FANCD2 foci in telophase (Chan et al., 
2009) and symmetrical 53BP1 nuclear bodies in the following G1 (Lukas et al., 2011). Perhaps both 
the ‘broken’ and ‘donor’ chromosomes require ongoing repair following BIR, and would explain 
why not all 53BP1 nuclear bodies contain MiDAS foci, as one daughter cell would inherit a MiDAS 
duplex and coat it in 53BP1, and the other daughter cell would inherit the original unreplicated 
segment of DNA and coat it in 53BP1 as well. If MiDAS is BIR-like (conservative) and does not 
complete gap filling then one daughter would inherit the original unreplicated segment of DNA and 
the other a deletion that can potentially span the length of the unreplicated segment. In the context 
of the DFS model, the potential for deletions such as this occur a mean of 1-2 times per cell cycle, 
and would resemble genetic loss reminiscent of telomere shortening, but from the body of 
chromosomes. Alternatively, MiDAS could be semi-conservative (figure 33, , bottom), consistent 
with the symmetric telomeric FANCD2 foci (Chan et al., 2009) and symmetrical 53BP1 nuclear 
bodies in the following G1 (Lukas et al., 2011). Semi-conservative MiDAS would likely result in 
less genetic loss when compared to the conservative version, and so is a satisfying solution to the 
predicted high frequency of DFSs. 
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If the unreplicated segment is not cleaved by MUS81-EME1, or replicated by MiDAS, then sister-
chromatids will remain physically linked during chromosome segregation in anaphase, forming a 
FANCD2-flanked and BLM-coated UFB. Dr Alberto Moreno quantified the frequency of UFBs in 
unperturbed HeLa cells to be ~1-2 per anaphase cell, in agreement with the predicted frequency of 
DFSs. If BLM helicase and topoisomerase IIIɑ activities successfully unwind the unreplicated 
segment of DNA then each daughter cell inherits a symmetrical segment of ssDNA, which could 
potentially be coated by 53BP1 and protected from HR in G1 and repaired by high-fidelity HR 
during S phase (figure 33, ). Like semi-conservative MiDAS, this mechanism would likely stably 
maintain genetic information, a requirement that the high frequency of DFSs would necessitate. It 
would also explain why 53BP1 nuclear bodies are at a constant frequency through G1 and decline 
during S phase (figure 6 and 7), which 	 does not. If semi-conservative MiDAS only partially 
replicates previously unreplicated DNA then symmetrical 53BP1 nuclear bodies in daughter cells 
would be expected to contain a low frequency of MiDAS foci and RPA. ~20% of G1-specific 
53BP1 nuclear bodies contain MiDAS foci (figure 31C) and ~7% contain RPA (figure 28B). Both 
frequencies increase after aphidicolin treatment and partial licensing depletion respectively, 
possibly because the average length of unreplicated segments has increased, making merely partial 
gap-filling by MiDAS more likely. 
 
Overall, these results are consistent with the idea that there are multiple mechanisms that function to 
resolve under-replication at specific cell cycle stages, starting with fork stabilisation and restart in S 
phase, through to the accumulation and disappearance of 53BP1 nuclear bodies in the following S 
phase. Each mechanism can feasibly resolve un-replicated segments of DNA, and given the order in 
which they function, are reminiscent of layered safety nets under a trapeze gymnast: if fork restart 
fails, then MUS81 is recruited to repress UFB formation and/or facilitate MiDAS; if MiDAS fails, 
then UFBs form and BLM helicase is recruited to unwind the DNA. Whether daughter cells inherit 
DSBs from MUS81-mediated cleavage, ssDNA segments from BLM helicase activity, and/or 
nucleotides synthesised by MiDAS, then 53BP1 is recruited to those lesions to protect against 
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inappropriate HR until high-fidelity repair in S phase. Given the predicted frequency of ~1-2 DFSs 
per S phase, it would make sense that a requirement of their resolution would be the preservation of 
the genetic information contained within the unreplicated DNA. If so, it would seem semi-
conservative MiDAS and/or the pathway that leads to  should be favoured over the potentially 
deleterious conservative version of MiDAS or the pathway that leads to 	. 
 
5.3) G1-sepcific 53BP1 nuclear bodies in primary and cancer human cell lines 
Despite the similar genome size, origin frequency and origin distribution between HeLa and IMR-
90 cells, HeLa cells exhibit approximately double the number of 53BP1 nuclear bodies as IMR-90 
cells (figure 4A and figure 19D) (Al Mamun et al., 2016, Picard et al., 2014). It is possible that the 
difference between the untransformed cell line, IMR-90, and the transformed cancer cell line, HeLa, 
is ploidy. The telomere-to-genome size ratio is greater in HeLa cells, which will have ~150 
telomeres in G1 and ~300 by G2 and M, compared to IMR-90 which will have ~100 in G1 and 
~200 in G2 and M. As discussed and modelled in Newman et al. 2013, telomeres are unusual in that 
if the last replication fork that comes from the body of the chromosome stalls then it is equivalent to 
a DFS event, in that a segment of DNA remains unreplicated, but are more likely to occur as only a 
single fork must stall. Additionally, telomeres are G-rich, contain repetitive sequences, are coated in 
proteins and form secondary structures, all of which can contribute to fork stalling (Webb et al., 
2013). This hypothesis was validated in yeasts by how non-randomly close the last origins are to the 
telomere, an average of ~0.4 kb, compared to the average replicon length of ~26 kbp (Newman et 
al., 2013). Additionally, Theis et al. 2010 compared the loss rate of a 160 kbp origin-less segment 
of DNA in the body of a chromosome to the same segment at the end of a chromosome, and found 
that there was a ~200-fold increase. The DFS model predicted a ~1000-fold increase and Newman 
et al. 2013 speculated whether there is a mechanism to resolve under-replication at telomeres. 
Indeed, telomerase-null S. cerevisiae cells mostly die but the few that survive use an ALT pathway 
that involves recombination between uneven telomeres to maintain their length (Teng and Zakian, 
1999). BLM helicase is required for ALT in human cells (Stavropoulos et al., 2002), localises to 
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telomeres, and depletion by RNAi causes an increase in telomere free ends (Barefield and 
Karlseder, 2012). Inducing ALT by inhibition of TRF2 (telomere repeat-binding factor, a member 
of the shelterin complex that protects telomeres) causes an increase in 53BP1 nuclear bodies in the 
following G1, and repair factors including 53BP1 colocalise with unprotected telomeres (Takai et 
al., 2003). It is possible that the ~1.5 fold increase in telomeres in HeLa cells compared to IMR-90 
are creating more difficult to replicate regions of DNA that infrequently require 53BP1 localisation. 
 
Alternatively, the reduced frequency of 53BP1 nuclear bodies could be explained by the presence of 
an intact licensing checkpoint in IMR-90 cells, that ensures a sufficient complement of licensed 
replication origins before cells enter S phase. However, this is not reflected in the origin-mapping 
data of IMR-90, where HeLa and IMR-90 are detected as having a similar genome size and number 
of origins (Al Mamun et al., 2016, Picard et al., 2014), which is reflected in the predicted 
frequencies of DFSs (figure 2C, the difference that is there is largely in the coefficient of variation, 
R, which is slightly smaller in IMR-90 cells). 
 
Finally, the reduced frequency of 53BP1 nuclear bodies in IMR-90 cells could be explained by the 
presence of a well-regulated DNA damage response. In normal cells, DNA damage and replication 
stress are detected by the DNA damage response network by the central regulator kinases ATM and 
ATR respectively. ATM and ATR transduce their signals via p53 which can then coordinate 
apoptosis, senescence or cell cycle arrest (among other activities) (Marechal and Zou, 2013). In the 
absence of p53 activity, a hallmark of many cancers, cells proliferate uncontrollably. A sufficient 
number of DFSs in an IMR-90 S phase could trigger ATR- and p53-mediated cell cycle arrest (and 
restarted again after resolution) or senescence, causing an underestimate of DFSs as detected by 
53BP1 nuclear bodies. 
 
Either way, the increased reliance on resolution of under-replication in cancer cells could be 
exploited as an anti-cancer drug target. Indeed, recently published work from the Blow lab indicates 
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that cancer cells are hypersensitive to the partial inhibition of licensing (Gardner et al., 2017). A 
library of small molecules was screened for activity that reduces the amount of chromatin-bound 
MCMs in U2OS cells. A class of 2-arylquinolin-4-amines that disrupted ORC binding to DNA in 
both Xenopus cell-free extract and human cells was discovered. U2OS proliferation is 
hypersensitive to treatment with the most potent licensing inhibitor discovered by the screen, when 
compared to the same treatment of the primary cell line IMR-90 (Gardner et al., 2017). U2OS cells 
lack an intact licensing checkpoint and likely entered S phase sub-minimally licensed and greatly 
destabilised their genomes, whereas the licensing checkpoint in IMR-90 cells would merely have 
stalled them in G1. Cycling drug treatments could potentially stop host cells from senescing whilst 
remaining lethal to the cancer cells. Combining the treatment of the licensing inhibitor with 
something that inhibits resolution of under-replication could be significantly more lethal to cancer 
cells (for example, figure 17B), whilst little more lethal to host cells as they are blocked from 
entering S phase. 
 
5.4) Implications of the DFS model on genome size and origin distribution 
Increasing genome size from megabases in yeasts to gigabases in metazoans causes the probability 
of one or more DFSs to increase from ~0.1% to ~70% of S phases (Al Mamun et al., 2016). In 
yeasts, optimising the distribution of origins still has a significant effect on proportionately reducing 
the predicted frequency of DFSs (Newman et al., 2013), but for human cells, evenly spacing origins 
would not compensate for the huge increase in genome size (Al Mamun et al., 2016). Al Mamun et 
al. 2016 hypothesise that mechanisms that resolve DFSs lifts the burden of optimising origin 
distribution in higher-eukaryotes.  
 
Speculatively, this could explain why metazoans have lost any recognisable origin consensus 
sequence, and why the S. cerevisiae genome has lost most of its introns. Regulating the positions of 
ARSs could be how yeasts ensure the relatively even spacing between their origins, so the absence 
of metazoan ARSs could be explained by the loss of the benefit of even spacing in gigabase 
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genomes with under-replication resolution mechanisms, and why human ORC is primary DNA 
sequence-agnostic (Schaarschmidt et al., 2004, Vashee et al., 2003). The S. cerevisiae genome is 
known to have few introns, having lost them compared to an intron-rich fungal ancestor (Hooks et 
al., 2014). Budding yeasts that spontaneously lost introns by transposon or recombination events 
may have had an advantage over other yeasts by further optimising their genome to reduce DFSs. 
 
From these considerations, it seems clear that one of the major requirements for expanding the size 
of a genome from megabases to gigabases are mechanisms that can resolve spontaneously occurring 
under-replication.
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